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The immune system 
 
The human immune system is dedicated to protect the body against harmful pathogens 
like bacteria, parasites and viruses1. This complicated defence system comprises many 
different cell types, which all work together to serve immunity. The functioning of the 
immune system is based on two distinct types of responses, the innate and the adaptive 
immune response. The innate immune system, in cooperation with physical barriers like the 
skin, forms the first line of defence against invasion by pathogens. Cells that orchestrate 
the innate response are macrophages, monocytes, natural killer cells (NK cells), 
granulocytes, neutrophils and dendritic cells (DC). The adaptive immune response forms 
the second line of defence, which depends on the activity of effector T and B cells, and is 
notable for its specificity for selected proteins (antigens) derived from invading pathogens 
and the generation of memory for these antigens. This makes the response to recurring 
encounters with the pathogens increasingly efficient. The specificity is mediated by 
receptors that, alltogether, have a very large variety of antigen binding capacity. For 
instance, with their T cell receptor (TCR) T lymphocytes recognize small peptides derived 
from pathogens, which are presented to them via molecules of the major histo-
compatibility complex (MHC). B lymphocytes have membrane immuno-globulins to bind 
specific antigens from the pathogen. Upon binding they turn into antibody-producing 
plasma cells. The excreted antibodies can in turn bind to the pathogen and make the 
invading structures more recognizable for the immune system. 
In these processes antigen presenting cells (APCs) play a key role. Decisions on 
whether T or B cells should expand and eliminate specific targets are made by APCs. 
Antigen presenting B-cells, macrophages and DC all have the capacity to engulf foreign 
material and process this into peptide fragments, which can be presented on their MHC 
molecules. There are two types of MHC molecules, which have distinct functions. Whereas 
all cells of the body express MHC class I, the expression of MHC class II is a unique feature 
of APCs. In general, MHC class I molecules present peptides derived from intra-cellular 
structures and MHC class II molecules from extra-cellular structures. In this way, all cells 
can make themselves recognizable for the (own) immune system, whereas initiation of T or 
B cell expansion remains a task for dedicated APC. 
However, exogenous antigens can also enter the MHC class I pathway of APCs by a 
process called ‘cross presentation’2. Functionally, cross-presentation is thought to be crucial 
for priming CD8+ T cell dependent responses against tumor cells or cells infected by 
viruses. Usually APC do not initiate responses to antigens from these ‘self’ structures and 
the mechanism of cross-presentation therefore is of interest because it appears to involve 
overcoming a normally impenetrable barrier. Within the APC population, DCs are by far the 
most professional in cross-presentation. The DC’s decision whether to cross-present an 
antigen or not is closely related to the contextual recognition of ‘danger’. This ‘danger’ can 
present itself to the DC as conserved ‘pathogen-associated molecular patterns’ (PAMPs) 
derived from for instance viruses, but also as molecular ‘flags’ on the outside of infected or 
malafide cells. PAMPs and the molecular flags can trigger specialized molecules on the DC, 
like for instance the ‘Toll-like receptors’ (TLRs). Inducing cross-presentation of tumor 
antigens via DCs is a common strategy in tumor immunology. 
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Fig. 1: Dendritic cell life-cycle. After DCs perceive antigen in the context of danger signals, they 
migrate into lymphoid tissues where they present the antigens to T and B cells. These effector cells play 
important roles in the subsequent clearing of the pathogen. 
 
Dendritic cells 
 
The past decade has led to an enormous progress in our understanding of dendritic cells 
and their control of the immune system3,4. DCs originate from bone marrow precursors and 
have the unique capacity to migrate to peripheral tissues, where they differentiate into 
immature DCs (Figure 1). In this stage, DCs are marked for their exquisite capacities to 
engulf material from both foreign and self origin. In case of inflammation or infection, the 
immature DCs undergo a process called maturation. Mature DCs are increasingly able to 
migrate into T cell rich areas of the secondary lymphoid organs, where they present 
antigen-derived peptides to T cells and B cells and activate NK cells. Once activated, these 
cells form the pool of effector cells that can effectively fight infections and serve immunity. 
In contrast, antigen capture in the absence of infection or inflammation, so in the absence 
of DC maturation stimuli, can lead to T cell tolerance rather than immunity. Activation of 
DCs therefore is a decisive factor in the development of efficient immunity. 
In human blood, several populations of DCs and DC precursors are discerned. 
CD11c+CD123low cells are termed “myeloid DCs” (mDCs), whereas CD11c-CD123high DCs 
have morphological features similar to plasma cells and are therefore termed “plasmacytoid 
DCs” (pDCs). The differences between pDCs and mDCs include their tissue distribution, 
cytokine production and growth requirements. The mDC lineage exists of at least two 
subsets: Langerhans cells, which are found in stratified epithelia like the skin; and 
interstitial DCs that are found in all other tissues. pDCs are found primarily in the blood and 
lymphoid organs and are considered important cells in innate antiviral immunity and 
autoimmunity5. 
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T cells in immunity and tolerance 
 
Two main types of T cells can be distinguished: CD4+ T helper (Th) cells and CD8+ 
cytotoxic T cells (CTL). CTL recognize antigens presented by APC in the context of MHC 
class I, and are able to directly kill target cells. Th cells recognize antigens in the context of 
MHC class II and are involved in regulating the responses of other components of the 
immune system. Th cells can be divided into several subsets according to their functional 
phenotype6. The cells producing IL-2 and IFN-γ for the support of CTLs and NK cells are 
called Th1 cells. The cells producing IL-4 and IL-5 for the help in B cell responses are 
called Th2 cells. 
Initiation of antigen-specific responses is a complex process, which needs tight 
regulation. The diversity of antigens that can be recognized by different TCRs is enormous. 
However, overlap between antigens from microbes and self-tissue exists. Several selection 
mechanisms and regulatory processes prevent the induction of autoimmune diseases 
induced by self-specific T cells. In the thymus, selection of T cells (based on their TCR) 
prevents highly self-specific T cells from entering the circulation7. The activation of T cells 
that do enter the circulation is subsequently controlled by DCs and Regulatory T cells 
(Treg). If T cells recognize an antigen presented by APC, but lack adequate co-stimulation 
by these APCs, they will either ignore the antigen or get eliminated. This process of 
regulated cell death is termed ‘activation induced cell death’ (AICD). 
Furthermore, Tregs will inhibit the induction and effector phase of autoreactive T 
cells. Tregs carry the markers CD4 and CD25, and it is suggested that these cells are 
actively induced in the thymus. Different subsets of Treg seem to exist, which all have a 
different origin and mode of suppression8. The most commonly studied ‘naturally occurring 
Treg’, induced in the thymus, is present in the periphery of a naïve host and therefore can 
be reffered to as ‘intrinsic Treg’. When stimulated via their TCR these cells are non-
proliferative, but they are known to strongly inhibit the activation of effector T cells in a 
cell-contact dependent manner. Transfer of T cell populations from which the intrinsic Treg 
have been depleted into T cell deficient mice causes severe induction of autoimmune 
disorders, illustrating the importance of T cell regulation9. Recently, it has been shown that 
depletion of Treg can even actively boost tumor rejection in a variety of tumormodels8,9. A 
second group of Tregs is formed by the ‘induced Tregs’. These cells, termed Th3 or Tr1 
originate from naïve CD4 T cells and are induced in the periphery. It is generally believed 
that their induction is the result of antigen encounter in the presence of IL-10 and TGF-β. T 
cell clones stimulated by IL-10 such as derived from DC or tumors secrete different 
cytokines than conventional Th1 or Th2 cells. To discriminate Tregs from conventional T 
cells, expression of activation marker CD25 is commonly used. However, intermediate 
CD25 expression can also be found on highly activated conventional T cells, which 
complicates effective sorting. The forkhead-family transcription factor FoxP3, important in 
the development of Tregs and expressed in all Treg types, therefore seems to be a better 
alternative.  
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Immunotherapy of cancer and in situ tumor destruction 
 
The ever-increasing knowledge of the immune system and its diverse components has 
created opportunities and ideas for new treatments of immune-related diseases. 
Immunotherapy has, for instance, become a promising strategy for the treatment of 
cancer. Vaccinations include injection of tumor antigens with adjuvans that activate the 
immune system, or tumor antigen-loaded DCs (discussed in chapter 2). In many mouse 
models, prophylactic DC vaccination was shown to protect from a subsequent tumor 
challenge. Therapeutic treatment, a more relevant therapy for cancer patients, proved to 
be more difficult. In many cases the tumor and the body’s own regulatory mechanisms will 
actively dampen the responses induced by these vaccines. In order to break this state of 
tolerance, several new vaccination strategies are currently under investigation. In this 
thesis we investigated if in situ tumor destruction could be used for inducing long-lasting 
immunity by loading and activating DCs directly in situ. The results of this study would gain 
novel insights on DC behaviour in vivo, but also would have their impact on the application 
of ex vivo-generated DC vaccines. 
For long it has been recognized that heating or freezing of tumors is an effective 
way of in situ tumor destruction. Today several local ablation techniques are in use, like 
cryo, radiofrequency, microwave, or laser-mediated tumor ablation. Of these methods, cryo 
and radiofrequency ablation have been used most frequently in clinical settings. Cryo 
ablation in patients freezes the local lesion, which results in direct tumor cell death and 
microvascular thrombosis. For radiofrequency treatment, a small electrode (15G) placed 
within the tumor delivers a radiofrequency current generating ionic agitation that is 
converted into frictional heat and subsequent breakdown of proteins and cell membranes. 
This leads to coagulation of most of the tumor and to a minor extent to cellular apoptosis 
in the distal parts of the tumor. The technical developments in the application equipment 
and monitoring devices strongly increased the applicability of in situ tumor ablation 
methods. Currently, tumor ablative techniques are not only applied to tumors located at 
superficial sites but also to tumors located within the body such as bone tumors, renal 
cancer and especially liver tumors. Application of RFA, either alone or in combination with 
resection (>4 cm), yielded 1 and 2 year survival rates of 80% and 60% respectively11-14. 
For cryo ablation median survival times vary from 26 to 32 months10,15,16. These data 
compare favourable to systemic chemotherapy, which results in a median overall survival 
of approximately 17 months. This difference may however be the result of patient 
selection. 
Unfortunately, when radiofrequency ablation is applied for the destruction of larger 
sized lesions, local recurrence rates of over 35% have been reported12. However, survival 
is mostly limited by the appearance of new metastatic lesions. These data illustrate the 
requirement of a systemic anti-tumor therapy in addition to local tumor ablation. 
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Scope of this thesis 
 
Dendritic cells are the most potent antigen-presenting cells of the immune system and 
represent a promising tool in the therapeutic vaccination against cancer. However, a better 
understanding of how DCs succeed to induce and modulate immunity is necessary to 
optimally exploit DCs in anti-cancer vaccines.  
The scope of this thesis was to investigate if in situ tumor destruction could be 
used for inducing long-lasting immunity by loading and activating DCs directly in situ. The 
results of this study would gain novel insights on DC behaviour in vivo, but also would have 
their impact on the application of ex vivo-generated DC vaccines. 
 In Chapter 3, the induction of anti-tumor responses following in situ tumor 
ablation is described. Herein, we used a newly developed murine B16-OVA tumor model to 
explore: 1) the immunological consequences of in situ tumor destruction and 2) the 
efficacy of a combination approach of tumor destruction and immunostimulation. Applying 
this model system we demonstrate that following radiofrequency ablation, a weak but 
detectable immune response develops, which can be augmented by a blocking mAb 
against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) at the time of tumor 
destruction.  
In Chapter 4 we show that the antigen specific immunity observed after local 
tumor destruction is mediated by DC. Furthermore, two types of tumor ablation are 
compared in this study. Upon tumor destruction by radiofrequency large numbers of 
draining lymph node DC acquire antigen. This number is, however, doubled when cryo 
ablation was used to destroy the tumor tissue. Compared to conventional DC vaccination, 
far more antigen positive DC could be discerned in the lymph node after ablation. Analysis 
of DC maturation revealed that both destruction methods were able to enhance DC 
maturation. This chapter also shows that in situ tumor ablation can be efficiently combined 
with immune modulation by depletion of regulatory T cells. This leads to increased 
numbers of tumor-specific T cells in tumor-bearing mice, protecting them from lethal tumor 
challenges. 
Chapter 5 provides a more in-depth view on the DC inducing immunity upon 
tumor ablation. It illustrates that in situ tumor destruction can be seen as an ‘in vivo DC 
vaccine’. The tumor debris generated following ablation can provide antigens that are 
taken up by DC. An additional immunostimulatory PAMP like CpG-ODN matures DC, 
induces cross-presentation and enhances the anti-tumor response in a synergistic way. 
Chapter 6 demonstrates that PAMPs are not only relevant in vivo for DC, but also 
for regulatory T cells. When TLR2 ligands are provided to regulatory T cells, they 
temporarily lose their suppressive abilities and acquire the capacity to proliferate. The 
relevance of TLR2 triggering in regulatory T cells is demonstrated in an in vivo infection 
model. 
Finally, in Chapter 7 the implications of these novel findings for DC/Treg function, and the 
use of DC in vaccination strategies are discussed. 
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Dendritic cells in anti-tumor vaccination 
 
The decisive role of DCs in the activation of immune responses has initiated the 
development of DC vaccines against cancer8. Numerous mouse studies applying bone-
marrow-derived mDCs loaded with tumor antigens provided evidence that DC-based 
vaccination could be effective in fighting cancer (reviewed in 10 and 11). The ability to 
generate large amounts of human DCs subsequently boosted research on DC vaccination in 
humans. Most human studies to date use monocytes to produce DCs ex vivo. When 
cultured in the presence of GM-CSF and IL-4 for a period of three to six days, monocytes 
develop into immature mDCs. Next to monocytes, CD34+ cells are also used to culture 
mDCs8. Clinical trials applying ex vivo generated monocyte-derived DCs indeed showed 
that DC vaccination is feasible and effective in some patients12,13.  
However, many questions regarding immunogenicity of tumor antigens and DC 
maturation and migration remain unanswered. In addition, ex vivo generation of DC 
vaccines for each patient is costly and labor intensive. In this chapter, we will review the 
developments in the field of ex vivo generated DC vaccines, and discuss novel approaches 
aiming to target DCs directly in vivo. We will do this in the context of three crucial 
processes: antigen loading of DCs, DC maturation and DC migration. 
 
 
DC-based vaccines: The ex vivo generation 
 
Ex vivo loading of dendritic cells 
In studies applying ex vivo produced DC vaccines, several strategies have been explored to 
obtain presentation of antigenic peptides in the context of MHC class I and II molecules 
(See also Figure 1). Exogenous loading of DCs with synthetic HLA binding peptides has 
been the most commonly used approach8,14. A major advantage of this approach is that the 
immune response induced by the vaccine can be readily monitored using for example 
peptide-MHC tetramers. Although vaccination studies using ex vivo loaded DCs have given 
us important insights, the use of peptides also has its constraints. The limited knowledge 
regarding optimal tumor antigens and the restriction of a peptide to a certain HLA type 
limit the number of patients and types of cancer to be treated. Furthermore, the relatively 
short half-life (several hours) of the peptide-MHC complexes is likely to affect the potency 
of this type of vaccine. Strategies to prolong the presentation of peptide-MHC complexes 
include loading of DCs with peptide analogues with increased affinity for MHC class I 
molecules, the genetic modification of DCs by transfection with tumor antigen encoding 
cDNA or transduction with viruses encoding the selected target antigen. Furthermore, in 
vitro synthesized RNA encoding tumor antigens has shown to stimulate production of 
tumor proteins in the DCs themselves15. 
Alternatively, DCs can be loaded ex vivo with tumor lysate, dead tumor cells, or 
total tumor-derived RNA. Studies applying for example vaccination of metastatic melanoma 
patients with monocyte-derived DCs loaded with tumor lysate have indeed led to the 
induction of melanoma specific T cell immunity16. All these approaches circumvent the need 
to define the appropriate tumor antigens and thus rely on the capacity of the DCs to select, 
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process and present the relevant antigens. Since auto-antigens will be co-loaded in parallel 
with the desired tumor antigens, the occurrence of potential auto-immune phenomena 
should be carefully monitored. Other strategies for loading DCs ex vivo include loading with 
recombinant proteins17, protein-liposome complexes18, exosomes19, or immune 
complexes20. 
Recent mouse studies explored the injection of ex vivo generated DCs directly into 
the tumor. For example, intra-tumoral injection of syngeneic DCs into malignant murine 
gliomas led to infiltration of the tumor by T cells and the concomitant occurrence of tumor 
regression. These studies formed the basis for early phase I clinical trials like the one 
performed by Mazzolini and co-workers. In this study, patients with metastatic 
gastrointestinal carcinomas were treated by intra-tumoral injections of autologous IL-12-
transfected monocyte-derived DCs21. The treatment resulted in increased levels of IFN-γ 
and IL-6 in the majority of the patients as well as peripheral blood natural killer activity in 
some patients. Further studies optimizing current protocols are, however, necessary to 
improve clinical efficacy. 
Irrespective of the strategy selected to load the DCs, it is now evident that 
activation of both CD4+ and CD8+ T cells is highly beneficial for the induction of anti-
tumor immunity. Therefore, loading of both MHC class I and MHC class II molecules on the 
DC is important to boost a strong immune response. Whereas pulsing of DCs with a 
nominal peptide epitope results in direct loading of MHC class I molecules, efficient 
presentation of intact tumor antigens or tumor cells relies on the unique capacity of DCs to 
cross-present exogenous antigens in MHC class I2. Although the molecular pathways 
involved and the factors that trigger cross-presentation are still poorly understood, recent 
studies in mice suggested that cross-presentation is dependent on the intracellular stability 
of the antigens22 and is tightly controlled by DC maturation23,24. These novel insights 
demonstrate that antigen uptake, cross-presentation, and DC maturation are interlinked, 
and imply that timing of each of these processes is important for the optimal induction of 
immunity. 
 
Maturation of ex vivo generated dendritic cells 
Upon infection or inflammation, immature DCs are activated and differentiate into mature 
APC that are well equipped to prime effector T cell responses. DC maturation is associated 
with several coordinated events, including loss of endocytic and phagocytic receptors, 
upregulation of expression of co-stimulatory molecules such as CD58, CD80 and CD86, 
changes in morphology and re-organization of the DC’s lysosomal and MHC class II 
compartments. DC maturation is highly complex and should be regarded as a flexible 
process of which the outcome is depending on the type of signals a DC receives in the 
periphery. For example, depending on the maturation signals received, a mature DC is able 
to produce large amounts of the pro-inflammatory cytokine IL-12, a key Th1-promoting 
cytokine25. 
Maturation of DCs can be accomplished by several distinct signals that alert the 
resting DCs to the presence of pathogens or tissue injury26,27. These triggers originate from 
either pathogen associated molecular patterns (PAMPs) or molecules released from 
damaged host tissue, both of which have been reported to activate Toll-like receptors 
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(TLRs)28. In addition, inflammatory cytokines such as IL-1, TNF-α and IL-6 can induce DC 
maturation. Mature DCs can be further activated by cell-cell contact and subsequent 
signaling via members of the TNF/TNF-receptor family, like CD40/CD40L. CD40 
engagement on DCs by CD154 present on activated T cells, triggers full DC activation and 
enhances DC migration from the periphery to the draining lymph nodes. In the lymph 
node, these activated DCs are optimally suited to induce powerful effector CTL. CD40L has 
frequently been used for in vitro activation of murine DCs. When used on DCs derived from 
MHC class II-deficient mice, soluble CD40L was shown to generate DCs with the capacity 
to elicit primary and memory CD8+ T cells upon injection in vivo, so even in the absence of 
help from CD4+ T cells29. For this reason, triggering CD40 is often pictured as a 
therapeutic compound for cancer, especially when combined with TLR-triggering. 
Until today, 11 TLRs have been described for which many specific ligands have 
been identified (reviewed in 28,30). TLR1, TLR2, and TLR6 interact with various lipopeptides, 
TLR3 with double-stranded RNA (dsRNA), TLR4 with lipopolysaccharide (LPS), TLR5 with 
flagellin, TLR7 and TLR8 with GU-rich ssRNA and synthetic imidazoquinolines, TLR9 with 
unmethylated CpG DNA and TLR11 with a profolin-like molecule isolated from Toxoplasma 
gondii31. TLR10, which has not yet been detected in mice, is expressed on human B cells 
and pDCs32, but so far its ligand has not been identified. The signaling pathways associated 
with ligation to each of these TLRs are not identical and therefore distinct biological 
responses are initiated upon ligation. Human monocytes and mDCs express all TLRs except 
TLR7 and TLR9, whereas pDCs selectively express receptors 1, 7 and 933,34. The differential 
expression of TLRs by distinct DC subsets is thus indicative for the difference in function of 
these DC-subsets within the immune system. 
The necessity of DC maturation to induce potent immune responses has now been 
well established. Whereas immature DCs have proven to be weak immune stimulators and 
even can be tolerogenic, mature DCs induce functionally superior CD8+ T cells and 
concomitant anti-tumor immunity35. Accordingly, injection of monocyte-derived immature 
DCs in cancer patients yielded little T cell-mediated immune responses, whereas following 
injection of mature DCs these responses were readily detected14,36. 
The most commonly used method to mature DC in the clinic consists of a cocktail 
of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and prostaglandin E2, a hormone-like 
structure, which is secreted upon inflammation8. Currently, other stimuli including mixtures 
of TLR-ligands and inflammatory cytokines are explored to improve DC maturation and 
function. For example, human DCs cultured in a combination of IL-1β/TNF-α with type I 
and II interferons (IFN-α and IFN-γ) and the TLR-ligand poly I:C were very potent IL-12 
producers and better inducers of CTLs in vitro37. Moreover, it was demonstrated that 
activation of DCs by solely pro-inflammatory cytokines yielded DCs that supported CD4+ T 
cell clonal expansion, but failed to efficiently direct helper T cell differentiation. In contrast, 
exposure of these cells to pathogen components generated DCs that did promote T cell 
help37,38. Recent studies suggest that the interplay of multiple TLRs and other pathogen 
receptors like C-type lectins and nucleotide-binding oligomerization domains (NODs, 
intracytoplasmic microbial-recognition proteins sensing for specific peptidoglycan 
muropeptides) may work synergistically (reviewed in39). Simultaneous stimulation of these 
different pathogen receptors might indeed more closely resemble the natural situation 
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where pathogens containing several molecular triggers will initiate multiple defense 
mechanisms. A better understanding of DC maturation and the potency of the differently 
matured DCs to induce and modulate immune responses will be highly beneficial for the 
rational design of DC-based vaccination strategies. 
 
Migration of ex vivo produced dendritic cells 
The migration of DCs from the sites where they encounter antigen to the draining lymph 
nodes is a fundamental part of their life cycle and is closely linked to their maturation40-42. 
Chemokines and their receptors, matrix molecules and adhesion molecules, on the DCs as 
well as on the surrounding tissues are coordinating this important journey. DC migration 
into lymphatic vessels and their subsequent localization within the lymph nodes is found to 
be controlled by the chemokine receptor CCR7 and its ligands CCL19 and CCL2143. Studies 
in CCR7 deficient mice demonstrated that CCR7 is crucial for migration of dermal and 
epidermal DCs, but not for Langerhans cells44. Maturation of DCs results in reduced tissue 
retention by the downregulation of chemokine receptors, whereas CCR7 and CD62L are 
upregulated42. 
 DC migration is not only dependent on chemokine patterns, but also involves a 
complex set of other mediators. Eicosanoids like leukotrienes and prostaglandins are 
involved in DC migration from the skin. These lipid mediators, in cooperation with the total 
lipid profile (LDL vs. HDL, oxidized vs. non-oxidized) can influence migration either 
positively or negatively45. Another factor of basic importance for DC migration is the 
balance between matrix metalloproteinases and their inhibitors. This has shown to 
influence migration independent of their maturation status46. 
Optimal migration of administered DC vaccines will require a dynamic regulation of 
these various mediators, which will have to be adapted to the maturation status of the DC. 
Nevertheless, in current vaccination with ex vivo produced DCs, in general less than 5% of 
intra-dermally injected mature DCs reach the draining lymph nodes. This was for instance 
demonstrated in a patient trial, which used radioactive labeled monocyte-derived DCs to 
monitor migration40. Data from mouse models employing bone marrow DCs confirmed this 
efficiency range47,48. On the other hand, it needs to be studied in more detail if increasing 
migrating DC numbers actually also supplies optimal numbers for immune response 
induction. Finally, the route of administration of the vaccine also leads to different 
distribution of DCs in lymphoid tissues. It was shown that this distribution not only 
determines the location of the primary immune response, but also the tissue-specific 
homing of memory cells and the ability to control outgrowth of tumors at different sites in 
the body49. Optimizing migration of ex vivo produced DC vaccines would not only enhance 
efficacy, but would also allow us to use other sources or types of DCs (normally present in 
small numbers), with less massive culturing. 
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DC-based vaccines: The in situ generation 
 
Taking into consideration the complex mechanisms that control and regulate crucial DC 
functions, like antigen processing, DC maturation and migration, as well as cytokine 
production, it will be a major challenge to optimize all these parameters for ex vivo DC 
vaccines. In addition, generation and ex vivo manipulation of DCs is laborious and costly. 
Therefore, the ability to load and mature DCs directly in vivo would greatly facilitate the 
application of DC-based vaccines and may well improve vaccine efficacy. A variety of 
strategies has been explored to create such ‘in vivo DC vaccines’, which will be reviewed in 
the next section. 
 
In vivo loading of dendritic cells 
The first step in the design of any ‘in vivo’’ DC vaccine is to load directly in vivo with tumor 
antigens. Several studies have explored targeting of tumor antigens to endogenous DCs 
using either proteins or mAbs against cell-surface antigens that preferentially bind to DCs 
(Fig. 1). Several mouse models demonstrated that uptake of antigens by DCs can be 
improved dramatically by conjugating them to molecules that direct towards antigen 
presenting cells, including DCs. For instance, APCs are able to take up complexes of heat 
shock proteins (HSP) and peptides via surface receptors like CD91. These HSP-peptide 
complexes have shown to elicit peptide-specific CTL responses and tumor immunity50. Also 
bacterial or viral proteins, chemically coupled to target antigens have been used 
successfully to promote processing and cross-presentation in DCs. Antigen specific T cell 
responses could be obtained for instance with cholera toxin, binding to the GM1 receptor51, 
or with parvovirus-like particles52. 
Antigen targeting of endogenous DCs, mediated by monoclonal antibodies (mAbs), 
has focused on specific lectin-like receptors that are expressed by DCs, as many of these 
receptors are involved in the uptake of pathogens. For instance, infusion of a mAb directed 
against DEC-205 resulted in the rapid accumulation of the mAb plus a coupled antigen in 
DCs53. Interestingly, this type of targeting not only resulted in MHC class II presentation, 
but also in MHC class I presentation, enabling the induction of CD8+ T cell responses. Anti-
DEC-205 mAbs covalently attached to hen egg lysozyme (HEL)46-61 peptides or genetically 
engineered to contain T cell epitopes were also efficiently targeted to DCs and resulted in 
activation of MHC class II-restricted CD4+ T cells directed against the target antigen54,55. 
In a recent in vitro study, antibodies against the human C-type lectin DC-SIGN were also 
shown to strongly enhance antigen presentation by human monocyte derived DCs56,57. 
Likewise, the use of a fusion protein of melanoma antigens and antibodies directed against 
the mannose receptor contributed to the generation of multiple HLA-restricted antigen 
specific T cell responses58. 
As DCs constitute only a small percentage of blood leukocytes (<0.1%), several 
studies have used the DC growth factors Flt-3 ligand and GM-CSF to expand mouse59 and 
human60 DC subsets in vivo. Interestingly, the +/- ten fold increase in the numbers of DCs 
by administration of these growth factors could induce anti-tumor immunity in mouse 
tumor models, but to a far greater extend when combined with infusion of DC maturating 
compounds. 
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Fig. 1: Approaches for antigen loading on dendritic cells. The potent antigen-processing and -
presenting functions of DCs have initiated the search for the optimal strategy to employ DCs as tumor 
vaccines. The figure shows that DCs can be loaded with tumor antigens in vitro as well as in vivo. Ex vivo 
generated DCs can also be injected directly into the tumor to accomplish the uptake of tumor-derived 
antigen in vivo. On the other hand, DCs can be loaded in vivo, e.g. by increasing DC numbers via growth 
factors or migration into the tumor via chemokine expression. In vivo targeting is done by coupling of 
antigens to DC specific receptors or HSPs. A relatively new approach involves loading DCs by in situ tumor 
destruction. 
 
 
These studies suggest that increasing the number of circulating DCs leads to 
presentation of tumor antigens by DCs, but is in itself not a very efficient way to induce 
anti-tumor immunity. To increase loading of endogenous DCs with tumor antigens in vivo, 
they also can be attracted to the tumor site by expression of DC attracting chemokines in 
the tumor tissue (reviewed in 42). Studies by Furumoto et al. demonstrate that expression 
of the chemokine CCL20 at the tumor site attracted large numbers of circulating DCs into 
the tumor mass61. Consistent with the requirement of DC maturation for efficient immune 
response induction, eradication of existing tumors depended on the additional 
administration of the TLR-ligand CpG-ODN. 
The finding that in vivo expanded DCs are able to acquire tumor antigens raises the 
question how efficient this process occurs in the natural situation. DCs and macrophages 
are both well known for their capacities to phagocytose antigens, but an important 
distinction between these cells is their differential ability to induce immune responses. The 
basis for this difference remains to be studied in more detail, but is likely related to the 
strategic location of certain DC subsets within the LN and their ability to retain antigens 
within their endocytotic compartments, whereas macrophages rapidly degrade antigens in 
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their lysosomes62. Based on the idea to employ the intrinsic capacity of DCs to scavenge 
antigens and to retain these antigens for a prolonged time, we and others have 
investigated in situ tumor destruction as a tool to load endogenous DCs. Following cryo 
ablation or radiofrequency ablation, large amounts of tumor material (e.g. necrotic tumor 
cells) are released and remain in the tumor bearing individual. Recent data indeed indicate 
that using radiofrequency ablation or cryo ablation up to 25% of endogenous draining 
lymph node DCs acquire antigen, whereas other APC were essentially negative (our 
unpublished results). Tumor eradication by radiotherapy63 or chemotherapy64 has also been 
demonstrated to provide a potential antigen source for the induction of anti-tumor 
immunity. However, a role for DCs has not yet been addressed in these models. An 
advantage of in vivo loading of DCs by in situ tumor destruction over other in vivo DC 
loading approaches is that there is no need for retroviral infection, construction of 
recombinant proteins or prior knowledge of the right tumor antigens. One of the potential 
drawbacks of in situ tumor destruction approaches could be that in vivo loaded DCs suffer 
from the immune suppressive environment present at the tumor site that might affect DC 
maturation and/or migration. Furthermore, it remains to be investigated how important 
exclusive targeting of tumor antigens to DCs is for induction of potent immune responses 
in vivo. Preferential loading of DCs might be optimal in the initiation phase of the immune 
response, but antigen uptake by other APC, like B cells or macrophages (as occurs 
following in situ tumor destruction), could possibly contribute as well and be important to 
boost T cell expansion and improve antibody-mediated responses.  
In situ release of antigens can be obtained in several ways. Although not studied 
comprehensively, factors like amount of antigens released, quality of antigens released and 
time frame of antigen exposure will likely be different in these various strategies, but 
important for the loading of APC. Table 1 shows some of the approaches to obtain in situ 
tumor cell-death, which are possibly effective in loading DC in vivo. The different methods 
are more extensively discussed in Chapter 7 of this thesis. 
 
 
Method Mode of action  
Chemotherapy Mostly creates apoptosis. Slow 
release of antigens 
Comprises many compounds that are 
more or less toxic to cells 
Tumor ablation Mostly creates necrosis. More 
rapid release of antigens 
Ablation can be accomplished by cold, 
radiofrequency, laser, ultra-sound or 
microwaves 
Radiation  Mostly creates apoptosis. Slow 
release of antigens 
 
   
Table 1: Various ways to obtain in situ tumor antigen release 
 
 
Maturation of dendritic cells in vivo  
Although solid human tumors are frequently infiltrated by DCs that have captured and 
presented antigens, the onset of a proper immune response is nevertheless often 
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hampered. As DC maturation is of crucial importance for immune response induction, the 
lack of potent DC maturating compounds like microbial PAMPs may well be responsible for 
this. To efficiently mature DCs in vivo following loading with antigens, the same DC 
maturation stimuli as used for ex vivo DC maturation, like pathogen-derived TLR-ligands 
and CD40 activating mAbs, are commonly applied in mouse models. However, one should 
be aware that the nature of in vivo loading of DCs can also influence maturation. For 
instance, apoptotic or necrotic cells are both taken up by DCs but have a differential 
outcome with regard to DC maturation. Moreover, endogenous inflammatory stimuli 
produced upon inflammation may also have an impact on maturation27. This may especially 
be the case with in situ tumor destruction procedures, where endogenous danger signals 
are readily released from the damaged tissue/tumor, which may contribute to immune 
activation. 
Several studies have suggested that necrotic cell material can efficiently mature 
DCs and induce systemic immunity, whereas antigens from apoptotic bodies might fail to 
do so and induce in vivo tolerance65,66. Opsonisation of apoptotic cells by complement 
components has demonstrated to revert the observed tolerance induction67. Similarly, 
expression of HSPs in dying tumor cells has proven to efficiently induce immune responses 
and to be essential in the in vivo cross-priming of CD8+ T cells50. Interestingly, it has been 
suggested that HSPs are endogenous ligands for TLR2 and 468. The identification of uric 
acid as an endogenous immune stimulus69 further provides evidence that endogenous 
danger signals may contribute to immune activation and stimulate anti-tumor immunity. 
In addition, DCs in the vicinity of the tumor can be loaded with antigen and 
concomitantly matured by in situ administration of exogenous stimuli containing PAMPs or 
by activating antibodies. For example, systemic or peri-tumoral injections of agonistic anti-
CD40 antibody caused expansion of CD8+ T cells that infiltrated and permanently 
eradicated murine tumors70. Also in case of anti-DEC-205 mAb-mediated delivery of 
antigens to DC, CD40 triggering, inducing DC maturation, was an essential factor for 
immune response initiation53. 
TLR-triggering has shown to be one of the most potent inducers of DC maturation 
in vivo. Recently, the TLR3 ligand poly I:C was shown to increase the numbers and 
function of antigen-specific CD8+ T cells in a murine model, which led to protection from a 
tumor challenge in mice treated with a DC vaccine71. The compound imiquimod, an 
imidazoquinoline that has been recognized as a ligand for TLR7 and TLR8 might also be of 
interest for combinational therapy. Pre-treatment of the DC injection site with imiquimod 
induced migration of ex vivo generated mouse DCs and obviated the need for ex vivo 
maturation72. Although many TLR-ligands are currently under investigation as tools for in 
vivo activation of DCs, there has been a particular focus on the TLR9 ligand CpG-ODN in 
the past years. Unmethylated CpG-ODN stimulates DCs to express co-stimulatory 
molecules, increase antigen presentation and secrete particularly Th1-associated cytokines, 
such as IL-12. Moreover, the addition of CpG-ODN can overcome the inhibitory effects of 
immune suppressive factors secreted by B16 melanoma cells on bone marrow derived DCs 
and restore their capacity to activate allogeneic T cells61. CpG-ODN also improved the MHC 
class I peptide-processing pathway, leading to an increased number of cross-presented 
epitopes on the cell surface of DCs73. These effects therefore render CpG-ODN a promising 
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adjuvant for in vivo activation. Indeed, the anti-tumor efficacy of CpG-ODN has been 
reported in a number of preventive and therapeutic models (reviewed in 74). In these 
studies regression of tumors was seen when CpG-ODN was injected intra- or peri-
tumorally. The efficacy of CpG-ODN was, however, often negatively correlated with the size 
of tumors and also seemed to be less when the treated tumor was less immunogenic. 
Interestingly, CpG-ODN in combination with radiation therapy was shown to delay tumor 
growth in sarcoma-bearing mice63 and to induce tumor remission in rats with 9L-glioma75. 
In agreement with this, we have recently found that in situ tumor ablation of large 
established murine tumors by cryo ablation can efficiently be combined with CpG-ODN 
(Chapter 5). 
Future research will have to determine the exact mode of action of TLR-enhanced 
immune response induction by DCs. It would for instance be of particular interest to gain 
more insight in how TLR signaling cross-talks with antigen uptake. Another important 
challenge in future research will be to find inflammatory triggers like for instance activation 
of members of the TNF receptor superfamily with antibodies that can work synergistically 
with aforementioned TLR stimuli in creating highly efficient DC vaccines. Finally, one should 
realize that in contrast to ex vivo maturation of purified DC, in vivo administration of TLR-
ligands or immune activating mAbs will also activate many other cells besides DCs. TLR 
expression is not limited to DCs and over-stimulation might induce negative side effects. 
 
Migration of in vivo loaded dendritic cells 
Studies with ex vivo produced DC vaccines have taught us that DC migration is tightly 
controlled. DC maturation, chemokine receptor and chemokine expression by DCs in situ in 
combination with various tissue-derived factors have all shown to influence DC migration. 
Although many interesting questions about migration have been answered using ex vivo 
produced and labeled DC vaccines, these studies also indicated that migration of ex vivo 
generated DC is rather inefficient as compared to the in vivo situation. For in vivo DC 
vaccines, intra-tumoral expression of the mouse chemokine CCL21 revealed increased DC 
recruitment to tumor sites with concomitant enhancement of the T cell responses76. In 
addition, CCL20 gene transduction or intra-tumoral injections of CCL20 protein attracted 
DCs into the tumor core and induced potent anti-tumor responses in CT26 tumor-bearing 
mice61. On the other hand, CCL2/MCP-1 attracted different DC subsets and monocytes, but 
also promoted tumor angiogenesis through its action on endothelial cells and thus 
promotes tumor growth77. This indicates that careful selection of specific chemokine stimuli 
is required to attract the right DC subsets. In case antigens are targeted to endogenous 
DCs, e.g. through surface receptors or by DC specific promoters, natural migration of DCs 
will not be induced automatically. Although these DCs do not need to travel to the tumor 
site to take up antigens, they still need to migrate to the lymph nodes to present their 
antigens. Therefore, it may be beneficial to vigilantly select combinations of chemokines in 
combination with maturation inducing stimuli to accomplish efficient migration of antigen-
loaded DCs to the lymph nodes. 
 
 
 
Chapter 2 
32 
DC-based vaccines: How to overcome immune suppression 
 
Tumors can actively down-regulate anti-tumor immunity and even create a state of 
immunological unresponsiveness or self-tolerance to tumor antigens (reviewed in 78). 
Moreover, in tumor-associated lymph nodes, T cells expressing a CD4+CD25+ regulatory 
phenotype (Regulatory T cells, Tregs) can be found, that can actively suppress DC 
function13. To exploit the full benefit of DC vaccination, it is therefore important to learn 
more about the inhibitory pathways that prevent the immune system to eliminate tumors. 
 
Tumor-derived inhibitory factors and dendritic cells 
Tumor cells produce immune inhibitory factors, such as IL-10, TGF-β, VEGF and 
prostaglandins that may lead to a decrease in numbers and function of DCs78. For instance, 
IL-10 and TGF-β have been suggested to affect differentiation, migration and activation of 
DCs42. Moreover, DCs from IL-10 transgenic mice were found to have significantly 
suppressed IL-12 production and they failed to generate anti-tumor responses79. 
Interestingly, the use of an IL-10 neutralizing antibody increased the capacity of mouse 
DCs to respond to TLR-ligands80. It has also been postulated that tumor-associated factors 
like IL-10 and TGF-β introduce an imbalance between the expression of co-stimulatory and 
co-inhibitory molecules, which leads to DCs that support tolerance rather than induce 
immunity. For example, IL-10 and TGF-β have both been shown to reduce the expression 
of the co-stimulatory molecules CD80 and CD86 by DC78, whereas the expression of the 
inhibitory molecule B7-H1 on DCs is upregulated by factors within the tumor environment. 
B7-H1 is present on various tumors and on mDC in draining lymph nodes from ovarian 
carcinomas81. Its ligand PD-1, a negative regulator of T cell responses, is also expressed by 
a significant number of tumor-associated T cells. Antibody-mediated blockade of B7-H1 
signaling on human T cells or DC improved DC-mediated T cell activation and inhibited 
mouse B16 melanoma and CT26 colon cancer growth82. These data suggest that forcing 
expression of B7-H1 on DCs can be regarded as a mechanism of tumor-induced immune 
evasion. 
Also the attraction of tolerance inducing subtypes of DCs may be promoted by the 
presence of a tumor. In breast carcinoma it was shown that immature DCs appeared to 
reside within the tumor and mature DCs only in peri-tumoral areas, while total myeloid DC 
numbers were decreased83. Moreover, large numbers of DCs that accumulated in tumor 
draining lymph nodes of patients were shown to express the immunoregulatory enzyme 
indoleamine 2,3-diogygenase (IDO)84, which provides a potential mechanism of DC-
mediated suppression of anti-tumor immunity, since IDO inhibits the activation of T cells. 
The recruitment of a population of IDO-expressing DCs would therefore be advantageous 
for tumor growth. In agreement, exposing mice to the IDO inhibitor 1-methyl-tryptophan 
(1MT) indeed delayed Lewis lung carcinoma growth in syngeneic mice in vivo84. 
 
Regulatory T cells and immune suppression 
CD4+CD25+ regulatory T cells (Treg) have been shown to be of critical importance 
in regulation of T cell dependent immune responses and in creating the immunological 
tolerance to self and non-self (reviewed in 6). These regulatory T cells are able to suppress 
Dendritic cells in anti-tumor vaccination 
33 
T cell function in a cell contact dependent manner and represent one of the feedback 
mechanisms used by the immune system to limit excessive immune responses. This 
suggests that naturally occurring Tregs that are engaged in the maintenance of self-
tolerance may at the same time impede immuno surveillance against autologous tumor 
cells and limit the effect of vaccination. Indeed, Tregs have been found in tumor-associated 
lymph nodes, where they were shown to suppress conventional T cells, but also DC 
function6. Therefore, the combination of tumor vaccination and manipulation of the 
suppressing functions of Treg may deliver significant improvement of cancer 
immunotherapy. In fact, depletion of CD25+CD4+ T cells before a subsequent tumor 
challenge provided effective anti-tumor immunity in otherwise non-responding mice6. 
Depletion of Treg can be accomplished by depleting mAbs recognizing molecules present 
on Treg, but also chemotherapy was shown to decrease circulating regulatory T cell 
numbers85. The latter might be of critical importance when patients are treated with 
lympho-depleting chemotherapy and subsequent adoptive transfer of tumor directed T 
cells86. 
Also crosslinking of CTLA-4 on Treg has been suggested to play a role in (Treg-
mediated) immune suppression87. CTLA-4 blockade is known to lower the threshold for T 
cell activation, but Tregs also express high levels of CTLA-4. Blockade of CTLA-4 in animal 
models was shown to improve the effectiveness of cancer immunotherapy, but intriguingly, 
depletion of CD25+ cells and simultaneous blockade of CTLA-4 even acted synergistically 
on tumor rejection of B16 melanoma following vaccination88. The first human studies 
applying CTLA-4 blockade have now been reported. The results demonstrated tumor 
regression in some patients but also various autoimmune manifestations were noted89,90. 
The CTLA-4 injections in these studies were all accompanied by a preceding vaccination. 
Interestingly, administration of anti-CTLA-4 mAbs in tumor-bearing mice undergoing in situ 
tumor destruction by chemotherapy enhanced tumor regression and survival in the 
absence of vaccination91. Consistently, the release of antigens by radiofrequency ablation 
of established tumors, followed by anti-CTLA-4 treatment is highly effective in producing in 
vivo anti-tumor immunity, mediated by specific T cells92. 
 
 
DC-based vaccines: Where we stand 
 
Dendritic cells are the most professional antigen-presenting cells of our immune system. 
Mouse studies have clearly demonstrated their unique potency in the induction of anti-
tumor immunity. The first studies applying ex vivo produced DC-based vaccines in cancer 
patients have demonstrated that they are safe and have minimal side effects12. Although 
the majority of studies investigated the therapeutic effects of DC vaccines in late-stage 
cancer patients with metastasis, clinical and immunological responses have been observed. 
However, the results are variable and long-lasting clinical responses were limited and not 
observed in all studies. It’s fair to state that the use of immature rather than mature DCs in 
several studies may have affected the immunological and clinical outcome, as immature DC 
are now well accepted to be less potent for the induction of strong anti-tumor immune 
responses. The fact that DC maturation is highly complex, combined with the recent 
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findings that the potency of a DC vaccine is dependent on the type of maturation signals a 
DC receives, further imply that even the mature DC used could be considered as sub-
optimal. In our opinion, small two-armed studies in combination with appropriate 
characterization of both the DC vaccine and immunomonitoring of the response induced is 
crucial for further development of DC-based vaccines. We believe that the true potential of 
these immunostimulatory cells has not yet been fully exploited. 
 For a broad applicability of DC-based vaccines in the future it is important to be 
able to load and mature DC directly in vivo by for example in situ tumor destruction in 
combination with DC maturation stimuli. This also will allow optimal cross-talk of the DC 
with all the other components of the immune system especially when combined with other 
approaches that counteract the immune-suppressive conditions frequently observed in 
cancer patients (See also Figure 2). 
 
 
DC-based vaccines: Where we go 
 
Immunotherapy applying tumor-antigen-loaded DCs has proven to be feasible and effective 
in some patients, but a better understanding of how DCs succeed to induce and modulate 
immunity is necessary to optimally exploit the DC’s full potential in vaccines. Variables that 
have to be optimized in the next years include the mode of DC preparation, the DC 
subtype, the dose and timing interval of vaccination, the route of administration, the mode 
of antigen loading and especially DC maturation. Novel approaches aiming at the in vivo 
loading of DC vaccines have shown promising results, but will nevertheless only be 
effective when we learn to define the most optimal maturation stimuli in vivo. 
Understanding the complex interactions between the processing of the in vivo provided 
antigens and maturation stimuli, including their time constraints, will be of critical 
importance to induce optimal cross-presentation and subsequent CD8 T cell responses. 
Finally, it will be of particular interest to design DC vaccines that can be combined with 
other anti-tumor therapies. One could think of therapies that help the DC vaccine in 
performing its task, like switching off regulatory T cells, or therapies that affect other 
aspects of tumor growth, like anti-angiogenesis treatments. 
The challenge for scientists in the next five years will be to further extend our fundamental 
knowledge of DC immuno-biology and to implement these findings in the rational design of 
DC immunotherapy for the treatment of cancer patients. Such DC-based vaccination 
studies, either alone or in combination with other therapies, in patients with low tumor 
burden will uncover the full potential of DC vaccines and determine its position alongside 
the conventional cancer treatment modalities. 
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Fig. 2: In vivo interventions to obtain an optimal CD8+ T cell anti-tumor response using in 
situ tumor destruction. A) In situ tumor destruction provides large amounts of antigen available for 
uptake and processing by DCs. Tumor antigens are loaded on DCs that migrate towards the draining 
lymph nodes or are already present in these lymph nodes. B) Exogenously administered or endogenously 
produced stimuli, such as inflammatory cytokines, HSPs or TLR-ligands can work synergistically in creating 
effective, mature DCs. C) The antigens are processed and are presented on MHC molecules to T cells in 
the lymph node. Interventions like the blockade of CTLA-4 or prevention of immune regulatory processes 
by for instance regulatory T cells may further stimulate T cell immunity. D) Activated T cells migrate to the 
destructed tumor or to micrometastases, where they kill remaining live tumor cells. The killed tumor cells, 
might subsequently provide new antigens for DCs. 
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Abstract 
 
Tumor-destructing techniques, like radiofrequency ablation (RFA), allow eradication of 
large tumors. Potentially, in situ tumor destruction can also provide the immune system 
with an antigen source for the induction of anti-tumor immunity. Antigen presenting cells 
could take up antigens in the periphery after which they induce specific immune responses. 
Recent data show that especially antigen presenting dendritic cells (DC) are crucial for the 
induction of potent immune responses. However, virtually nothing is known regarding the 
induction of immune responses after in situ tumor destruction in neither mice nor men. 
Herein, we used the well-defined murine B16-OVA melanoma cell line to develop a novel 
tumor model to explore: 1) the immunological consequences of in situ tumor destruction 
and 2) the efficacy of a combination approach of tumor destruction and 
immunostimulation. Applying this model system we demonstrate that following RFA, a 
weak but detectable immune response develops, directed against OVA, but also against a 
broader range of B16 antigens. Adoptive transfer experiments further indicate that anti-
tumor reactivity can be transferred to naïve mice by splenocytes. To augment the response 
observed, we administered a blocking mAb against cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) at the time of tumor destruction. Interestingly, this strongly enhanced 
anti-tumor immunity resulting in long-lasting tumor protection. These results illustrate that 
in situ tumor destruction can provide a useful antigen source for the induction of anti-
tumor immunity, provided that additional immunostimulatory signals are co-administered. 
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Introduction 
 
In situ tumor ablation with a thermal energy source such as Radiofrequency (RFA), Laser, 
Microwave, or Cryo ablation has received increasing attention over the past decades as a 
minimally invasive technique for treatment of focal cancer, and encouraging results have 
been obtained. Especially, RFA treatment is widely used for local ablation of liver tumors 
with a size of up to 4 cm1,2. RFA has been proven to be a safe procedure with a 
complication rate below 10%. The technique can be performed during open surgery or as a 
minimal invasive procedure when applied percutaneously or via laparoscopy. RFA has been 
used successfully in the treatment of bone tumors3, lung tumors4, renal cancer5 and 
primary or metastatic liver tumors1,2,6,7. Although RFA treatment is not applicable to all 
patients, RFA and comparable techniques require fewer resources, result in faster recovery, 
and in most cases, offer reduced morbidity and mortality compared to surgical resection. 
Unfortunately, many of these patients will die from multiple metastases that remain 
untreated. Therefore, the addition of a relevant systemic therapy would be highly valuable. 
Upon tumor ablation in situ, large amounts of tumor debris are released that could 
potentially be taken up by the immune system. For long it has been discussed whether or 
not ablated tumor debris is able to induce a systemic immune response, but a systematic 
analysis has not been reported yet and convincing evidence is therefore lacking. Few 
studies report on an occasional patient with spontaneously regressing metastases and 
reduced numbers of developing secondary foci post-ablation8,9. However, based on the 
results of vaccination studies with large amounts of irradiated autologous tumor cells or 
tumor lysates10,11, it is not very likely that a large amount of tumor debris by itself is 
sufficient to induce a potent anti-tumor response. Moreover, recent insights in the 
requirements for the induction of an effective immune response demonstrate that 
maturation of antigen presenting cells, especially dendritic cells, is a prerequisite for the 
induction of adaptive immunity12,13. The importance of immune activation for the induction 
of anti-tumor immunity has been well established. Expression of, for instance, the B7 
molecules appeared to be sufficient to induce T cell mediated rejection of a variety of 
tumors14,15. Likewise, local injections of stimulating antibodies against the co-stimulatory 
molecule CD40 lead to enhanced systemic anti-tumor responses in mice16. Similar results 
have been obtained by antibody triggering of other stimulatory members of the tumor-
necrosis factor receptor (TNFR) family: OX40, 4-1BB, CD27, CD30 (reviewed in 17). In 
addition to these stimulatory pathways, also blockade of inhibitory receptors, e.g. CTLA-4, 
has been applied successfully to induce tumor rejection18. In recent years, ex vivo 
generated dendritic cells (DC) loaded with tumor antigens have been studied and shown to 
evoke tumor-specific responses in cancer patients19,20. Potentially, the tumor debris 
generated after in situ tumor destruction can be used as an antigen source for the immune 
system. Combining in situ tumor destruction with immune-potentiating strategies might 
represent a relatively simple way of in situ immune response induction. 
Here we report the development of a mouse tumor model that allowed us to 
explore the potential of in situ tumor destruction alone or in combination with 
immunomodulatory approaches. The results demonstrate that following RFA a weak but 
detectable immune response is induced. Furthermore, administration of CTLA-4 blocking 
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antibodies that lower the threshold for T cell activation potentiates the immune response 
leading to increased tumor protection. 
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Results 
 
Development of an in situ tumor ablation model 
To investigate the induction of anti-tumor immune responses following in situ tumor 
destruction, we developed a mouse B16-OVA model in which Radiofrequency ablation 
(RFA) was used to destruct established tumors. Initial experiments with the RFA equipment 
indicated a tight balance between incomplete ablation of B16-OVA tumors resulting in 
recurrences and too severe ablation of the tumor-surrounding tissue. Therefore, we 
optimized the size of the tumor at the moment of destruction, duration of the ablative 
cycles, and the impedance. Two consecutive treatment cycles of 80 sec. with an impedance 
of 400 ohms, together covering the whole tumor area (7 mm in diameter), yielded the best 
results (not shown and Fig. 1b). Using this treatment regimen, post operation survival rates 
of 100% were obtained with a recurrence rate of 20% (Fig. 1b). We observed that 
whenever recurrences occurred a few days after treatment, they appeared at the edge of 
the treated area, and progressed rapidly. Wounds healed completely in 20 to 30 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Induction of a tumor specific immune response following RFA. (A) Time schedule outlining 
the different treatments as used in the experiments. Ten days after tumor inoculation the B16-OVA 
melanoma tumors (7mm) were ablated by RFA. Forty days after RFA mice were re-challenged. (B) The 
overall survival of animals after ablation. T=0 corresponds to the time of ablation. (C+D) Forty days after 
ablation 15x103 B16-OVA cells (C) or 15x103 EL4 mouse thymoma cells (D) were injected s.c. in the 
contralateral leg (z). Normal growth was monitored by injection of 15x103 B16-OVA cells into naïve mice 
(dotted lines). T=0 corresponds to the time of injection of the tumor re-challenge. P<0,005 for panel c 
(n=7-11, one representative experiment out of three independent experiments is shown). 
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Immune responses after RFA 
Using the aforementioned model, we determined whether specific anti-tumor reactivity 
could be detected after RFA. Hereto, B16-OVA tumor-bearing mice were RFA treated and 
then re-challenged with either B16-OVA cells or non-related EL4 thymoma cells. A detailed 
time schedule of the different treatments is given in figure 1a. Re-challenges were given 40 
days after ablation to exclude direct effects of the RFA treatment on the tumor re-
challenge. As surgical excision of the established tumor was not possible due to the 
occurrence of local recurrences in the majority of these mice, age-matched, untreated 
naïve mice were used as controls. As shown in figure 1c, RFA of B16-OVA resulted in a 
clear delay in the outgrowth of B16-OVA tumor cells and a low level of protection (20% of 
the mice). In contrast, no delay in outgrowth of the non-related EL4 mouse thymoma was 
observed (Fig. 1d). These data imply that a weak but tumor-specific immune response had 
developed after in situ tumor destruction by RFA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Adoptive transfer of immune reactivity. Forty days after RFA, mice were injected with 25x103 
B16-OVA cells to boost the response. Ten days later, splenocytes (A) or serum (B) of these mice were 
harvested and transferred to naïve mice. Three days later, recipient mice received a challenge with 15x103 
B16-OVA cells (z). Control transfers were performed using spleen cells and serum from mice that received 
25x103 B16-OVA 10 days prior to the isolation of spleen and serum ({). Normal growth was monitored by 
injection of 15x103 B16-OVA cells into naïve mice (dotted lines). T=0 corresponds to the time of injection 
of the tumor challenge. P<0,02 for RF vs. control donor in panel A (n=5 per group, one out of two 
independent experiments is shown). 
 
 
Adoptive transfer of specific immunity 
To further demonstrate the involvement of the immune system, we investigated whether 
the observed effects on tumor growth and protection could be transferred from RFA-
treated mice to naïve mice via serum or splenocytes. Interestingly, transfer of 35x106 
splenocytes of RFA treated mice resulted in delayed tumor outgrowth and partial protection 
against a lethal B16-OVA challenge (Fig. 2a). Transfer of serum of the same mice only 
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resulted in a minor delay in tumor outgrowth (Fig. 2b). No delay in tumor growth was 
observed after transfer of control splenocytes or serum from mice that received B16-OVA 
cells 10 days prior to the isolation of splenocytes and serum. (Fig. 2a+b). These results 
indicate that the observed immune response is mainly cell-mediated. The finding that 
splenocytes derived from mice that carry non-ablated B16-OVA tumors are unable to 
transfer anti-tumor reactivity, demonstrates that specific immunity is not simply induced by 
a growing B16-OVA tumor, but is in addition dependent on ablation of the tumor. 
Long lasting immunity against B16-OVA 
Next, we investigated whether the RFA-treated mice that had rejected the initial re-
challenge, were protected against a second re-challenge with B16-OVA and wildtype B16-
F10, its less immunogenic counterpart. As only a limited number of surviving mice were 
available, groups of 3 to 4 mice were re-challenged with a lethal dose of B16-OVA in one 
flank, while B16-F10 was given contra laterally.  Interestingly, mice that had rejected the 
first B16-OVA challenge were completely protected against a second B16-OVA re-challenge 
70 days later (Fig. 3). This observation demonstrates that immunological memory was 
present in these mice. Furthermore, also a delayed outgrowth of the wild type B16-F10 
tumor was observed as compared to controls (Fig. 3). These data indicate that the immune 
response is not only directed against the immuno-dominant OVA epitope but also towards 
a broader range of B16 antigens. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Memory- and anti-B16 immune response. Mice that had rejected a B16-OVA re-challenge 
after RFA treatment of a B16-OVA tumor (see Fig. 1) received a second set of re-challenges (z). On the 
left flank 15x103 B16-OVA cells (left panel) and on the right flank 10x103 B16-F10 wildtype cells (right 
panel) were injected. The same tumor cell injections were given to naïve mice ({). T=0 corresponds to 
the time of injection of the second tumor re-challenge. (n=3-4 per group, one out of two independent 
experiments is shown). 
 
a-CTLA-4 enhances immunity against B16-OVA and induces specific CTL 
Administration of blocking mAbs against CTLA-4 has previously been used to facilitate the 
induction of T cell responses by disrupting the negative regulatory function of CTLA-423. 
Therefore, we explored whether in situ tumor destruction in combination with CTLA-4 
blockade could enhance the anti-tumor immunity in our model. Hereto, blocking anti-CTLA-
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4 antibody 9H10 or a control antibody was administered on days 0, 3 and 6 after RFA and 
mice were re-challenged 40 days later. As shown in Fig. 4, the combination of RFA and 
CTLA-4 treatment resulted in an increase in protection against a lethal B16-OVA injection 
from 25 to 75% of the mice. No increase in protection was observed when control IgG was 
administered after RFA (Fig. 4). Furthermore, anti-CTLA-4 treatment without RFA was not 
sufficient to eradicate either the primary tumor or a tumor challenge given 40 days post 
antibody injection (not shown). 
To determine whether antigen specific T cells are induced after RFA with or without 
CTLA-4 blockade, we analysed the presence of OVA-specific CD8+ T cells by MHC-tetramer 
staining after a single re-stimulation of spleen and lymph node cells. As shown in figure 5a, 
a low number of OVA specific cytotoxic T cells (CTL) was detected 10 days after RFA 
treatment plus control IgG. However, in RFA mice that in addition received CTLA-4 
treatment, a 20-fold increase in OVA-specific CTL was observed (Fig. 5a). No OVA 
tetramer-positive cells were discerned in naïve mice. 
Analysis of IFN-γ production in response to B16-OVA tumor cells confirmed the 
increased anti-tumor reactivity in RFA plus CTLA-4-treated mice and further demonstrated 
that these specific CTL are functional (Fig. 5b). 
 
Collectively, these findings demonstrate that in situ tumor destruction can provide a 
useful antigen source for the induction of anti-tumor immunity. Weak anti-tumor T cell 
responses are generated after RFA-mediated tumor ablation that can be significantly 
enhanced by co-administration of blocking CTLA-4 antibodies. 
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Fig. 4: Co-administration of blocking CTLA-4 mAbs enhances the anti-tumor effect. At day 0, 3 
and 6 after RF ablation of B16-OVA, mice received 200µg of anti-CTLA-4 antibody (z) or control IgG ({). 
Forty days after ablation a re-challenge with 15x103 B16-OVA cells was given in the contralateral leg. 
Normal tumor growth was monitored by injection of the same amount of cells into naïve mice (dotted 
line). T=0 corresponds to the time of injection of the tumor re-challenge. P<0,05 for both lines. (n=7-11 
per group, one out of two independent experiments is shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Increased OVA-specific CTL numbers and IFN-γ production following CTLA-4 blockade. 
(A) At day 10 after ablation, a mix of lymph node and spleen cells was obtained from mice treated with 
RFA and control IgG, mice treated with RFA and anti-CTLA-4 antibodies, or naïve mice. T cells were 
harvested and cultured in the presence of irradiated B16-OVA cells and IL-2 for 10 days, followed by 
staining with OVA-Kb tetramers and anti-CD8b. Depicted numbers are percentages tetramer-positive cells 
within the CD8b+ population. (B) IFN-γ production by the stimulated T cell cultures indicated above was 
analyzed by ELISA. * = p<0,01 when compared to naïve, as determined by St. t-test. Mean values with 
SD from triplicates are shown, from one out of two independent experiments. 
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Discussion 
 
Radiofrequency ablation (RFA) is a minimally invasive treatment for local tumor 
destruction that generates large amounts of tumor debris2. Using a newly developed in situ 
tumor destruction model, we now demonstrate that following RFA a weak, but tumor-
specific immune response is induced, resulting in protection against a lethal tumor re-
challenge in 20% of the mice. The anti-tumor reactivity can be transferred to naïve mice by 
splenocytes and is directed against multiple tumor antigens. Moreover, the response 
induced by RFA can be potentiated by co-administration of blocking CTLA-4 antibodies. 
For long it has been recognized that heating or freezing of tumors is an effective 
way of tumor destruction in situ. In recent years, technical developments in equipment and 
monitoring devices have strongly increased the applicability of RFA1,2,5,6,25,26. Currently, RFA 
is widely used for destruction of tumors, particularly in the treatment of inoperable liver 
metastases. Tumor debris remaining after in situ tumor destruction is a potential antigen 
source for the induction of anti-tumor immunity. However, little is known regarding the 
induction of anti-tumor immune responses following RFA. Preliminary studies in pig and 
rabbit revealed an influx of immune cells in the periphery of the coagulation area directly 
after RFA, together with an increased T cell proliferation27,28. 
We have now demonstrated in a mouse B16-OVA tumor model that in situ tumor 
ablation results in the induction of immunity against a lethal tumor re-challenge given 40 
days after tumor ablation. The time span between tumor ablation and tumor re-challenge 
excludes any direct or non-specific immune effect of the RFA treatment on the growth of 
the tumor re-challenge. Our finding that ablation of 5-7 mm large B16-OVA tumors resulted 
in a delay in tumor growth and partial protection against a subsequent B16-OVA but not 
EL4 tumor re-challenge is indicative for the involvement of a tumor-specific immune 
response. Adoptive transfer experiments of splenocytes of ablated mice further 
demonstrated for the first time, that the protective anti-tumor response observed after RFA 
is predominantly mediated via the cellular arm of the immune system. The finding that no 
delay in tumor growth or protection was observed after transfer of splenocytes from mice 
that carry B16-OVA tumors for 10 days without RFA, demonstrates that the effect is at 
least in part dependent on RFA treatment of the primary tumor. 
The mechanism by which RFA induces or enhances immune responses is still poorly 
understood. Ablative treatments are known to release tumor debris, and a rise in the 
tumor-associated ‘carcinoembryonic antigen’ (CEA) has indeed been detected following 
ablation of colorectal liver metastasis (own observations). A limited number of studies also 
reported a rise in C-reactive protein, IL-6, soluble TNF-RI and IL-2 after cryoablation of 
tumor tissue29,30, but little is known about the cytokine release after RFA. Potentially, 
scavenging of the tumor debris by immune phagocytes in combination with the release of 
inflammatory cytokines could be responsible for the observed weak immune responses 
after RFA. The experiments now indicate that low, but detectable amounts of specific 
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CD8+ T cells are induced following RFA, which likely also requires CD4+ T cells. Upon 
combination with CTLA-4 blockade (see below) these CD8+ T cells further expand. The 
involvement of NK cells and elevated cytokine levels in the delayed outgrowth of tumors 
can formally not be excluded. However, we consider this unlikely because of the time-span 
of 40 days between ablation and tumor re-challenge. Moreover, the absence of anti-tumor 
effects upon a re-challenge with EL-4 cells following ablation of a B16-OVA tumor and vice 
versa is indicative for the induction of a tumor-specific immune response (Fig. 1 and not 
shown). Whether the effect of RFA is solely based on the induction of a ‘de novo’ immune 
response, occurs as a consequence of the elimination of the suppressive effect of the 
B16OVA tumor on T cell function, or both, remains to be determined. 
Re-challenge experiments in surviving mice, revealed that once mice had rejected 
B16-OVA, they were completely protected against a new tumor challenge. These data 
indicate that in the few mice surviving the first challenge, a bonafide systemic memory 
response was generated. A clear delay in the outgrowth of the wildtype B16-F10 tumor 
was also observed in the surviving mice. We note that a direct re-challenge with wild-type 
B16-F10 after ablation of B16-OVA only resulted in a small delay in outgrowth (not shown). 
These data indicate that the immune response induced by RFA is directed against multiple 
B16 antigens. However, they also suggest that upon rejection of B16-OVA tumors the pool 
of B16-F10-reactive T cells is expanded or further broadened by epitope-spreading31 to 
obtain the delay in B16-F10 outgrowth in the surviving mice. 
The aforementioned data indicate that in our B16-OVA model a weak, but specific 
anti-tumor response can be achieved following RFA in a limited number of mice. Data on 
anti-tumor responses in patients after local ablative treatment have only incidentally been 
reported8,9. Based on our current knowledge on immune response induction in general, and 
the unique requirement for mature professional antigen presenting cells in particular, the 
aforementioned results imply that immune activation following RFA is sub-optimal. 
Similarly, vaccination with irradiated tumor cells or tumor cell lysates alone does not result 
in the induction of a potent anti-tumor immune response in mice or man10,11. 
Several strategies have been reported to augment an immune response, including 
the administration of stimulatory antibodies to CD40, 4-1BB or blocking mAbs against 
CTLA-4. Repetitive administration of blocking CTLA-4 mAb has been shown to cure mice 
from established tumors 32,33 and in combination with anti-tumor vaccination CTLA-4 
blockade significantly enhanced the potency of the vaccine34,35. In our in situ tumor 
destruction model, we demonstrate that the anti-tumor effect is markedly improved if 
ablation was accompanied by CTLA-4 blockade. Since CTLA-4 blockade by itself could not 
abrogate the outgrowth of the tumor (not shown), these data indicate that the ablation of 
the tumor and the anti-CTLA-4 treatment act synergistically. CTLA-4 has previously been 
shown to maintain the threshold for a T cell to proceed to full activation and to limit the 
proliferative ability of activated antigen-specific T cells18. Indeed, upon combining CTLA-4 
blockade with RFA increased numbers of interferon-γ producing, and OVA-specific CTL 
were detected. Recent reports also suggest an important role of CTLA-4 in the function of 
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CD4+CD25+ regulatory T cells36,37. Involvement of these regulatory T cells in the tumor 
destruction model can therefore not be excluded, and is currently under investigation. 
In the clinical setting, RFA has been successfully applied for treatment of colorectal 
liver metastases7. More recently, encouraging results have also been obtained in the 
treatment of breast cancer patients25. However, these studies are mainly focused on the 
successful eradication of the treated tumor foci, whereas little or no clinical benefits have 
been reported for untreated lesions. Furthermore, when RFA is applied for the destruction 
of large-sized tumors (>4cm), local recurrence rates increase strongly. Therefore, an 
efficient systemic anti-tumor therapy in addition to ablation could be highly beneficial. The 
results described here, indicate that RFA, in combination with immunomodulation, can 
induce a systemic immune response and might therefore enhance the efficacy of RFA 
treatment and protection against local recurrences as well as the development of 
metastasis. Therefore, RFA treatment might offer interesting novel possibilities in 
combination with existing immunotherapy strategies. The data in this paper suggest that 
tumor debris is a useful antigen source for the immune system, provided that additional 
immunostimulatory signals are co-administered. 
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Materials and Methods 
 
Animals 
Male and female C57BL/6n mice were purchased from Charles River Wiga (Sulzfeld, 
Germany) and kept under specified pathogen-free conditions in the Central Animal 
Laboratory, Nijmegen University (Nijmegen, the Netherlands). All experiments were 
performed according to the guidelines for animal care of the Nijmegen Animal Experiments 
Committee. For ablations and tumor experiments, 9-11 week-old mice were used. 
 
Tumors 
Mice were injected subcutaneously in the middle of the right femur with 5x105 cells of the 
OVA-transfected murine melanoma cell line B16-F10 (B16-OVA, clone MO5), which was 
kindly provided by dr. Kenneth Rock (Dana Farber Cancer Institute, Boston, MA, USA)21 or 
with the murine thymoma cell line EL4 (ATCC). Cells were cultured as described, harvested 
and injected in a 1:3 mixture of Matrigel (BD Biosciences, Alphen a/d Rijn, the Netherlands) 
and PBS in a total volume of 50 µl as used before22. Evaluation of tumor size was 
performed every three days using calipers. Tumor volumes were scored with the formula 
(A x B2) x 0,4, in which A is the largest and B is the shortest dimension. Tumors were 
selected for ablation when their diameter measured between 5 to 7 mm. Mice carrying 
macroscopic satellite lesions (2 out of 50 mice) were excluded from the experiments, as 
complete ablation of such lesions appeared difficult. In tumor re-challenge experiments, 
mice were sacrificed when tumors reached a volume of ± 850 mm3. 
 
Radiofrequency ablation 
Animals were anaesthetized by isoflurane inhalation and properly shaved at the tumor area 
and on the contra lateral flank. After placement and proper attachment of the contra lateral 
side onto an electricity-conducting pad (grounding pad), the tumor area was disinfected 
with alcohol. A RFA needle with active tip of 8 mm (SMK-15, Cotop, Amsterdam, the 
Netherlands) was inserted s.c. and placed in the middle of the tumor. After placement of 
the RFA needle, impedance could be evaluated on the RF lesion generator system (Model 
RFG-3B, Radionics, Burlington, MA, USA). Next, treatment was started by delivering RFA 
energy. During two treatment cycles of 80 sec., temperature could be monitored by means 
of a thermistor and thermocouple in the tip of the probe. Treatment was considered 
successful if a tip temperature of 75-80°C could be reached. 
 
Re-challenges 
Forty days after ablation of tumors, mice were challenged by subcutaneous injection on the 
contra lateral femur with either 15x103 B16-OVA cells, 10x103 B16-F10 cells (kindly 
provided by I.J. Fidler) or 15x103 EL4 cells. The amount of tumor cells was based on 
titration experiments demonstrating that this number of cells yielded a solid 100% tumor 
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take, while leaving an appropriate experimental window to study the effects of RF ablation. 
Some mice that rejected the first re-challenge received a second re-challenge. These were 
inoculated on the left and the right flank. Injections were performed in PBS in a total 
volume of 100 µl. Statistical analysis for all re-challenges was performed using the log rank 
Kaplan Meier estimation. 
 
Adoptive transfers 
At day 35 after ablation, mice were boosted with a subcutaneous challenge of 25x103 B16-
OVA cells to enhance an active immune response. Control mice also received 25x103 B16-
OVA cells. Ten days afterwards, serum and spleens were isolated and single cell 
suspensions were obtained by crushing and a passage through nylon mesh. Lymphocytes 
were concentrated by density gradient centrifugation (Lympholyte-M, Cedarlane 
Laboratories, Sanbio, Uden, the Netherlands). Then, recipient naïve mice received 35x106 
lymphocytes or 200 µl serum intravenously in the tail vein from RFA-treated or control 
donor mice. These mice were challenged with 15x103 B16-OVA cells three days later. 
 
CTLA-4 treatment 
The hamster hybridoma 9H1023 was cultured and, using standard isolation procedures, IgG 
was collected. Total hamster IgG was used as control antibody (Jackson Immunoreagents, 
West Baltimore Pike, PE, USA). Directly after RFA, at day 3 and at day 6 mice received an 
intraperitoneal injection of 200 µg anti-CTLA-4 or hamster IgG in a total volume of 200 µl. 
 
Tetramer stainings 
A T cell culture was obtained from splenocytes and draining lymph nodes of mice 10 days 
after ablation of a B16-OVA tumor. Cells obtained from naïve age-matched mice were used 
as controls. Stimulation of these cells (1x105) was performed by addition of irradiated, IFN-
γ-treated, B16-OVA cells (5x104) in IL-2 (10 Cetus U/ml) supplemented culture medium. At 
day 5 and day 10 (prior to staining) cells were collected, after which dead cells were 
removed by a Ficol-Hypaque gradient. The OVA specific CTL clone OVA-2 was cultured as 
described 24 and used as positive readout (data not shown). At day 10 of culture, cells 
were stained for 15 minutes at RT by OVA-tetramers (H2Kb) conjugated to APC, which 
were a kind gift of S.H. van der Burg (LUMC, Leiden, The Netherlands). Subsequently, cells 
were counterstained for CD8b-FITC (BD Pharmingen) and propidium iodide (Sigma) and 
analyzed on a FACS-CaliburTM system (BD) with the CELLQuest software. Values are 
presented as percentages of tetramer positive cells within the total CD8b+ population. 
 
IFN-γ  ELISA 
The same bulk cultures as described for the tetramer stainings were used to collect 
supernatant 24 hours after stimulation. Capture and biotinylated detection antibodies 
directed to mouse IFN-γ were purchased from BD Pharmingen and, using standard ELISA 
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procedures, IFN-γ concentration was measured in 50 µl of supernatant. Data were 
analyzed for statistical significance by Student’s T-test. 
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Abstract 
 
Dendritic cells (DC) are professional antigen presenting cells that play a pivotal role in the 
induction of immunity. Ex vivo-generated, tumor antigen-loaded mature DC are currently 
exploited as cancer vaccines in clinical studies. However, antigen loading and maturation of 
DC directly in vivo would greatly facilitate the application of DC-based vaccines. We 
formerly showed in murine models that radiofrequency-mediated tumor destruction can 
provide an antigen source for the in vivo induction of anti-tumor immunity, but the role of 
DC herein has not been elucidated. In this paper we evaluate radiofrequency and cryo 
ablation for their ability to provide an antigen source for DC and compare this with an ex 
vivo-loaded DC vaccine. The data demonstrate that upon tumor destruction by 
radiofrequency ablation, up to 7% of the total draining lymph node DC contained antigen, 
whereas only few DC from the conventional vaccine reached the lymph node. Interestingly, 
following cryo ablation the amount of antigen-loaded DC is almost doubled. Analysis of 
surface markers revealed that both destruction methods were able to induce DC 
maturation. Finally, we show that in situ tumor ablation can be efficiently combined with 
immune modulation by anti-CTLA-4 antibodies or regulatory T cell depletion. These 
combination treatments protected mice from the outgrowth of tumor challenges, and led to 
in vivo enhancement of tumor-specific T cell numbers, which produced more IFN-γ upon 
activation. Therefore, in situ tumor destruction in combination with immune modulation 
creates a unique, ‘in situ DC-vaccine’ that is readily applicable in the clinic without prior 
knowledge of tumor antigens. 
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Introduction 
 
Dendritic cells (DC) are crucial antigen presenting cells for the initiation of primary T cell 
responses1,2. Immature DC are well equipped to take up and process antigen from their 
surroundings, but they lack sufficient co-stimulatory signals required for productive T cell 
activation. In a stimulatory environment, like in an infection, immature DC undergo 
activation, maturation and acquire the capacity to cross-present exogenous antigens in 
MHC class I. Particularly, the Toll-Like Receptor (TLR) family of proteins initiates the DC 
maturation process upon recognition of conserved pathogen-associated molecular patterns 
(PAMPs), like LPS or unmethylated CpG oligodeoxynucleotides (CpG-ODN). Upon 
maturation, co-stimulatory molecule and MHC-peptide complex expression increases and 
cytokines like IL-12 skew the functional outcome of the response3. DC that did not perceive 
an activating environment while taking up antigen do not mature and induce tolerance 
rather than immunity. The importance of immune activation for the induction of anti-tumor 
immunity has been well established. Next to direct activation of DC by PAMPs, a broad 
range of indirect strategies has been explored to accomplish activation of the immune 
system. Expression of, for instance, co-stimulatory molecules on tumors can induce T cell-
mediated rejection of a variety of tumors4. In addition to these stimulatory pathways, also 
blockade of inhibitory receptors, e.g. CTLA-4, has been applied successfully to induce 
tumor rejection5,6. In this respect, also in vivo depletion of regulatory T cells, that are able 
to suppress conventional T cell expansion, has been shown to evoke anti-tumor 
immunity7,8. 
Since murine models demonstrate that especially DC are effective in inducing 
effective immune responses, ex vivo generated DC are currently applied to stimulate anti-
tumor immunity in clinical trials9-13. Although tumor-specific responses have been obtained 
with tumor antigen-loaded DC-based vaccines, many questions remain unanswered10,14. 
Especially the migration of ex vivo generated DC-based vaccines from i.d./s.c. injected 
depots to the draining lymph nodes has been shown to be inefficient in both mouse models 
and patients11,15,16. Moreover, ex vivo generation and loading of DC is time consuming and 
costly. In vivo loading and maturation of DC would therefore improve the applicability of 
DC vaccination to a great extend. 
Recent studies using antigens coupled to antibodies directed against the mouse DC 
antigen DEC-20517 or attraction of DC to the tumor via retrovirus-mediated expression of 
the DC-attracting chemokine CCL2018 illustrate the possibility to directly load tumor 
antigens onto DC in vivo. We previously showed in a murine model that the tumor debris 
left in the body after in situ tumor destruction by radiofrequency ablation is an in vivo 
tumor antigen source for the immune system. Adoptive transfer experiments demonstrated 
that the immunity induced is T cell-dependent, but the role of DC herein has not been 
described. Tumor ablative treatments, like cryo or radiofrequency ablation, are successfully 
used in clinical settings to destruct different types of tumors19-23. Nevertheless, cancer 
patients treated with ablative regimens mostly develop systemic recurrences as a 
consequence of the outgrowth of distant micro-metastases, implying that in general no 
protective immune response is induced. This observation is consistent with our findings 
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that efficient induction of immunity following ablation requires that additional immune 
activation stimuli are given simultaneously24. 
 We now show that in situ tumor destruction by either cryo or radiofrequency 
ablation can be employed to efficiently provide antigens to DC in vivo. A side by side 
comparison of the two ablative techniques demonstrates that following cryo ablation of 
established B16 tumors (5-7mm) up to 13% of DC in the draining LN acquire tumor-
derived antigen. Radiofrequency ablation results in 7% of LN DC being loaded with tumor 
antigen, which is still a far better yield compared to a conventional in vitro generated DC 
vaccine. We further show that both destruction methods in itself were able to enhance DC 
maturation in vivo to an equal extend. Finally, we report that both tumor ablation 
techniques can be efficiently combined with immuno-modulatory approaches, like blockade 
of CTLA-4 signaling or regulatory T cell depletion, to induce functional CD8+ T cells 
creating systemic anti-tumor-immunity. 
Therefore, in situ tumor destruction combined with immuno-modulatory approaches 
constitutes a powerful ‘in situ DC-vaccine’ for which no prior knowledge of tumor antigens 
is needed. 
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Results 
 
Immune responses following radiofrequency or cryo ablation 
We previously demonstrated that radiofrequency ablation of established (5-7mm) murine 
tumors resulted in weak, but tumor specific anti-tumor reactivity. However, the mechanism 
by which immunity is induced and the role of DC herein remain largely unknown. 
Therefore, we explored the fate of tumor debris generated by two distinct tumor ablation 
approaches and the putative role of DC in the subsequent induction of immune responses. 
To first compare the induction of immunity after both techniques, B16-OVA tumor-bearing 
mice were treated with either radiofrequency or cryo ablation and then re-challenged with 
either B16-OVA cells or non-related EL4 thymoma cells. A detailed time schedule is given 
below figure 1. Re-challenges were given 40 days after ablation to exclude direct effects of 
the ablations on the tumor re-challenge. As shown in figure 1, radiofrequency ablation of 
B16-OVA resulted in a clear delay in the outgrowth of B16-OVA tumor cells as compared to 
naïve controls and a low level of protection (20% of the mice, lower right panel). 
Interestingly, when mice received cryo ablation, slightly more mice were protected (50% of 
the mice, upper right panel). In contrast, no delay in outgrowth of the non-related EL4 
mouse thymoma was observed (left panels). These data imply that a weak, but tumor-
specific immune response had developed after both in situ tumor destruction techniques. 
In all experiments, cryo ablation was slightly more effective than radiofrequency ablation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Anti-tumor immunity following radiofrequency or cryo ablation. Mice with established 
B16-OVA melanomas (5-7mm) were ablated by cryo (cryo, upper panels) or radiofrequency ablation (RF, 
lower panels). Forty days later, a re-challenge with 15x103 EL4 (left panels) or 15x103 B16-OVA cells (right 
panels) was given s.c. in the contra-lateral leg. Figures depict survival curves demonstrating specificity of 
the response and growth reduction/protection after ablation. As a control, tumor growth was monitored by 
injection of the same tumor dose into naïve mice (dotted lines). T=0 corresponds to the time of injection 
of the tumor re-challenge. P<0,005 for both B16 lines vs. control. One out of four representative 
experiments is shown (n=5-11). 
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Efficient in vivo antigen acquisition by LN CD11c(+) DC following ablation 
To determine the fate of tumor antigens and the involvement of DC in the observed anti-
tumor immune responses, we studied in vivo antigen acquisition by DC following 
radiofrequency and cryo ablation. Mice carrying established B16-OVA tumors (5-7mm) 
received an intra-tumoral injection of 111Indium-labeled KLH or 111In-OVA tracer proteins 
prior to ablation to monitor the fate of tumor-debris. γ-Camera imaging demonstrated that 
111In proteins remained in the tumor for at least 72 hrs, whereas unbound 111InCl3 rapidly 
distributes throughout the mice (Fig. 2a). Even following both ablation procedures 111In-
KLH and OVA largely remained at the treated site whereas only minor local spreading was 
observed. In case 111In-OVA was used slightly more spreading to the liver was seen 
compared to KLH, which is likely dependent on the molecular characteristics of OVA. 
Biodistribution analysis revealed an ablation dependent accumulation of radioactivity in the 
draining LN’s when 111In-KLH (Fig. 2b-d) or 111In-OVA (not shown) was used. Although 
significantly different from untreated tumor-bearing mice, radiofrequency ablated mice 
showed significantly less accumulation of radioactivity compared to cryo ablation (Fig. 2b). 
Little or no activity was found in the non-draining LN’s, liver, kidneys or spleen with or 
without ablation (Fig. 2c), whereas the organs contained high concentrations of 
radioactivity following injection of unbound 111InCl3 (not shown). Applying magnetic bead 
sorting on the pan-DC marker CD11c we analyzed the cells in the draining LN’s containing 
111In-KLH. As shown in Fig. 2d, following ablation the cell-associated radioactivity was 
largely present in the CD11c(+) fraction at one and even three days after ablation. Despite 
the fact that the CD11c(+) DC only comprised a minor fraction of total LN cells, they 
accounted for up to 25% of total cell-associated activity present in the LN’s (cryo ablation, 
not shown). Consistent with Fig. 2b, uptake of 111In-KLH following radiofrequency ablation 
was significantly lower compared to cryo ablation. 
These data thus demonstrate that the tumor-debris created by ablation acts as an 
antigen depot and that released antigens preferentially accumulate in CD11c(+) DC in the 
draining LN. They also show that the method of destructing a tumor is highly relevant for 
the subsequent uptake dynamics of tumor antigens.  
 
Accumulation of antigen positive LN DC following ablation or conventional DC vaccination. 
To compare the in vivo loading of DC by ablation with an externally loaded conventional DC 
vaccine, we analyzed the numbers of antigen positive LN DC after performing both 
techniques. In order to trace the antigen-experienced DC by flowcytometry, ovalbumin 
conjugated to the fluorophore Alexa-488 (OVA-Alexa) was injected i.t. prior to ablation and 
DC derived from GFP-transgenic mice were used as an ex vivo DC vaccine. These GFP DC 
were matured with LPS, loaded with the relevant OVA-Kb peptide (SIINFEKL) and 1x106 DC 
were next injected subcutaneously (s.c.) or around an established (5-7mm) B16-OVA 
tumor (p.t.). As shown in Fig. 3a, over 12% of all draining LN CD11c(+) DC became OVA-
Alexa(+) after cryo ablation, whereas after radiofrequency ablation 7% of DC acquired the 
antigen. These data are in line with the accumulation of antigens in DC observed with 
111In-proteins (see also Fig. 2). Consistent with other studies11,16,25, only small numbers 
(<1%) of the ex vivo generated GFP DC reached the draining lymph node (Fig. 3b). 
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Fig. 2: Preferential uptake of tumor-derived antigens by LN dendritic cells. (A) To study the fate 
of tumor antigens after ablation, 20 µCi of 111In-Cl3 (left panel), 111In-KLH (middle panels) or 111In-OVA 
(right panels) was injected into established B16-OVA tumors (5-7mm). Tumors were left untreated or 
ablated by cryo ablation (cryo) or radiofrequency ablation (RF) directly after these injections. γ-camera 
imaging was performed at the indicated time points. For 111In-Cl3-injected mice the contours, tumor and 
liver are visible. One representative mouse out of three is shown. (B-C) Biodistribution of 111In-KLH was 
determined in dissected LNs and organs of mice injected i.t. one day before. Tumors were either left 
untreated or ablated directly after KLH injection. Radioactivity values from LN’s of 4 mice per group are 
presented as mean percentages of injected dose with s.d., whereas the values for the organs are also 
corrected for weight. Mice in panel C received cryo ablation, but comparable results were obtained with RF 
ablation. (D) LN suspensions from non-ablated and ablated mice (5 mice pooled per group) that received 
i.t. 111In-KLH were subjected to magnetic bead sorting of CD11c(+) cells. After sorting at day 1 and 3 after 
ablation, the cell-associated radioactivity was measured in the CD11c(+) and CD11c(-) (not shown) cell 
fraction. Values are presented as counts per minute, corrected for 1x106 cells and natural decay, with sd 
from triplicates. *= P<0,005 compared to no ablation. 
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Moreover, plotting the absolute numbers of DC present in the draining lymph node further 
revealed a significant increase in total DC numbers after ablation, accompanied by an 
increased lymph node volume (Fig. 4 and not shown). This implies that the absolute 
number of DC actually loaded with tumor antigen is even higher than can be concluded 
from the relative percentages of antigen-loaded DC shown in Fig. 3a. 
These data thus indicate that ablation is far more effective in obtaining tumor 
antigen-loaded DC in the draining LN as compared to conventional DC vaccination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Increased numbers of antigen positive DC in draining LN following ablation. (A) FACS 
analysis of CD11c(+) DC isolated from pooled LN suspensions of naïve, tumor-bearing or tumor-ablated 
mice (n=6 per group). Mice received 20 µg ovalbumin conjugated to Alexa-488 (OVA-Alexa488) i.t. just 
prior to the time point of ablation. Two days after the indicated treatments, CD11c(+) DC were isolated 
from draining lymph nodes, stained for CD11c (clone HL3), gated, and plotted for OVA-Alexa488 content. 
Values shown are percentages of OVA-Alexa488(+) cells within the CD11c(+) fraction. (B) BMDC were 
cultured from GFP-transgenic mice, loaded with peptides and matured ex vivo with LPS. 1x106 DC were 
injected peri-tumoral (p.t.) in tumor-bearing mice or subcutaneously into naïve mice (s.c.). Two days later 
CD11c(+) DC were isolated from pooled LN suspensions (n=6 per group), stained, gated, and plotted for 
GFP. As controls for all experiments, naïve mice were used that did not receive any injection (naïve). 
 
 
Ablation-dependent maturation of antigen positive LN DC. 
Next, we studied the maturation of DC in relation to antigen uptake. Therefore, OVA-
Alexa(+) or OVA-Alexa(-) (in vaccination: GFP(+) or (-)) DC were analyzed for expression 
of the DC maturation marker CD80. OVA-Alexa(+) DC showed a 3-fold increase in CD80 
expression relative to OVA-Alexa(-) DC in tumor-bearing and naïve mice (MFI’s 987, 318 
and 310 resp.) (Fig 5a). Moreover, CD80 expression further increased following cryo or 
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radiofrequency ablation on OVA-Alexa(+) DC but had no effect on OVA-Alexa(-) DC (MFI 
1690 vs. 362 and 1567 vs. 361 resp.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
This indicates that DC that acquired OVA-Alexa, as an indicator of tumor-debris, 
preferentially up-regulate CD80, while this effect is further enhanced by ablation. 
Importantly, the induction of maturation by radiofrequency ablation is equal to the 
induction by cryo ablation, even though less antigen uptake was observed. Analysis of the 
GFP-DC in the LN for CD80 expression, demonstrated that the exogenously loaded GFP(+) 
DC were significantly more mature than the resident endogenous GFP(-) DC (Fig. 5b) The 
observed MFI’s were comparable to those seen on antigen positive DC after ablation and 
were similar after peri-tumoral or subcutaneous injection (Fig. 5b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Ablation induces 
maturation of antigen 
positive DC. OVA-Alexa488 
positive or negative CD11c(+) 
cells (A), or GFP positive or 
negative CD11c(+) cells (B), 
obtained in the experiments 
shown in figure 3, were analyzed 
separately for expression of the 
maturation marker CD80. Values 
indicated are mean MFI’s with sd 
from three independent 
experiments. *=P<0,005, 
**=P<0,05 both vs. no ablation. 
Fig. 4: Absolute CD11c(+) 
cell count per LN. Data are 
obtained from experiments 
described in Fig. 3 and 
presented as means with sd 
from three independent 
experiments. *=P<0,005 vs. 
naïve, **=P<0,01 both vs. no 
ablation. 
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Similar, but somewhat less profound results were obtained with CD86 expression (not 
shown). 
The combined data thus not only indicate that ablation results in more efficient DC 
loading but also that ablation-induced CD80 expression of the OVA-Alexa(+) DC in the LN 
equals the CD80 expression on the DC from the LPS-matured ex vivo DC vaccine. 
 
CTLA-4 blockade following ablation enhances systemic anti-tumor immunity. 
We previously showed that immune modulation by blockade of CTLA-4 signaling enhances 
anti-tumor immunity after radiofrequency ablation. We now studied whether CTLA-4 
blockade could be also used in the cryo ablation model. Figure 6 shows that the weak anti-
tumor response observed after cryo ablation alone indeed could be enhanced by 
combination with CTLA-4 blockade. Comparable results were obtained when 
radiofrequency ablation was applied (Fig. 6a). Control experiments showed that CTLA-4 
injection alone had no significant effect on primary tumors or rechallenges (Fig. 6b, left 
and right panel resp.). Analysis of the mice for OVA-specific T cells revealed that far more 
specific T cells were present ten days after the combination treatment as compared to 
ablation alone (Fig. 6c). To determine the activation status of these T cells, IFN-γ 
production was measured after activation with B16-OVA cells. Interestingly, T cells derived 
from mice treated with anti-CTLA-4 and ablation showed increased IFN-γ production upon 
recognition of antigen compared to the IgG treatment (Fig. 6d). In correspondence with 
the rechallenge model, somewhat less IFN-γ producing, specific T cells were detected after 
radiofrequency ablation than after cryo ablation. 
 
Depletion of regulatory T cells prior to ablation enhances systemic anti-tumor immunity. 
Next, we investigated whether depletion of regulatory T cells prior to ablation was also able 
to enhance tumor immunity. Hereto, mice received anti-CD25 antibodies 4 days before 
ablation of their B16-OVA tumors. The anti-CD25 antibodies did not have any effect on the 
outgrowth of the B16-OVA tumors, yielding similar tumor-sizes at the day of ablation (see 
also Fig. 7b). Figure 7a shows that Treg depletion enhances the initially weak anti-tumor 
responses after both ablative techniques. This effect is comparable to the effects seen with 
anti-CTLA-4 treatment (see also figure 6). Treg depletion alone had no significant effect on 
primary tumors or rechallenges (Fig. 7b). Tetramer analysis confirmed the presence of IFN-
γ producing, tumor-specific T cells after the combination treatment, whereas after each 
individual treatment these cells were absent (Fig. 7c and 7d). In correspondence with the 
rechallenge model, somewhat less specific T cells were detected after radiofrequency 
ablation then after cryo ablation. 
Collectively, these data thus suggest that antigen uptake following ablation does 
only lead to enhanced numbers of activated tumor-specific T cells, when suppressive 
regulation is switched off. In situ tumor destruction plus immune activation leads to a more 
potent systemic anti-tumor response than either treatment modality alone. This treatment 
regimen allows for direct antigen-loading of DC in vivo without delivery of defined tumor 
antigens as in conventional DC vaccination. 
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Fig. 6: Anti-CTLA-4 improves therapeutic outcome of ablation. 0, 3 and 6 days after ablation of 
B16-OVA tumors, mice were injected i.p. with 200 µg anti-CTLA-4 antibodies or control IgG. (A) 40 days 
following ablation of tumor-bearing mice receiving antibodies, a tumor rechallenge was performed as 
described before. Figures depict survival curves demonstrating growth reduction/protection after ablation 
plus CTLA-4 treatment. As a control, tumor growth was monitored by injection of the same tumor dose 
into naïve mice (dotted lines). T=0 corresponds to the time of injection of the tumor re-challenge. P<0,05 
for CTLA-4 vs. IgG in both cryo and RF figures. One out of three representative experiments is shown 
(n=5-11). (B) Control experiment showing that CTLA-4 treatment by itself is insufficient to eradicate the 
primary tumor or re-challenges. Mice with established B16OVA tumors (5-7mm) were injected with 200 µg 
anti-CTLA-4 antibodies at day 10, 13 or 16 after tumor inoculation (solid line, arrows) or PBS (dotted line). 
Next, tumor growth was monitored in time (left panel). CTLA-4 treatment or PBS given 40 days prior to a 
B16OVA challenge (15x103 cells) did not affect survival of the mice (right panel). (C) At day 10 after 
ablation, a mix of LN and spleen cells was obtained from mice treated as indicated. T cells were harvested 
from spleen and LN and restimulated with irradiated, IFN-γ-treated B16-OVA cells and IL-2 for 10 days, 
followed by staining with OVA tetramers (Kb) and anti-CD8b. Depicted numbers represent the percentages 
of tetramer-positive cells within the CD8b+ population. (D) T cells from the same bulk cultures were used 
for restimulation with B16OVA cells. Supernatant from these cultures was harvested 24h later and 
analyzed for IFN-γ content by standard ELISA methods. Shown are means with sd from triplicates, *= 
P<0,05 vs. IgG. Experiments shown in figures (B-D) were repeated twice with comparable results. 
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Fig. 7: Depletion of regulatory T cells improves therapeutic outcome of ablation. 4 days prior to 
ablation of B16-OVA tumors, mice were injected i.p. with 200 µg anti-CD25 antibodies or control IgG. (A) 
40 days following ablation of tumor-bearing mice receiving antibodies, a tumor rechallenge was performed 
as described before. Figures depict survival curves demonstrating growth reduction/protection after 
ablation plus Treg depletion. As a control, tumor growth was monitored by injection of the same tumor 
dose into naïve mice (dotted lines). T=0 corresponds to the time of injection of the tumor re-challenge. 
P<0,05 for aCD25 vs. IgG in both cryo and RF figures. One out of three representative experiments is 
shown (n=5-9). (B) Control experiment showing that Treg depletion by itself is insufficient to eradicate the 
primary tumor or re-challenges. Mice with established B16OVA tumors (5-7mm) were injected with 200 µg 
anti-CD25 antibodies (solid line, arrow) or PBS (dotted line). Next, tumor growth was monitored in time 
(left panel). Treg depletion or PBS given 40 days prior to a B16OVA challenge (15x103 cells) did not affect 
survival of the mice (right panel). (C) At day 10 after ablation, a mix of LN and spleen cells was obtained 
from mice treated as indicated. T cells were harvested from spleen and LN and restimulated with 
irradiated, IFN-γ-treated B16-OVA cells and IL-2 for 10 days, followed by staining with OVA tetramers (Kb) 
and anti-CD8b. Depicted numbers represent the percentages of tetramer-positive cells within the CD8b+ 
population. (D) T cells from the same bulk cultures were used for restimulation with B16OVA cells. 
Supernatant from these cultures was harvested 24h later and analyzed for IFN-γ content by standard 
ELISA methods. Shown are means with sd from triplicates, *= P<0,05 vs. IgG. Experiments shown in 
figures (B-D), were repeated twice with comparable results. 
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Discussion 
 
Ex vivo generated mature dendritic cells (DC) have been shown to evoke tumor-specific 
responses in cancer patients10,26. DC vaccination is, however, time consuming and 
expensive, and in many cases the anti-tumor response falls short in strength to cure 
patients with established tumors. Herein, we report that tumor-debris created by 
radiofrequency and cryo ablation comprises an effective antigen source for DC. Moreover, 
we show that tumor ablation could be efficiently combined with immune modulating 
approaches. This creates an effective ‘in situ DC-vaccine’ capable of inducing protection 
against lethal tumor re-challenges. 
In situ tumor destruction with cryo, radiofrequency, or laser ablation has received 
increasing attention as a treatment modality for focal cancer19,22,27-29. However, little is 
known regarding the induction of immune responses after in situ tumor destruction or the 
fate of the generated tumor-debris. In our experiments we applied a mouse B16 tumor 
model, in which ex vivo generated DC vaccines are mostly only effective in a prophylactic 
setting. Applying two types of ablation techniques, we now demonstrated that tumor-
debris remaining in situ after tumor destruction creates an effective antigen depot for the 
induction of therapeutic anti-tumor immunity by DC. Using two distinct exogenous antigens 
(OVA and KLH) and two different approaches (radioactive and fluorescent labeling) to 
monitor the fate of antigens, we showed that the majority of antigens remained at the 
ablated site and that very little antigen spreading was observed except to the draining LN. 
Within the draining LN, a large percentage of DC acquired antigen as soon as one day and 
for at least three days following ablation. The in vivo loading of DC upon cryo ablation was 
significantly more efficient than with radiofrequency ablation (Fig. 2, 3). The exact nature 
of this difference remains to be elucidated but is likely related to the kind of antigens that 
are created by the ablation and/or to the endogenous signals that are produced upon 
tumor destruction. 
Our results do not provide answers on how exactly DC acquire their antigens. It is, 
for instance, not known whether DC travel to the tumor and take up the antigens locally, or 
that the antigen floats to the lymph node via lymphatics, where lymph node resident DC 
engulf this material. According to a recent study demonstrating LN-DC that accumulated 
antigen deposited in subcutaneous tissue30, both options might be occurring at the same 
time. The authors showed that antigen was first detected in LN-residing DC, followed by a 
second wave of antigen positive DC that migrated from the periphery into the LN. Both 
waves were required for efficient immune response induction and were dependent on the 
presence of the challenge site. Our finding that both at day 1 and day 3 after ablation 
antigen-loaded DC could be discerned from the LN suggests that similar dynamics take 
place in our model. In this context, it is interesting to note that antigen loading in tumor 
bearing control mice seemed to decline in these 3 days (see also Fig. 2d). Furthermore, we 
observed that antigens from the tumor depot preferentially accumulate in DC, but not in B-
cells or macrophages (not shown). The basis for the observed antigen accumulation in DC 
remains to be studied in more detail, but is likely related to their strategic location within 
the LN and their ability to retain antigens within their endocytotic compartment, whereas 
macrophages rapidly degrade antigens in their lysosomes.  
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The primary goal of conventional DC-based vaccination is to obtain tumor antigen-
loaded DC in the draining lymph nodes that are properly activated so that they do initiate 
immune responses. When comparing antigen positive DC loaded by ablation with antigen 
positive DC from a conventional DC vaccine we could demonstrate that far more DC 
containing antigen were present in the draining lymph nodes when radiofrequency or cryo 
ablation was performed (Fig. 3). Moreover, both ablation procedures were able to 
significantly increase the absolute number of DC per LN, whereas vaccination was less able 
to do so (Fig. 4). Analysis of the maturation state of antigen-loaded and unloaded DC in 
naïve, tumor-bearing and tumor-ablated mice revealed two interesting phenomena. First, 
DC that contained antigen expressed significantly higher levels of co-stimulatory molecules 
than antigen negative DC. These data are in line with in vitro data indicating that antigen 
uptake can affect DC activation31. Second, ablation resulted in a significant further increase 
in co-stimulatory molecule expression on antigen positive, but not antigen negative DC. We 
note that neither antibodies present after positive MACS sorting, nor TLR-ligands often 
present in OVA-batches32 did bias the CD80 staining on DC, as DC purified by negative 
selection showed similar results and OVA-Alexa did not mature DC in vitro (not shown). 
The exact nature of these ablation-dependent signals need further clarification, but may 
well represent cytokines or other endogenous mediators released after ablation32-35. It has, 
for instance, been shown that heat shock proteins and uric acid are present in cell debris, 
which both influence DC and other parts of the immune system36,37. Importantly, the 
observed ablation-induced increase in the number and maturation state of antigen loaded 
DC is apparently not sufficient to induce complete tumor protection of mice. 
Combination of ablation with in vivo immune modulation by either blockade of 
CTLA-4 signaling or depletion of regulatory T cells was shown to have beneficial effects in 
our rechallenge model. In both cases it provided a further delay in tumor growth compared 
to ablation alone. Importantly, only when CTLA-4 blockade or regulatory T cell depletion 
were performed together with ablation, significant amounts of active OVA specific T cells 
could be observed. It will be interesting to investigate the nature of the signals resulting in 
DC maturation and subsequent T cell expansion, and the possible effects of CTLA-4 
blockade or Treg depletion on this. Moreover, possible future research can aim on 
combination of CTLA-4 blockade and Treg depletion. It was demonstrated in a murine 
tumor model that this combination had a striking synergistic effect on tumor immunity7. 
 Collectively, our data show that in vivo tumor destruction in combination with 
systemic immune modulation creates a unique and potent, ‘in situ DC-vaccine’. Although 
radiofrequency ablation seems to be less efficient in loading DC compared to cryo ablation, 
both techniques can be efficiently combined with immune modulation. The fact that both 
ablative treatments as well as both the immune interventions are currently applied in 
cancer patients, makes this promising ‘in vivo DC-vaccine’ readily applicable in clinical 
settings. 
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Materials and Methods 
 
Animals 
9-11 weeks old female C57BL/6n mice were purchased from Charles River Wiga (Sulzfeld, 
Germany). Animals were held under specified pathogen-free conditions in the Central 
Animal Laboratory (Nijmegen, the Netherlands). All experiments were performed according 
to the guidelines for animal care of the Nijmegen Animal Experiments Committee. 
 
Tumors 
Mice were injected subcutaneously at the right femur with 500x103 cells of the OVA-
transfected murine melanoma cell line B16F10 (B16-OVA, clone MO5), which was kindly 
provided by dr. Kenneth Rock38, or wt B16F10. Cells were cultured and injected as 
described before24. Tumor volumes were scored every three days with the formula (AxB2) x 
0.4, in which A is the largest and B is the shortest dimension. Tumors were selected for 
ablation when their diameter measured between 5 to 7mm (d9-10) and only if the tumor 
was relatively round (>98% of mice).  
 
Radiofrequency ablation 
Animals were anaesthetized by isoflurane inhalation and properly shaved at the tumor area 
and on the contra-lateral flank. After placement and proper attachment of the contra 
lateral side onto an electricity-conducting pad (grounding pad), the tumor area was 
disinfected with alcohol. A radiofrequency ablation needle with active tip of 8 mm (SMK-15, 
Cotop, Amsterdam, the Netherlands) was inserted s.c. and placed in the middle of the 
tumor. After placement of the radiofrequency ablation needle, impedance could be 
evaluated on the radiofrequency lesion generator system (Model RFG-3B, Radionics, 
Burlington, MA, USA). Next, treatment was started by delivering radiofrequency energy. 
During a treatment cycle of +/- 80 sec., temperature could be monitored by means of a 
thermistor and thermocouple in the tip of the probe. Treatment was considered successful 
if a tip temperature of 75-80°C could be reached. 
 
Cryo ablation 
Animals were properly shaven and anaesthetized by isoflurane inhalation. The tumor area 
was disinfected with alcohol and subsequently wetted with distilled water. The tip of the 
liquid nitrogen cryo ablation system (CS76, Frigitronics, Shelton, CT) was placed onto the 
tumor and after proper freeze attachment, treatment was started. During two treatment 
cycles of +/-70 seconds the tumor and a small strip around it were frozen to less than -
100ºC. Treatment was considered successful when the whole tumor appeared frozen 
macroscopically.  
 
Re-challenge model 
Forty days after ablation of B16-OVA tumors, mice were challenged by subcutaneous 
injection at the contra-lateral femur of either 15x103 B16-OVA cells or 15x103 EL4 cells 
(numbers defined by titration). Injections were performed in 100 µl PBS. Mice were 
sacrificed when tumors reached a volume of ± 850 mm3.  
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111Indium conjugation and antigen monitoring 
KLH (Calbiochem, Darmstadt, Germany) (10 mg/ml) was conjugated with 240 µg cDTPA 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) in 0.1 M NaHCO3, pH 8.2, during 30 min. 
Unconjugated DTPA was removed by dialysis against 0.1 M Na-citrate buffer, pH 5.0. The 
KLH-DTPA conjugate (1.5 mg) was incubated with 1.5 mCi 111InCl3 (Mallinckrodt, Petten, 
The Netherlands) in 1.2 ml 0.1 M Na-citrate buffer, pH 5.0, during 30 min. Similar 
procedures were followed for the 111In-OVA conjugate. Radiochemical purity of each 
preparation (>95%) was determined by instant thin-layer chromatography (ITLC, Gelman 
Sciences Inc., MI). For antigen monitoring experiments, mice received intra-tumoral 
injections of OVA/KLH labeled with 111In (111In-OVA, 111In-KLH) or ovalbumin conjugated to 
Alexa-488 (OVA-Alexa-488) (Molecular Probes, Leiden, the Netherlands). Conjugates (20 
µg (=20µCi)) were injected directly before ablation in 20 µl PBS. At various time points 
after injection of the protein conjugates, mice were anesthetized and scintigraphic images 
were acquired using a γ-camera with 111In collimator (Siemens Orbiter, Siemens Inc. 
Hoffmann Estate, IL) as described previously15. For biodistribution studies mice were killed 
at different time points after injection of the protein conjugates. Liver, kidney, spleen, 
draining LN (r. sup. ing.) and non-draining LN (l. sup. ing.) were collected, weighed and 
counted in a γ-counter (1480 Wizard, Wallac Oy, Finland). Injection standards were taken 
for physical decay correction. In DC sorting experiments, mice received 111In-KLH i.t., and 
at different time points post ablation CD11c+ DC were sorted as described below and 
counted in the γ-counter.  
 
Magnetic bead cell sorting and flow cytometric analysis 
For antigen uptake experiments (111In-KLH and OVA-Alexa), draining LN’s from 5-8 mice 
were pooled and after crushing, dissociation in DNAse/collagenase/EDTA, and passage 
through nylon mesh39, cells were counted and sorted by standard MACS isolation with a 
MACS Midi column (Miltenyi Biotec). Positive selection of DC was done using CD11c beads 
(clone N418, Miltenyi Biotec, B.Gladbach, Germany), whereas negative 
selection/enrichment was done on the CD90 T cell marker (Thy1.2, 30.H12, Miltenyi 
Biotec). Sorts were verified by CD3e or CD11c (HL3) staining (not shown). Subsequently, 
cells were stained and analyzed on a FACS-CaliburTM system (BD) with the CELLQuest 
software. Stainings were performed using the following mAbs: CD11c-APC (HL3), CD8b-
FITC (53-5.8), CD3e-PE (17-A2), biotinylated CD80 (1G10), and streptavidin-PE. All 
antibodies were purchased from BD Pharmingen (Alphen a/d Rijn, the Netherlands). 
 
DC culture from GFP-transgenic mice 
GFP-expressing DC were cultured and injected as described elsewhere25. Briefly, bone 
marrow was collected from GFP-transgenic mice and cultured for 7 days in the presence of 
GM-CSF and IL-4. At day 7, 1 µg/ml LPS was added for 24 h maturation. Next, the non-
adherent fraction was harvested, washed and loaded for 1 hr with the Kb-peptide of OVA 
(SIINFEKL). 1x106 cells were injected subcutaneously or peri-tumorally at the femur. 
Isolation of LN cells and sorting was identical as described above.  
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Antibody treatments 
In the anti-CTLA-4 treatment mice received anti-CTLA-4 antibody (clone 9H105) at day 0, 3 
and 6 after ablation. Treg depletion was performed by injection of anti-CD25 antibodies 
(clone PC61,40) 4 days prior to ablation. Injections (200 µg) were done intra-peritoneal in 
PBS. In all cases depletion was successful as verified by FACS (not shown).   
 
Tetramer staining and IFN-γ measurement 
A T cell culture was obtained from spleen and draining LN’s of mice 10 days after ablation 
of a B16-OVA tumor or from naïve control mice. Stimulation of these cells (100x103) was 
performed by addition of irradiated, IFN-γ-treated, B16-OVA cells (50x103) in IL-2 (10 
CU/ml) supplemented culture medium. At day 5 and day 10, cells were collected and 
cleaned in a density gradient. At day 10 of culture, cells were stained for 15 min at RT by 
OVA-tetramers (H-2Kb) conjugated to APC (Pelimers, Sanquin, Amsterdam, the 
Netherlands), counterstained with CD8b, and analyzed by FACS. Same bulk cultures were 
used to collect supernatant 24 hours after stimulation with irradiated B16-OVA cells. 
Capture and biotinylated detection antibodies directed to mouse IFN-γ were purchased 
from BD Pharmingen and, using standard ELISA procedures, IFN-γ concentration was 
measured in 50 µl of supernatant. 
 
Statistical analysis 
Data were analyzed for statistical significance by Student’s T-test, except for the Kaplan 
Meier survival curves for which a log rank test was used. 
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Abstract 
 
Dendritic cells (DC) are professional antigen presenting cells that play a pivotal role in the 
induction of immunity. Ex vivo generated, tumor antigen-loaded mature DC are currently 
exploited as cancer vaccines in clinical studies. However, antigen loading and maturation of 
DC directly in vivo would greatly facilitate the application of DC-based vaccines. We have 
previously shown that in situ tumor destruction by ablative treatments efficiently delivers 
antigens for the in vivo induction of anti-tumor immunity. In this paper we demonstrate 
that although 20% of the draining lymph node DC acquire antigen after in situ cryo 
ablation, only partial protection against a subsequent tumor re-challenge is observed. 
However, we also demonstrate that a combination treatment of cryo ablation plus TLR9 
stimulation via CpG-ODN is far more effective in the eradication of local and systemic 
tumors than either treatment modality alone. Analysis of the underlying mechanism 
revealed that in situ tumor ablation synergizes with TLR9 stimulation to induce DC 
maturation and efficient cross-presentation in tumor-bearing mice, leading to superior DC 
function in vivo. Therefore, in situ tumor destruction in combination with CpG-ODN 
administration creates a unique, ‘in situ DC-vaccine’ that is readily applicable in the clinic. 
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Introduction 
 
Dendritic cells (DC) are the most potent antigen presenting cells of the immune 
system1. Immature DC reside in peripheral tissues where they take up and process 
antigens from their surroundings. In a stimulatory environment, like in an infection, 
immature DC undergo maturation and acquire the capacity to cross-present exogenous 
antigens in MHC class I 2,3. Particularly, the Toll-Like Receptor (TLR) proteins initiate the 
DC maturation process upon recognition of conserved pathogen-associated molecular 
patterns, like LPS or unmethylated CpG oligodeoxynucleotides (CpG-ODN)4-6. Maturation is 
accompanied by migration of the DC to the draining lymph node (LN), where they 
subsequently present antigens to immune cells to induce immunity. DC that did not 
perceive an activating environment do not mature and induce tolerance rather than 
immunity7. 
Since DC are critical in inducing effective immune responses, ex vivo generated DC 
are currently applied to stimulate anti-tumor immunity in clinical trials1,8-11. Although tumor-
specific responses have been obtained with tumor antigen-loaded DC-based vaccines, 
many questions regarding effective tumor antigens and DC migration remain 
unanswered8,12. Moreover, ex vivo generation of DC vaccines is time-consuming and costly. 
In vivo loading and maturation of DC would therefore greatly improve the applicability of 
DC vaccination. 
Recently, an antibody directed against the mouse DC antigen DEC-205 was shown 
to target OVA antigens preferentially to DC in vivo13. An alternative approach to create an 
in situ DC vaccine applied retrovirus-mediated expression of the chemokine CCL20 in 
tumors to increase the number of intra-tumoral DC14. As previously shown for ex vivo 
generated DC vaccines15, both studies confirmed that maturation of in vivo loaded DC by 
either agonistic anti-CD40 antibodies or the TLR9-ligand CpG-ODN was essential to induce 
a potent immune response. 
 Tumor-debris left in the body after in situ tumor destruction is suggested to be a 
potential tumor antigen source for DC in vivo, and would provide a direct way of in situ DC-
targeting, without the need for retroviral infection or construction of recombinant proteins. 
Tumor ablative treatments, like cryo or radiofrequency ablation, are successfully used in 
clinical settings to destruct different types of tumors16-20. Tumor ablation has been 
associated with the occurrence of immune activation, especially via the induction of 
inflammatory cytokines21,22. Nevertheless, patients treated with an ablative regimen 
generally develop systemic recurrences as a consequence of the outgrowth of distant 
micro-metastases, implying that in general no protective immune response is induced. 
Indeed, we recently demonstrated in a new mouse model for in situ tumor ablation that 
only weak anti-tumor immune responses are induced following tumor ablation alone23. 
Adoptive transfer experiments however showed that the immunity induced is tumor specific 
and T cell-dependent23. 
 Here, we demonstrate that when ablation of established B16 tumors (5-7mm) is 
combined with CpG-ODN administration, potent anti-tumor immune responses are induced. 
Results show that following ablation, an antigen depot is created from which 20% of DC 
found in the draining LN internalized tumor antigens. Moreover, the data indicate that 
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tumor ablation synergizes with CpG-ODN administration to not only enhance the number 
and maturation state of LN-DC, but also to increase cross-presentation2, leading to the 
efficient induction of CD8+ T cells. In situ tumor destruction together with DC activation by 
CpG-ODN constitutes a powerful ‘in situ DC-vaccine’ that is readily applicable in the clinic 
without prior knowledge of tumor antigens. 
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Results 
 
Cryo ablation creates an antigen depot essential for the induced anti-tumor immunity 
To determine whether the induction of protective immunity following in situ tumor-
destruction was dependent on the presence of the antigen depot, established B16OVA 
tumors (5-7mm) were cryo ablated. Successfully ablated mice (70% remains recurrence-
free) were re-challenged with either B16OVA or non-related EL4 thymoma cells according 
to the time schedule in Fig. 1a. In part of the mice, the ablated tumor was excised directly 
following ablation. In line with previous data (our unpublished results), cryo ablation of 
B16OVA tumors resulted in partial protection against a lethal B16OVA re-challenge (Fig. 
1b), but had no effect on the outgrowth of EL4 tumors (Fig. 1c). Excision of cryo ablated 
B16OVA tumors directly after ablation completely abrogated the observed anti-tumor effect 
(Fig. 1b). These data demonstrate that the tumor-specific immune response induced 
following cryo ablation is critically dependent on the presence of the ablated tumor 
material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Basal immunity is dependent on depot formation. (A) Time schedule outlining the different 
treatments as used in the experiments. Ten days after inoculation, the B16OVA melanomas (5-7mm) were 
cryo ablated. (B-C) Directly after ablation, the tumor was excised (x) or left in situ ({). Forty days later, 
tumor-free mice were re-challenged with B16OVA (B) or the non-related EL4 tumor (C). The survival of 
mice is depicted in which T=0 corresponds to the time of injection of the tumor re-challenge. As a control, 
tumor growth was monitored by injection of the same tumor cell dose into naïve mice (dotted lines). 
P<0,005 for ablation vs. excision. One out of two representative experiments is shown (n=5-10). 
 
Enhanced anti-tumor immunity upon ablation with CpG-ODN administration. 
The results from figure 1 also emphasize that the developed immunity to tumor 
rechallenges is sub-optimal. To explore whether the TLR9 ligand CpG-ODN 1668, could 
result in enhancement of the anti-tumor response, CpG-ODN was administered as a single 
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peri-tumoral injection directly following ablation. We observed that CpG-ODN injection 
alone, without ablation, did not have any effect on either the outgrowth of the primary 
tumor (Fig. 2c) nor lethal tumor re-challenges 40 days later (Fig. 2d). Interestingly, the 
combination of ablation of the tumor plus CpG-ODN administration resulted in complete 
protection against the B16OVA re-challenge 40 days later (Fig. 2a). These data thus 
demonstrate that the combination of in situ tumor destruction and CpG-ODN administration 
is superior in inducing anti-tumor immunity relative to either treatment alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Potent anti-tumor 
immunity following combined 
ablation/CpG-ODN treatment. 
Mice with established B16OVA 
melanomas (5-7mm) were cryo 
ablated. One hour after ablation, mice 
received 100 µg CpG-ODN (z) or PBS 
({) peri-tumorally. Forty days later, a 
re-challenge with 15x103 B16OVA 
cells was given s.c. in the contra-
lateral leg. (A) Survival curve 
demonstrating complete protection of 
tumor outgrowth after ablation with 
CpG-ODN.  P<0,005 for both lines vs. 
control. One out of three 
(B) Survival curve of tumor-free mice 
from A, after secondary re-challenges. 
After rejection of the first B16OVA re-
challenge, mice were re-challenged 
with 10x103 wild-type B16F10 cells 
inoculated s.c. on the left flank, and 
15x103 B16OVA cells on the right. 
Depicted is survival from the B16F10 
tumors (n=5-6 per group) in which 
P<0,005 for Abl./CpG vs. control. All 
B16OVA tumors were rejected again 
(not shown). As a control, tumor 
growth was monitored by injection of 
the same tumor dose into naïve mice 
(dotted line). T=0 corresponds to the 
time of injection of the tumor re-
challenge. One out of two 
representative experiments is shown. 
(C-D) Control experiment showing that CpG-ODN by itself is insufficient to eradicate the primary 
tumor or re-challenges. Established B16OVA tumors (5-7mm) were injected with 100 µg CpG-ODN 
(solid line, arrow) or PBS (dotted line). Tumor growth was monitored in time (C). S.c. injection of 
100 µg CpG-ODN (solid line) or PBS (dotted line), 40 days prior to a B16OVA challenge (15x103  cells) 
did not affect survival of the mice (D). 
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To study immunity to different antigens than the immuno-dominant OVA protein, 
the protected mice from figure 2a received a second set of rechallenges, including wild-
type B16F10 tumors. These mice completely rejected the re-challenge with B16OVA (not 
shown) but, more interestingly, were also partly protected against the poorly immunogenic, 
parental B16F10 tumor cells (Fig. 2b). Importantly, this occurred only when mice received 
co-treatment with CpG-ODN. This suggests that the combination treatment induces a 
potent memory response which is not only directed against the immuno-dominant epitopes 
but also to other (unknown) antigens expressed by the parental tumor. 
 
Cryo ablation leads to efficient in vivo antigen acquisition by LN CD11c(+) DC and 
synergizes with CpG-ODN in in vivo DC maturation. 
As we have recently found that following tumor ablation antigens are almost solely present 
in the CD11c(+) fraction at one and even three days after ablation (our unpublished 
results), we set out to explore the effect of in situ tumor destruction plus CpG-ODN 
administration on DC. These effects could provide a possible mechanism responsible for 
the potent induction of anti-tumor immunity. In order to visualize uptake of antigens by 
flowcytometry, chicken egg ovalbumin conjugated to the fluorophore Alexa-488 (OVA-
Alexa) was injected intra-tumoral (i.t.) prior to ablation. As shown in Fig. 3b, over 20% of 
all CD11c(+) DC became OVA-Alexa(+) after cryo ablation, whereas much less antigen 
uptake was observed in non ablated mice (<5%). Co-administration of CpG-ODN did not 
significantly effect the loading of DC in the draining LN.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: OVA-Alexa488 uptake following combined ablation/CpG-ODN treatment. (A-B) FACS 
analysis of CD11c(+) DC isolated from pooled LN suspensions of naïve, tumor-bearing or tumor-ablated 
mice (n=6 per group). Mice received 20 µg ovalbumin conjugated to Alexa-488 (OVA-Alexa488) i.t. just 
prior to the time point of ablation. One hour later, 100 µg CpG-ODN was injected peri-tumorally as 
indicated. Two days after the indicated treatments the number of OVA-Alexa(-) and OVA-Alexa(+) DC was 
determined. Fig. 3a shows a typical FACS plot after a CD11c positive beads sort. OVA-Alexa488(+) cells 
were solely present in the CD11c(+) fraction as shown by the CD11c(-) cells in the positive as well as the 
negative bead fractions. In Fig. 3b the CD11c(-) population is gated out. Values shown in panel B are 
percentages of OVA-Alexa(+) cells within the CD11c(+) fraction. 
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Next, we studied the effect of cryo ablation and CpG-ODN on DC maturation. 
Hereto, OVA-Alexa(+) or OVA-Alexa(-) DC were analyzed for expression of the maturation 
markers CD80 and CD86. Phenotypical analysis of OVA-Alexa(+) DC showed a 3-fold 
increase in CD80 expression relative to OVA-Alexa(-) DC in tumor-bearing and naïve mice 
(MFI’s 1007, 332 and 315 resp.) (Fig. 4a and b). Following ablation, CD80 expression 
further increased on OVA-Alexa(+) DC but had no effect on OVA-Alexa(-) DC (MFI 1374 
and 369 resp.). This finding indicates that DC that acquired OVA-Alexa, preferentially up-
regulate CD80, which is further enhanced by cryo ablation. 
CpG-ODN injection alone also resulted in a significant increase in CD80 expression 
on OVA-Alexa(-) DC in both control and tumor-bearing mice (MFI 315 to 536, 332 to 605) 
and in a further increase on OVA-Alexa(+) DC from tumor-bearing mice (MFI 1007 to 
1342) (Fig. 4b). When CpG-ODN injection was combined with ablation, an additive 
maturation of OVA-Alexa(-) DC (MFI 369 to 999) was observed. Most surprisingly, CD80 
expression on OVA-Alexa(+) DC increased tremendously relative to DC from tumor-bearing 
mice (MFI 1374 to 2682). This effect on DC maturation of OVA-Alexa(+) DC is synergistic 
when compared to the effects seen when ablation or CpG-ODN are provided separately. 
Moreover, the observed synergy was not related to eradication of the tumor and its 
immune suppressive environment, as in vivo ablation of ex vivo created tumor lysates 
demonstrated comparable synergy on maturation (Fig. 5). Similar, but somewhat less 
profound effects were observed for CD86 expression (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Synergistic maturation of DC after combined ablation/CpG-ODN treatment. (A-B) FACS 
analysis of CD11c(+) DC isolated from pooled LN suspensions of tumor-bearing or tumor-ablated mice 
(n=6 per group). Mice received 20 µg ovalbumin conjugated to Alexa-488 (OVA-Alexa488) i.t. just prior to 
the time point of ablation. One hour later, 100 µg CpG-ODN was injected peri-tumorally as indicated. Fig. 
4a shows typical FACS histograms of co-stainings with CD80 on OVA-Alexa(+) DC, presented as bars in 
Fig. 4b. Data indicate that high levels of CD80 expression are only observed when CpG-ODN and ablation 
are combined. Values in panel B are shown as mean fluorescence intensities with sd from three 
independent experiments, *=P<0,05. 
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Increased DC numbers in draining lymph nodes after cryo ablation plus CpG-ODN 
administration. 
Analysis of the absolute numbers of CD11c(+) DC in the draining LNs following the 
different treatments demonstrated that both injection of merely CpG-ODN or the presence 
of a tumor resulted in a two-fold increase in DC numbers relative to naïve mice (Fig. 6). 
Ablation alone resulted in a 3-fold increase in the numbers of LN-DC, while tumor ablation 
combined with CpG-ODN treatment was again most effective. This implies that the total 
number of DC actually loaded with tumor antigen is even higher than can be concluded 
from the relative numbers. 
 
CpG-ODN following ablation enables cross-presentation of tumor derived antigens  
To assess the function of DC following ablation, CpG-ODN administration, or the 
combination treatment, we determined the ability of the CD11c(+) DC to cross-present 
antigens to MHC class I and II-restricted OVA-specific T cell hybridomas. Significant 
activation of MHC class II-restricted DO11.10 cells was readily observed upon co-culturing 
with CD11c(+) DC isolated from tumor ablated mice (Fig. 7a). In contrast, CD11c(+) DC 
from tumor-bearing mice without ablation did not activate DO11.10, nor did CD11c(-) cells. 
The administration of CpG-ODN to these mice increased DO11.10 activation only to a small 
extend. CpG-ODN administration after ablation significantly increased DO11.10 activation 
by CD11c(+) cells compared to tumor ablation or tumor alone and now also the CD11c(-) 
cell fraction of these mice displayed DO11.10 activating properties. 
Next, we analyzed the cross-presenting capacity of these DC by testing their ability 
to activate the MHC class I-restricted OVA-specific B3Z T cells. Strikingly, only DC from 
mice treated with cryo ablation plus CpG-ODN were able to efficiently activate B3Z T cells 
Fig. 5: DC maturation is dependent on 
ablation. (A) 10x106 B16OVA cells were lysed 
by freeze thaw cycles and injected s.c.. After 
co-injection of OVA-Alexa and CpG-ODN as 
indicated, the injection depot was cryo ablated 
or left untreated. Next, CD80 expression on 
Alexa-488 positive DC (6 mice pooled per 
group) was determined. Depicted are MFI’s 
obtained from one of two experiments with 
comparable results. 
Fig. 6: Effects on total DC counts Shown 
are absolute CD11c(+) numbers per LN after 
magnetic bead sorting. Results are shown as 
means with sd, *=P<0,05. Data were obtained 
from three independent experiments. 
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(Fig. 7b). Little or no activation of B3Z T cells could be discerned after ablation or CpG-
ODN administration alone. Since DC from ablated mice that did not receive CpG-ODN 
treatment did process and present antigens to the MHC class II-restricted DO11.10 T cells, 
these data demonstrate that efficient cross-presentation after ablation by DC in vivo is co-
dependent on CpG-ODN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Efficient cross-presentation 
following combined ablation/CpG-
ODN treatment. (A-B) Two days after 
ablation of B16OVA tumors with or 
without co-injection of 100 µg CpG-ODN, 
CD11(+) DC were sorted from draining 
LN’s (n=7-8). Subsequently, they were 
cultured overnight with MHC class I or 
MHC class II, OVA-specific T cell 
hybridomas (B3Z and DO11.10 resp.). T 
cell activation was measured by IL-2 
production (DO11.10, (A)) or LacZ 
production (B3Z, (B)). B6-sigOVA is a 
cell-line presenting high levels of the 
MHC class I OVA peptide-complex but no 
OVA class II peptide-complexes on its 
cell surface. Figures show means with sd 
from triplicates, *=P<0,05. One 
experiment out of two is shown. (C) 
Induction of OVA-specific CTL was 
determined. At day 10 after ablation, a 
mix of LN and spleen cells was obtained 
from mice treated as indicated. T cells 
were harvested and restimulated with 
irradiated, IFNγ-treated B16OVA cells 
and IL-2 for 7 days, followed by staining 
with OVA tetramers (Kb) and anti-CD8b. 
Depicted numbers represent the 
percentages of tetramer-positive cells 
within the CD8b+ population. 
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Finally, we analyzed mice with ablated B16OVA tumors (in the absence of 
exogenously added OVA) for the presence of OVA-specific CD8+ T cells by Kb-tetramer 
analysis. The data revealed that, consistent with the observed cross-presentation, 
abundant OVA-specific CD8+ T cells were only present in combined ablation/CpG-ODN 
treatment (Fig. 7c). 
Collectively, these data thus indicate that cryo ablation plus CpG-ODN results in 
synergistically improved DC functions of OVA-Alexa(+) DC, as well as a large increase in 
the total numbers of these DC. 
 
CpG-ODN injection following ablation generates therapeutic anti-tumor immunity 
Since ablation is often used in advanced disease, when micro-metastasis are present, the 
potency of the model was analyzed in a stringent wild-type B16F10 metastasis model. 
Hereto, B16F10 tumor-bearing mice were injected with 30x103 B16F10 cells in the contra-
lateral flank 3 days prior to the ablation/CpG-ODN treatment of the primary B16F10 tumor. 
Subsequently, the growth of this ‘metastasis’ was monitored. Interestingly, next to 
successful elimination of the primary tumor in mice treated with ablation/CpG-ODN, 
regression of the established contra-lateral B16F10 metastasis was observed in 40% of the 
mice, and a growth reduction in the others. As expected, cryo ablation or CpG-ODN alone 
had no or little effect on outgrowth of the metastasis and gave 100% tumor take (Fig. 8a). 
In the course of the experiments described above, we made the intriguing 
observation that CpG-ODN administration improved the success-rate of the B16OVA cryo 
ablation itself. Whereas 30% of the mice normally developed a local recurrence within 15 
days following cryo ablation, ablation plus CpG-ODN treatment completely prevented the 
outgrowth of local recurrences (Fig. 8b). 
These results thus demonstrate that ablation directly followed by CpG-ODN 
administration has a fast local effect in addition to the induction of a broad protective 
memory response. 
 
 In conclusion, these data indicate that in situ tumor destruction plus TLR9 
stimulation leads to a more potent local and systemic anti-tumor response than either 
treatment modality alone. This treatment regimen allows for direct antigen-loading and 
maturation of DC in vivo without delivery of defined tumor antigens. 
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Fig. 8: CpG-ODN improves therapeutic outcome of ablation. (A) Stringent wild-type B16 metastasis 
model. Three days before ablation of a wild-type B16F10 tumor with (z) or without ({) co-administration 
of 100 µg CpG-ODN, 30x103 B16F10 cells were inoculated contra-laterally of the primary tumor. After 
ablation was performed, growth of the metastasis was monitored. Tumor take was monitored by injection 
of the same tumor dose into naïve mice (dotted line). S.c. injection of CpG-ODN contra-lateral of the 
metastasis was performed as a control (∆). T=0 corresponds to the time of injection of the metastasis. 
P<0,005 for ablation/CpG vs. ablation alone. One out of two representative experiments is shown (n=5-12 
per group). (B) After ablation of B16OVA tumors, mice were monitored for tumor recurrence at the site of 
ablation. Shown are mice that received only ablation or ablation with 5 or 100 µg CpG-ODN peri-tumorally. 
Values are obtained from several experiments resulting in 20-60 mice per group. 
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Discussion 
 
In recent years, ex vivo generated mature dendritic cells (DC) have been shown to evoke 
tumor-specific responses in cancer patients24-26. DC vaccination is, however, time 
consuming and expensive, and in many cases the anti-tumor response falls short in 
strength to cure patients with established tumors. Herein, we report that tumor-debris 
created by ablation of established tumors comprises an effective antigen source for DC in 
vivo. Moreover, we show that tumor ablation synergizes with the TLR9-ligand CpG-ODN to 
augment DC function and cross-priming in vivo. This creates an effective ‘in situ DC-
vaccine’ capable of inducing protection against lethal tumor re-challenges as well as 
regression of pre-existing metastases. 
In situ tumor destruction with cryo, radiofrequency, or laser ablation has received 
increasing attention as a treatment modality for focal cancer16-20,27-29. However, little is 
known regarding the induction of immune responses after in situ tumor destruction or the 
fate of tumor-debris. Applying a mouse B16 tumor model for cryo ablation, we recently 
demonstrated that tumor-debris remaining in situ after tumor destruction creates an 
effective antigen depot for DC in vivo. Using intra-tumoral injection of 111indium-labeled 
KLH proteins prior to ablation, we could monitor the fate of tumor-debris and demonstrate 
that tumor derived antigens were efficiently taken to the draining lymph node. We showed 
that within the draining LN, up to 20% of DC contained antigen as soon as one day and for 
at least three days following ablation (our unpublished results). The current analysis of the 
immune response induced following tumor ablation revealed that removal of the antigen 
depot directly after ablation completely abrogated the development of specific immunity. 
Although a tumor-specific immune response could be observed when leaving the tumor-
debris in situ, mice were poorly protected against a subsequent tumor challenge. These 
data indicate that, despite efficient loading of DC takes place, immune activation following 
tumor ablation is sub-optimal. 
In order to increase anti-tumor immunity following ablation, we explored 
stimulation of TLR9 by CpG-ODN either alone or in combination with ablation. Peri-tumoral 
injection of CpG-ODN has previously been shown to elicit coordinated T cell responses and 
induction of anti-tumor immunity in relatively immunogenic mouse models30. In more 
challenging settings with large tumor masses and less immunogenic tumors the efficacy of 
CpG-ODN alone was less profound. Using different tumor models we now demonstrate that 
ablation plus CpG-ODN treatment of 5-7mm B16OVA tumors resulted in complete 
protection against a lethal B16OVA tumor re-challenge, and co-incided with the presence of 
OVA-specific CD8+ T cells. As neither CpG-ODN, nor ablation alone was able to protect all 
mice, we conclude that both CpG-ODN and ablation both are essential in the induction of 
immunity. Recent mouse studies also indicated that CpG-ODN induced tumor growth delay 
and improved survival when combined with radiotherapy31 or chemotherapy32, although 
the mechanism responsible for these effects remained to be determined.  
Interestingly, the combination treatment of B16OVA tumors was also able to 
protect 50% of the mice against outgrowth of the poorly immunogenic parental B16F10 
tumor, indicating the simultaneous induction of responses against multiple epitopes. 
Moreover, local CpG-ODN stimulation also improved the efficacy of the ablation itself, most 
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likely by activation of the innate immune system. When applied to a wild-type B16F10 
metastasis model, ablation plus CpG-ODN treatment induced significant regression of pre-
existing B16F10 metastases (Fig. 8). In addition, we also made the striking observation 
during the course of our studies that local recurrence percentages at the ablated site were 
reduced from 30% to 0% when CpG-ODN was administered following ablation (Fig. 8). 
 To unravel the mechanism responsible for the induction of potent anti-tumor 
immunity following combination treatment in vivo, we focussed on the effects on DC. 
Analysis of the maturation state of antigen-loaded and non-loaded DC in naïve, tumor-
bearing, tumor-ablated and CpG-ODN-treated mice revealed several interesting 
phenomena. First, DC that contained antigen expressed significantly higher levels of co-
stimulatory molecules than antigen negative DC. These data are in line with in vitro data 
indicating that antigen uptake can affect DC activation33. Secondly, ablation resulted in a 
significant further increase in co-stimulatory molecule expression on antigen positive, but 
not antigen negative DC. Thirdly, CpG-ODN administration alone resulted in an increase in 
co-stimulatory molecule expression on antigen positive DC, but also on antigen negative 
DC. Importantly, the observed increase in the number and maturation state of antigen-
loaded DC, induced by CpG-ODN or ablation alone, is apparently not sufficient to induce 
complete tumor protection of mice. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: (a) Exogenous and endogenous tumor antigens lead to identical DC maturation. At day 
two after ablation with or without co-injection of 100 µg CpG-ODN, FACS analysis was done on sorted DC 
from LN’s. Prior to ablation, 20 µg ovalbumin conjugated to Alexa-488 (OVA-Alexa488) or PBS was 
injected i.t.. Histograms show a comparable induction of the CD80-high DC (arrows), independent of OVA 
administration. In the lower panel the CD80-high cells corresponded to the OVA-Alexa488(+) cells. (b) 
OVA-Alexa-488 contains no substantial amounts of activating TLR-ligands. D1 dendritic cells 
were incubated o/n with medium, 500 µg/ml OVA-Alexa-488, 1 µg/ml CpG-ODN or both. Next, CD80 
expression was analyzed. Other batches of impure OVA did show maturation (not shown). 
 
 
The finding that antigen uptake-dependent DC maturation was comparable with or 
without exogenously added OVA-Alexa (see also Fig. 9a) provides strong support for these 
model antigens truly mimicking endogenous tumor antigens. In addition to this, OVA-
specific T cells were readily observed following ablation plus CpG-ODN administration in a 
setting where no additional OVA was administered (Fig. 7c). We also note that neither 
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antibodies used during positive MACS sorting, nor TLR-ligands often present in OVA-
batches34 did bias the CD80/CD86 staining on DC, as DC purified by negative selection 
showed similar results and OVA-Alexa did not mature DC in vitro (not shown and Fig. 9b). 
Strikingly, CpG-ODN administration in combination with tumor ablation resulted in a 
tremendous increase in co-stimulatory molecule expression (Fig. 4b). These data are 
indicative for a synergistic interplay between signals induced by ablation and those 
resulting from TLR9 triggering. The exact nature of these ablation-dependent signals needs 
further clarification, but may well represent cytokines released after ablation35-37. 
Alternatively, endogenous TLR-ligands like stress-induced factors might be involved in the 
synergistic maturation of DC observed38-40. An additional explanation for this synergistic DC 
maturation could be the destruction of the tumor itself. Ablation of the tumor would 
eliminate tumor-induced factors preventing full responsiveness to CpG-ODN15. However, 
since synergistic DC maturation was comparable when ablation with CpG-ODN was 
performed on intact tumors or on injected B16OVA tumor lysates, in our model the 
negative influence of the tumor-milieu on DC function is limited (Fig. 5). 
The combined ablation and CpG-ODN treatment not only affected the phenotype of 
LN-DC but also their capacity to cross-present antigens and activate T cells. Although 
ablation alone was able to generate DC that presented antigens in MHC class II, CpG-ODN 
co-administration was essential to obtain MHC class I presentation and CD8 cytotoxic T cell 
activation. The role of CpG-ODN in cross-presentation by DC in vitro has recently been 
reported41,42, but had not been formally shown in vivo. Our data thus provide for the first 
time direct evidence for the crucial role of CpG-ODN in cross-presentation of antigens by 
DC in vivo. 
An alternative approach to target antigen to DC in vivo explored antibodies directed 
against the mouse DC antigen DEC-205, which were shown to target OVA antigens 
preferentially to DC in vivo13. Others applied retrovirus-mediated expression of the 
chemokine CCL20 in tumors to increase the number of intra-tumoral DC14. As previously 
shown for ex vivo generated DC vaccines, both studies confirmed that maturation of in vivo 
loaded DC by either agonistic anti-CD40 antibodies or the TLR9-ligand CpG-ODN was 
essential to induce a potent immune response. Our results demonstrated that the tumor-
debris left in the body after in situ tumor destruction forms a potent tumor antigen source 
for DC in vivo, and provides a much more direct way of in situ DC-targeting, without the 
need for retroviral infection or construction of recombinant proteins. 
 
 Collectively, these data show that in vivo tumor destruction in combination with 
CpG-ODN administration creates a unique and potent, ‘in situ DC-vaccine’. The fact that 
both treatment modalities are currently applied separately in cancer patients, makes that 
this promising ‘in vivo DC-vaccine’ is readily applicable in clinical settings. 
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Materials and Methods 
 
Animals 
9-11 weeks old female C57BL/6n mice were purchased from Charles River Wiga (Sulzfeld, 
Germany). Animals were held under specified pathogen-free conditions in the Central 
Animal Laboratory (Nijmegen, the Netherlands). All experiments were performed according 
to the guidelines for animal care of the Nijmegen Animal Experiments Committee. 
 
Tumors 
Mice were injected subcutaneously at the right femur with 500x103 cells of the OVA-
transfected murine melanoma cell line B16F10 (B16OVA, clone MO5), which was kindly 
provided by dr. Kenneth Rock43, or wt B16F10. Cells were cultured and injected as 
described before23. Tumor volumes were scored every three days with the formula (AxB2) x 
0.4, in which A is the largest and B is the shortest dimension. Tumors were selected for 
ablation when their diameter measured between 5 to 7mm (d9-10) and only if the tumor 
was relatively round (>98%).  
 
Cryo ablation and in vivo procedures 
Animals were properly shaven and anaesthetized by isoflurane inhalation. The tumor area 
was disinfected with alcohol and subsequently wetted with distilled water. The tip of the 
liquid nitrogen cryo ablation system (CS76, Frigitronics, Shelton, CT) was placed onto the 
tumor and after proper freeze attachment, treatment was started. During two treatment 
cycles of +/-70 seconds the tumor and a small strip around it was frozen to less than -
100ºC. Treatment was considered successful when the whole tumor appeared frozen 
macroscopically. In Fig. 1b, the ablated tumor was excised afterwards, after which the skin 
was seamed by clamps. For antigen monitoring experiments, mice received intra-tumoral 
injections of ovalbumin conjugated to Alexa-488 (OVA-Alexa-488) (Molecular Probes, 
Leiden, the Netherlands). Conjugates (20 µg) were injected directly before ablation in 20 µl 
PBS. CpG-ODN 1668 (5'-TCCATGACGTTCCTGATGCT-3') (total backbone 
phosphorothioated) (Sigma Genosys, Haverhill, UK) was used for in vivo immune 
activation. 100 µg CpG-ODN in 30 µl PBS was injected 1 hour after ablation, divided over 
three injections in the peri-tumoral area. In Fig. 5, 10x106 B16OVA cells were lysed by 
freeze thaw cycles and injected s.c. with OVA-Alexa, after which similar ablative treatment 
was performed as described above.  
 
Magnetic bead cell sorting and flow cytometric analysis 
For antigen uptake experiments, draining LN’s from 5-8 mice were pooled and after 
crushing, dissociation in DNAse/collagenase/EDTA, and passage through nylon mesh44, 
cells were counted and sorted by standard MACS isolation with a MACS Midi column. 
Positive selection of DC was done using CD11c beads (clone N418, Miltenyi Biotec, 
B.Gladbach, Germany), whereas negative selection/enrichment was done on the CD90 T 
cell marker (Thy1.2, 30.H12, Miltenyi Biotec). Sorts were verified by CD3e or CD11c (HL3) 
staining (not shown). Subsequently, cells were stained and analyzed on a FACS-CaliburTM 
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system (BD) with the CELLQuest software. Staining was performed using the following 
mAbs: CD11c-APC (HL3), CD8b-FITC (53-5.8), CD3e-PE (17-A2), biotinylated CD80 (1G10), 
biotinylated CD86 (GL-1) and streptavidin-PE. All antibodies were purchased from BD 
Pharmingen (Alphen a/d Rijn, the Netherlands). 
 
Antigen presentation to B3Z and DO11.10  
The B3Z T cell hybridoma contains lacZ that is induced upon engagement of its TCR that 
recognizes OVA peptide (257-264) in the context of H2Kb 45, whereas the DO11.10 T cell 
hybridoma, produces IL-2 upon engagement of its TCR that recognizes OVA-peptide (323-
339) bound to I-Ad (but cross-reacts to I-Ab). β-Galactosidase activity of the B3Z T cells 
(100x103/well) after overnight incubation with LN-derived, CD11c sorted DC (100x103/well) 
was determined by incubating with 0.15 mM chlorophenolred-β-d-galactopyranoside 
(Calbiochem), 9 mM MgCl2, 0.125% Nonidet P-40 and 100 mM β-mercaptoethanol in PBS 
for 4 h at 37°C, and OD595 was determined. Same procedures were performed with the 
DO11.10 cells, but here IL-2 production was determined using standard ELISA procedures. 
As control the B6MEC transfected with murine B7.1, H-2Kb, and a construct expressing an 
ER targeting signal sequence, followed by the OVA257–264 CTL epitope SIINFEKL (B6-B7.1-
sigOVA) was used46. 
 
Tetramer stainings 
A T cell culture was obtained from spleen and draining LN’s of mice 10 days after ablation 
of a B16OVA tumor or from naïve control mice. Stimulation of these cells (100x103) was 
performed by addition of irradiated, IFN-γ-treated, B16OVA cells (50x103) in IL-2 (10 
CU/ml) supplemented culture medium. At day 5 and day 10, cells were collected and 
cleaned in a density gradient. At day 10 of culture, cells were stained for 15 min at RT by 
OVA-tetramers (H-2Kb) conjugated to APC, which were a kind gift of S.H. van der Burg 
(LUMC, Leiden, The Netherlands) and counterstained for CD8b.2. 
 
Re-challenge and metastasis model 
Forty days after ablation of B16OVA tumors, mice were challenged by subcutaneous 
injection at the contra-lateral femur of either 15x103 B16OVA cells or 15x103 EL4 cells 
(numbers defined by titration). Some mice that rejected the first re-challenge received a 
second set of re-challenges with 15x103 B16OVA cells and 10x103 B16F10, inoculated on 
day 120 (end of Fig. 1a) on the right and left flank. Injections were performed in 100 µl 
PBS. Mice were sacrificed when tumors reached a volume of ± 850 mm3. In the metastasis 
model, 30x103 B16F10 cells were injected contra-laterally of the matching tumor to ablate. 
Three days later, cryo ablation was performed on the primary tumor and 100 µg CpG-ODN 
was administered peri-tumoral. Next, the growth of the metastasis was monitored. 
 
Statistical analysis 
All data were analyzed for statistical significance by Student’s T-test, except for the Kaplan 
Meier survival curves for which a log rank test was used. 
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Abstract 
 
Regulatory T cells (Treg) play a central role in the suppression of immune reactions and 
prevention of autoimmune responses harmful to the host. During acute infection however, 
Treg might hinder effector T cell activity directed towards the elimination of the pathogenic 
challenge. Pathogen recognition receptors from the Toll-like receptor (TLR) family 
expressed by innate immune cells are crucial for the generation of effective immunity. We 
have recently shown the CD4+CD25+ Treg subset in TLR2-/- mice to be significantly 
reduced compared with wildtype littermate control mice, indicating a link between Treg and 
TLR2. Here we report that the TLR2-ligand Pam3Cys, but not LPS (TLR4) or CpG-
ODN(TLR9), directly acts on purified Treg in a MyD88-dependent fashion. Moreover, when 
combined with TCR-stimulation, TLR2-triggering augmented Treg proliferation in vitro and 
in vivo and resulted in a temporal loss of the suppressive Treg phenotype in vitro by 
directly affecting the Treg themselves. Importantly, in TLR2-/- recipient mice, adoptively 
transferred wildtype Treg were neutralized by systemic administration of TLR2-ligand 
during the acute phase of a Candida albicans infection resulting in a 100-fold reduced 
Candida outgrowth. This demonstrates that also in vivo TLR2 controls the function of Treg 
and establishes a direct link between TLRs and the control of immune responses through 
regulatory T cells. 
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Introduction 
 
It is now evident that the rediscovered regulatory/suppressor T cells (Treg) play a 
dominant role in our immune system (reviewed in 1,2). Two types of Treg can be 
distinguished, CD4+CD25+ intrinsic Treg, that are already present in the naïve individual, 
and those induced in the periphery. T cell receptor (TCR) triggering renders intrinsic Treg 
able to suppress both CD4+ and CD8+ lymphocytes3,4 via a process that is cell-cell-contact 
dependent, though the exact mechanism is not yet identified. Several studies have shown 
that their depletion results in autoimmune syndromes like thyroiditis, gastritis, insulin-
dependent diabetes mellitus, colitis and arthritis5-8. On the other hand, active Treg hinder 
the induction of immune responses against pathogens and tumors9-11, emphasizing the 
importance of a tight control of these regulators themselves. Importantly, IL-23, IL-612 and 
strength of the TCR signal13 have been reported to release effector T cells from Treg 
mediated suppression.  
Besides these control mechanisms regulating the sensitivity of effector T cells to 
suppression, still many questions remain regarding regulatory mechanisms acting at the 
level of the Treg themselves. Treg are able to proliferate in normal un-manipulated mice14. 
In addition, the finding that CD80/CD86-deficient mice have significantly decreased 
numbers of Treg indicates a role for co-stimulation in Treg homeostasis15. Furthermore, 
mature DC have been reported to induce Treg expansion16. In line with this, TLR-triggered 
DC were recently shown to induce Treg proliferation by a cooperative action of IL-1 and IL-
617. Together, there is accumulating evidence that Treg anergy can be overcome when the 
right stimulatory environment is provided, showing that Treg play a dynamic role in the 
control of immune responses. 
One family of receptors involved in immune-regulation is the Toll-like receptor 
(TLR) family, a class of receptors that recognizes pathogen-associated molecular patterns 
(PAMPs) or endogenous inflammation-associated molecules18. So far, thirteen receptors 
have been identified with different or overlapping ligands. TLR1/2 heterodimers for 
example can recognize bacterial lipoproteins, TLR4 recognizes lipopolysaccharide (LPS) 
from Gram-negative bacteria and TLR9 recognizes bacterial DNA (unmethylated CG-
motifs). TLRs are abundantly expressed on innate immune cells, like macrophages and 
DCs, and TLR9-induced IL-6 production by DC releases effector T cells from Treg mediated 
suppression12. Recently, TLRs were also found on T cells including Treg19. Therefore, we 
hypothesized that some TLR-ligands might directly affect the Treg. We have previously 
shown that Treg numbers in the circulation of TLR2-/- mice, but not TLR4-/- mice, are 
significantly reduced compared to their wildtype littermate controls10. Moreover, we and 
others have shown that the immune response against the fungal pathogen Candida 
albicans is affected by Treg9,10. Using highly purified intrinsic Treg and conventional CD4+ T 
cells, we now show that TLR2-triggering on the intrinsic Treg themselves results in 
proliferation of these regulatory T cells in vitro and in vivo. Moreover, in presence of the 
TLR2-ligand Pam3Cys the suppressive phenotype of the regulatory T cells is temporarily 
abrogated in vitro and in vivo, thereby enhancing the anti-fungal response in an acute 
infection model. After removal of the TLR2-trigger the Treg fully regained their suppressive 
capabilities. These findings demonstrate that in addition to their effects on antigen 
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presenting cells (APC), TLR-ligands can directly act on the intrinsic regulatory T cell 
resulting in dynamic modulation of the immune response. 
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Results 
 
TLR2-signalling modulates CD4+CD25+ T cell levels in vivo. 
Recently, we demonstrated decreased numbers of circulating CD4+CD25+ regulatory T cells 
(Treg) in blood of TLR2-/- mice, but not of TLR4-/- mice10. These findings suggest a role 
for TLR2-signaling in Treg homeostasis and/or function. As TLR2-signaling is critically 
dependent on the adaptor molecule MyD8818, we now determined the relative number of 
regulatory T cells present in blood and spleen of MyD88 deficient mice and their wildtype 
littermate controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B-C) TLR2-signaling modulates CD4+CD25+ T cell numbers. (B) Blood from TLR2-/-, MyD88-/- 
and their wildtype littermate controls as well as from PAM-challenged mice was analyzed by flow 
cytometry for CD4 and CD25 expressing cells. Values in the upper-right quadrant indicate the percentage 
CD4+CD25+ T cells from the total number of CD4+ T cells. Data are representative of three independent 
experiments with four mice per group. (C) PAM induces an increase in FoxP3+ cells in the periphery. Mice 
(four per group) were challenged i.p. with 20 µg PAM and two days later the percentage of CD4+FoxP3+ T 
cell of the total CD4+ T cells in the blood was determined by flowcytometry. Data indicate the average 
relative increase with saline control set at 1. *=P<0.05 for saline control compared with PAM treated 
group) 
Fig. 1: (A) Decreased CD4+CD25+ T cell numbers 
in MyD88 deficient mice. Blood and spleens from 
MyD88-/- mice and their littermate +/+ controls (4 per 
group) were analyzed by flow cytometry for relative 
CD4+CD25+ T cell numbers. Data indicate mean 
percentage of CD4+CD25+ T cell numbers of total CD4+ 
T cells ±SEM. Representative results of three 
experiments are shown. (*=P<0.02 with wildtype 
controls).
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As shown in Fig. 1a, MyD88-/- mice, like TLR2-/- mice10, contained significantly lower 
numbers of CD4+CD25+ T cells compared to their wildtype controls. In contrast, the 
percentage of CD4+CD25- conventional Th cells did not differ between MyD88 and control 
mice (15.9 ± 1.2 and 17.6 ± 1.5 respectively) as well as TLR2-/- mice and their controls 
(17.7 ± 2.1 and 18.3 ± 1.9 respectively). In Fig. 1b and c, representative CD4+CD25+ T 
cell stainings from individual TLR2-/- and MyD88-/- mice and their wildtype (WT) littermate 
controls are shown. The decreased Treg numbers in both the TLR2- and MyD88-knockout 
mice indicate that a lack of TLR2-signaling is responsible for the observed decrease of 
CD4+CD25+ T cell numbers in vivo. 
These results thus demonstrate a relation between the TLR2/MyD88-signaling pathway and 
Treg numbers in vivo. 
 
TLR-triggering in the presence of APC modulates Treg in vitro. 
TLR2 is expressed by cells of the innate immune system, including APC, as well as by Treg 
cells19. TLR-triggering compounds are known to promote APC activation18, resulting in the 
production of cytokines affecting T cell function12. Alternatively, some TLR-ligands might 
directly act on the Treg cells themselves. To address the role of TLRs in Treg function, we 
analyzed the effect of different TLR-ligands on Treg proliferation in vitro. As expected, Treg 
cells cultured in the presence of irradiated unstimulated APC and soluble anti-CD3 did not 
display proliferation (Fig. 2a), in accordance with their anergic state20. Addition of various 
TLR-ligands to these APC/Treg cocultures significantly enhanced their proliferative capacity 
resulting in increased numbers of Treg (Fig. 2a). This observation is in line with a recent 
report describing inflammatory cytokine production by TLR-triggered DC results in 
increased proliferation of the Treg17. The effect of TLR-ligands on Treg proliferation is also 
reflected by the up-regulation of the T cell activation marker CD25. As shown in Fig. 2b, 
addition of TLR-ligands LPS (TLR4), Pam3Cys-SKKKK (PAM, TLR2), or CpG-ODN(TLR9) all 
resulted in a significant increase in CD25 expression on Treg. However, the increase in 
CD25 expression was most pronounced upon addition of PAM. Thus, these data show that 
in the presence of APC, TLR-ligands induce Treg proliferation and CD25 up-regulation. 
 
TLR2-triggering in the absence of APC modulates Treg in vitro. 
To investigate the direct effects of these TLR-ligands on intrinsic regulatory T cells and 
conventional CD4+CD25- Th cells, highly pure (>98%) Treg and Th cells were incubated 
with the TLR-ligands plus anti-CD3 antibodies and IL-2 but, importantly, in the absence of 
APC. Interestingly, only the addition of PAM, but not purified LPS or CpG, resulted in 
profoundly increased expression of T cell activation markers CD25 (Fig. 2c, and Fig. 3a) 
and CD69 (not shown) on Treg. Only limited effects of TLR-stimulation were observed for 
conventional Th cells.  
In contrast to highly purified LPS (TLR4-ligand), the synthetic TLR2-ligands Pam3Cys 
(TLR1/2) and MALP-2 (TLR2/6) as well as the natural TLR2 ligands in Peptidoglycan, 
commercial (non-pure) LPS and heat-killed Candida (all containing TLR2-ligands) induced 
CD25 up-regulation, indicating that besides synthetic TLR2-ligands, also natural TLR2-
ligands directly affect Treg (Fig. 3b).  
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Fig. 2: In vitro TLR2 signalling results in Treg proliferation. Below each graph, the specific T cell 
stimulation is indicated. (A) Proliferation of regulatory T cells in the presence of irradiated APC, anti-CD3 
and TLR-ligands. Irradiated APC and anti-CD3 (medium control, med) were cultured for three days with or 
without 104 purified Treg and with or without the addition of TLR-ligands: purified LPS (TLR4), PAM 
(TLR2) or CpG-ODN(TLR9). Values indicate average counts per minute (CPM) of triplicate wells ± SD. (*= 
P< 0.02 for medium control compared to TLR-ligands) (B-C) CD25 expression by purified CD4+CD25+/- T 
cells. (B) Treg were cultured for three days in the presence of irradiated APC and anti-CD3 (medium 
control) or with addition of purified LPS, PAM or CpG. CD25 expression was measured by flow cytometry. 
Values indicate average mean fluorescence intensity (MFI) of anti-CD25-FITC stained CD4+cells of 
triplicates ± SD. *=P<0.02 for medium control compared to TLR-ligands. (C) T cell activation in the 
absence of APC. Purified CD4+CD25+ Treg or CD4+CD25- conventional Th cells were cultured with IL-2 and 
soluble anti-CD3 (medium control) or with the addition of purified LPS, PAM or CpG-ODN (no APC 
present). After three days, CD25 expression was measured by flow cytometry. Values indicate average 
MFI of triplicates ± SD. One representative experiment out of three is shown. *=P<0.02 PAM vs medium 
control. 
 
 
Of note, differences between the basal levels of CD25 expression of Treg stimulated with 
either anti-CD3/APC or anti-CD3/IL-2 (Fig. 2b versus 2c) can be explained by the different 
amounts of (co)-stimulatory signals the Treg receive with each different stimulation 
approach. Both approaches use anti-CD3 but differ in the use of APC versus IL-2. Yet, in 
the absence of APC, TLR2-ligand PAM results in increased expression of T cell activation 
markers on Treg. 
 
TLR2-signalling by Treg themselves induces expression of CD25. 
To exclude that the effects caused by PAM were the result of a contamination in the 
synthetic PAM preparation, we tested Treg purified from TLR2- and MyD88-deficient mice. 
We found that only WT Treg cells responded to PAM with an increase in CD25 expression, 
whereas no effect was observed for TLR2-deficient and MyD88-deficient Treg (Fig. 4a), 
indicating that PAM acts through both TLR2- and MyD88-dependent signaling pathways.  
To further exclude that a small amount of contaminating cells within the FACS-sorted Treg 
preparations are responsible for the observed effects, we used CD4+CD25+ T cells from 
TLR2-/- mice that we found unable to respond to PAM (Fig. 4a). To mimic a cellular 
contamination, increasing amounts of wildtype syngeneic APC were added to FACS-sorted  
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Fig. 3: (A) Example of CD25 expression by freshly isolated regulatory T cells incubated for three days in 
medium with anti-CD3/IL-2 (thin line) or supplemented with TLR2 ligand PAM (thick gray line). (B) Effect 
of different TLR-ligands on Treg activation. PAM-expanded Treg cells were cultured with anti-CD3, IL2 and 
the indicated TLR-ligand (10 µg/ml purified LPS, 10 µg/ml commercial LPS, 2 µg/ml PAM, 2µg/ml MALP-2, 
10µg/ml LTA, 10µg/ml Peptidoglycan (PG), and 2 x105 heat-killed Candida/ml). The cells were incubated 
for three days and subsequently CD25 expression was analyzed by flow cytometry. Representative results 
from two experiments are shown. (C) In vitro suppression assay: PAM-expanded Treg were rested for at 
least six days in the absence of TLR-ligands and subsequently cocultured for three days with 104 fresh 
naïve CD4+ T cells, irradiated APC and anti-CD3. After three days, IFN-γ production was measured in the 
supernatant using the murine inflammation CBA kit.  
 
 
TLR2-/- Treg in the presence of PAM/anti-CD3. The results (Fig. 4b) showed that almost 
equal numbers of wildtype APC were needed to increase CD25 expression on the TLR2-
deficient Treg. This shows that in our experiments with highly pure WT Treg (Figure 2c and 
4a) PAM must directly act on the Treg.  
These data thus indicate that the TLR2-ligand PAM, but not TLR4 or TLR9 ligands, is able 
to directly trigger regulatory T cells in a MyD88-dependent manner.  
 
TLR2 signals induce Treg expansion in vitro. 
In an attempt to establish long-lived Treg cultures, TLR-ligands were added to a culture of 
purified Treg, feeder cells and supplemented with soluble anti-CD3 and IL-2. In a primary 
stimulation, the addition of PAM, LPS or CpG-ODN increased the proliferation of the 
regulatory T cells (Fig. 2b). In multiple experiments however, the addition of LPS or CpG-
ODNwas not sufficient to obtain viable regulatory T cell lines (not shown). In contrast, co-
culturing the Treg in the presence of PAM resulted repeatedly in the generation of a pure 
CD4+CD25+ T cell line. Analysis of proliferation of CFSE-labeled freshly isolated wildtype 
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and TLR2-/- derived Treg showed that wildtype but not TLR2-/- Treg responded to 
stimulation with anti-CD3 and TLR2-ligand (Fig. 4c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: PAM induces CD25 expression through TLR2-signaling. Below each graph, the specific T 
cell stimulation is indicated. (A) TLR2 and MyD88 expression is required for PAM-mediated increase of 
CD25 expression. Purified WT, TLR2-/- and MyD88-/- CD4+CD25+ T cells were cultured for three days with 
anti-CD3, IL-2 (medium control) or with the addition of PAM. Subsequently, the cells were harvested and 
CD25 expression was analyzed by flow cytometry. Values indicate average MFI from triplicate wells ± SD. 
(*= P< 0.02 with medium control). A representative result of three experiments is shown. (B) High 
numbers of wildtype APC are required to increase CD25 expression on TLR2-/- Treg cells. Purified 
CD4+CD25+ T cells from TLR2 -/- mice were incubated for three days with the increasing amounts of 
wildtype APC plus TLR2-ligand PAM and anti-CD3 and subsequently CD25 expression was analyzed by flow 
cytometry. Values indicate average MFI from triplicates ± SD (*= P< 0.05 with medium control). (C) 
Proliferation of CFSE-labeled freshly isolated wildtype and TLR2-/- Treg after stimulation with soluble anti-
CD3, IL-2 and PAM. After four days proliferation resulting in a decrease of fluorescent signal in the 
daughter cells, was analyzed by flow cytometry and ModFit analysis software. Representative results of 
two experiments are shown. 
 
The phenotypic characteristics of these PAM cultured Treg were consistent with the 
reported intrinsic Treg markers, including CD4, CD25, CTLA-4, GITR, CD1031,21 and the 
Treg specific transcription factor FoxP322-24 (Figure 5). Of note, TLR2-/- Treg that were 
treated in vitro with the same PAM-based expansion protocol did not proliferate (see Figure 
4c), but did express similar amounts of CD4, CD25, CTLA-4, GITR, CD103 and FoxP3 (data 
not shown). Importantly, wildtype Treg expressed low but significant amounts of TLR2 
mRNA (Figure 5b) as well as protein (Figure 5c), which further strengthens our hypothesis 
of TLR2-mediated control of Treg function. 
 
Cooperation between TLR2- and TCR-signalling results in Treg expansion. 
To address the effects of combined TLR2- and TCR-signaling in more detail, we analyzed 
the expression of the activation marker CD25 on in vitro expanded Treg in time. Our results 
show that TLR2-triggering of Treg cooperated with anti-CD3-mediated TCR stimulation 
resulting in maximal increased CD25 expression (Fig. 6a) as compared with either 
stimulation alone. This shows that these cells remained responsive towards TLR2  
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Fig. 5: Phenotype of PAM-expanded Treg. Expression of intrinsic Treg specific markers on PAM-
expanded resting (7 days after stimulation with PAM) regulatory T cells was analyzed by flow cytometry 
and quantitative PCR. (A) The PAM-expanded Treg expressed the markers CD4, CD25, GITR, CTLA-4 and 
CD103 (indicated by the thick gray lines, corresponding isotype controls are indicated with a thin black 
line). CTLA-4 was detected by standard intracellular staining procedure. (B) Expression of FoxP3 (left 
panel) and TLR2 (right panel) mRNA by resting PAM-expanded Treg and conventional CD25- T helper cells 
was determined by quantitative PCR. The quantitative PCR results are indicated as mean relative mRNA 
expression from 3 replicate measurements (shown as arbitrary units relative to PBGD) ± SD. (C) 
Expression of FoxP3 (left panel) and TLR2 (right panel) protein determined by flow cytometry on resting 
PAM-expanded T cells: Treg (indicated with gray lines) and conventional T helper cells (indicated with 
black lines), as well as freshly isolated T cells: CD4+CD25+ Treg (gray lines) and CD4+CD25- Th cells (black 
lines). Corresponding isotype controls are indicated by the dotted lines. Representative results from two 
experiments are shown. 
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Fig. 6: Proliferation of PAM-expanded regulatory T cells. (A) TLR2- and TCR-signals cooperate to 
increase CD25 expression on Treg. The Treg cells were incubated with either PAM, anti-CD3 or the 
combination of both in IL-2 supplemented medium. CD25 expression was analyzed daily by flow cytometry 
and indicated as relative MFI to the medium control. (B) Proliferation of Treg is induced by TLR2-signaling. 
PAM-cultured Treg were stimulated on anti-CD3 coated plates with IL-2 (medium control) or with addition 
of the indicated TLR-ligands. After three days, proliferation was measured by [3H]thymidine incorporation 
and shown as average CPM of triplicates relative to medium control ± SD. (C) Proliferation of CFSE-labeled 
PAM-expanded Treg. The labeled Treg were cultured for three days in the presence of IL-2 supplemented 
medium (med) or with the indicated stimulus (PAM and/or anti-CD3). Proliferation, resulting in a decrease 
of fluorescent signal in the daughter cells, was monitored by flow cytometry and (since in vitro cultured T 
cell lines display a more broad signal after CFSE labeling compared with freshly isolated T cells) analyzed 
using ModFit software. Representative results from three experiments are shown.  
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stimulation and that optimal Treg activation requires both TCR and TLR2 signaling. This is 
further demonstrated by the observation that the addition of PAM in combination with a 
strong TCR signal (applying plate bound anti-CD3) induced proliferation of the Treg, this in 
contrast to TLR4 or TLR9 ligands (Fig. 6b). The proliferation of Treg induced by TLR2-
triggering and/or TCR stimulation was further visualized by their CFSE dilution profile. 
Illustrative for their anergic state, comparing medium control treated Treg with anti-CD3 
stimulation, TCR signaling alone did not induce proliferation in these cells (Fig. 6c). 
However, the addition of TLR2-ligand alone induced some proliferation of the Treg as 
observed by the decrease in CFSE signal. However, maximal proliferation of the Treg was 
observed when both TCR- and TLR2-stimulations were applied. Of note, although PAM 
increased the proliferation of regulatory T cells up to 10 times, Treg proliferation remained 
low compared to the proliferation observed for conventional T cells.  
 
TLR2-expanded Treg remain suppressive. 
Importantly, to address if the expanded Treg were still capable of suppressing conventional 
T cell responses, we performed in vitro suppression assays. The PAM-expanded Treg were 
rested for at least five days in the absence of PAM and subsequently co-cultured with 
freshly isolated CD4+CD25- conventional T cells. Analysis of the T cell response after three 
days showed that the Treg efficiently suppressed the proliferation (Fig. 8a) as well as IFN-γ 
production (Fig. 3c) of freshly isolated conventional T cells (Th). Conventional CD25- Th 
cells that were expanded using the same TLR2-ligand-based culture protocol did not exert 
any suppressive effects (Fig. 8a). In addition, the supernatant of anti-CD3 activated Treg 
did not transfer any suppressive effects, nor did we detect any cytokine production by 
these Treg (using the mouse inflammation Cytometric Bead Array (not shown)). Moreover, 
when placed behind a semi-permeable membrane the PAM-expanded Treg failed to 
suppress Th-proliferation confirming that these Treg mediate suppression via cell-contact 
(Fig. 7).  
To address the functional quality of the PAM-expanded Treg we compared titrated 
amounts of freshly isolated wildtype and TLR2-/- Treg with the in vitro expanded PAM-Treg 
in an in vitro suppression assay. From the effective suppression of fresh Th cells by both 
wildtype and TLR2-/- Treg we can conclude that there is no qualitative difference between 
wildtype and TLR2-/- Treg (Fig. 8b). Moreover, the PAM-expanded wildtype Treg were at 
least as efficient as the freshly isolated Treg. Collectively, these data indicate that TLR2-
triggering results in the expansion of regulatory T cells that remain fully functional in the 
absence of TLR2-ligand.  
  
TLR2-triggering on Treg temporarily abrogates suppression in vitro 
To address the functional consequences of TLR-triggering on regulatory T cells, we 
performed suppression assays in the presence or absence of TLR2-ligand PAM. To proof 
that any effects of TLR2-triggering on suppression are dependent on TLR2-signaling by the 
Treg itself and not by conventional T cells or APC, we performed a suppression assay with 
both APC and conventional CD4+ T cells isolated from TLR2-/- mice but with freshly 
isolated wildtype (TLR2+/+) regulatory T cells. This setup ensures that TLR2 is solely 
expressed by the Treg subset and that all PAM-induced effects are caused via TLR2-
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signaling by the Treg. The results show that PAM induced some proliferation in the WT 
Treg, although proliferation of the Treg remained approximately 15-fold lower as compared 
to the TLR2-/- Th cells (Fig. 9a). As expected, PAM had no effect on TLR2-/- Th cell 
proliferation. In Treg/Th cocultures, WT Treg efficiently suppressed the proliferation of 
TLR2-/- conventional Th cells. In contrast, addition of TLR2-ligand to the co-culture 
completely abrogated suppression as observed by the restored TLR2-/- Th proliferation 
(Fig. 9a). To exclusively monitor proliferation of the Th subset in Treg/Th co-culture 
suppression assays, we used CFSE-labeled Th cells from TLR2-deficient mice and wildtype 
Treg in a suppression assay similar as described above. From the CFSE dilution profile (Fig. 
9b, the percentage of cells that proliferated >3 times is indicated) we can conclude that 
WT Treg inhibit the Th proliferation in the co-culture (to a similar extent as reported before 
for this kind of analysis17). The suppressive effect is however abrogated upon the addition 
of PAM. As expected, PAM had no effect on stimulated TLR2-/- Th cells. Moreover, when 
WT Treg were pretreated overnight with anti-CD3 and PAM, extensively washed and 
subsequently added to TLR2-/- Th cells in a co-culture suppression assay, their suppressive 
ability was also abrogated (data not shown). Therefore, these results demonstrate that 
PAM-mediated TLR2-signaling on Treg themselves is responsible for the observed 
neutralization of their suppressive effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: PAM-Treg suppression is cell-contact dependent. Transwell suppression assay: 106 Freshly 
isolated CFSE labeled CD4+ Th cells were incubated with 106 irradiated APC and 1µg/ml anti-CD3 per well 
of a 24-wells plate. If indicated 106 PAM expanded Treg and 106 irradiated APC were added in the culture 
with the fresh Th cells or in the upper-chamber of the transwell (pore size 0.4µm). After four days of 
culture, CFSE fluorescence was measured by flowcytometry. The value indicates the percentage of cells in 
the proliferative fraction. 
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Fig. 8: PAM-expanded Treg remain suppressive. (A) In vitro suppression assay: PAM-expanded Treg 
or control conventional Th cells (0.5 x 104) were rested for at least five days in the absence of TLR-ligands 
and subsequ ently cocultured for three days with 104 fresh naïve CD4+ T cells, irradiated APC and anti-
CD3. After three days, proliferation was measured and indicated as average CPM from triplicates ± SD. 
Representative results from three experiments are shown. (B) Comparison of suppressive capacity of 
freshly isolated wildtype and TLR2-/- Treg with PAM-expanded Treg. Fresh naïve CD4+ Th-cells (2 x 104) 
were cocultured with titrated numbers of Treg. After three days, proliferation was measured by 
[3H]thymidine incorporation. Relative suppression was calculated with proliferation in the absence of Treg 
(fresh CD4+ Th cells only) set at zero and proliferation at the Treg/Th ratio of 1 at 100%. 
Suppression/proliferation was measured from the average CPM from triplicate wells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: TLR2 controls Treg suppressor function in vitro. (A) To analyze the direct effects of TLR2-
triggering on Treg suppressor function in vitro, 104 TLR2-/- conventional T cells (Th) and 0.5 x 104 freshly 
isolated wildtype CD4+CD25+ Treg cells were (co)-cultured for three days. Soluble anti-CD3 and irradiated 
TLR2-/- APC were used to stimulate the T cells, ensuring that TLR2 was solely expressed by the Treg. If 
indicated, PAM was added at the start of the coculture. Data indicate average proliferation from triplicates 
± SD. (B) CFSE-labeled TLR2-/- Th (105) were cocultured for four days with 0.5 x 105 WT Treg as 
described in (A). CFSE fluorescence intensity was measured by flow cytometry. Analysis was performed on 
all the CFSE+ cells, using an exclusionary gate for the Treg subset (CFSE-negative CD25high). The 
percentage of cells that divided >3 times is indicated. Representative results from two independent 
experiments are shown. (*= P< 0.05)  
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TLR2 induces Treg expansion in vivo 
Interestingly, we observed that systemic PAM administration to wildtype mice resulted in 
an increase in CD4+FoxP3+ T cell numbers. This can be explained by a direct (see above) 
or indirect effect (for example via APC) of the TLR2-ligand. To address the in vivo 
significance of the direct effects of TLR2-triggering on Treg expansion, TLR2-/- mice were 
reconstituted with freshly isolated and fluorescent (CFSE) labeled OT-II transgenic Treg. 
This setup ensures that the infused Treg are the only TLR2-ligand responsive cells in these 
mice. The OT-II transgenic Treg express a TCR (Vα2+) specific for a chicken Ovalbumin-
derived peptide (OVA-peptide) in the context of the murine MHC class II I-Ab. The OT-II-
Treg reconstituted TLR2-/- mice were subsequently challenged with either PAM or OVA-
peptide alone, or with the combination of PAM and OVA-peptide. Our results show that no 
significant proliferation of the infused Treg was induced by either OVA-peptide or PAM 
alone (Fig. 10a). In contrast, when PAM and OVA-peptide were combined a significant part 
of the infused Treg had proliferated (75% versus 12% in the PAM alone treated mice,). We 
confirmed by flowcytometry that the proliferating T cells remained FoxP3-positive (data not 
shown). Thus TCR- and TLR2-signals cooperate to induce proliferation of Treg in vivo by 
directly affecting the Treg themselves.  
 
TLR2 modulates Treg function in vivo 
To asses if direct TLR2-signaling of Treg in vivo can result in a modulation of Treg function, 
we used an acute fungal (Candida albicans) infection model in which the kidney is the 
major fungal target organ10. We have previously shown that Treg inhibit the anti-fungal 
immune response as depletion of Treg prior to a Candida challenge resulted in decreased 
Candida outgrowth from the kidney10 and increased IFN-γ production by splenocytes10. 
Applying this infection model in TLR2-/- mice reconstituted with 4 x 106 syngeneic wildtype 
Treg, we ensured that all effects of PAM-administration must be caused by TLR2-triggering 
of the infused Treg, since these are the only TLR2-expressing cells in this system. The WT-
Treg reconstituted mice were challenged with an intravenous injection of live Candida and 
we monitored Candida outgrowth in the presence or absence of TLR2-ligand 
administration. The results show that the WT Treg-reconstituted TLR2-/- mice exhibited a 
2-log increase in Candida outgrowth compared to the non-reconstituted TLR2-/- controls 
(Fig. 10b), indicating that the infused Treg are potent inhibitors of the anti-Candida 
immune response. Strikingly, administration of TLR2-ligand to the WT Treg-reconstituted 
mice restored the level of Candida outgrowth to the level of the non-reconstituted TLR2-/- 
mice (Fig. 10b), indicating that the TLR2-trigger abrogated the suppressive effects of the 
infused Treg in vivo. The administration of TLR2-ligand alone to the TLR2-/- mice did not 
affect the Candida outgrowth (not shown). In addition, the administration of PAM-
expanded conventional Th cells (4 x 106, plus/minus PAM) did not affect the Candida 
outgrowth in the TLR2-/- mice (Fig. 10c). This shows that Treg but not conventional Th 
cells are able to inhibit the immune response against C. Albicans. Moreover, IFN-γ 
production by ex vivo Candida-stimulated splenocytes was analyzed. Candida stimulated 
splenocytes of the Treg-infused TLR2-/- mice produced significantly less IFN-γ compared to 
TLR2-/- controls (Fig. 10d). Moreover, this suppression of IFN-γ production was absent in 
splenocytes from mice that received both Treg and TLR2-ligands. Of note, TLR2-ligand 
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alone had no effect on cytokine production by TLR2-/- splenocytes ex vivo (not shown). 
The above-described results demonstrate that TLR2-triggering abrogated the suppressive 
capacity of the infused Treg in vivo. Since the infused Treg are the only TLR2 expressing 
cells in this in vivo system, the abrogation of suppression can only be explained by a direct 
effect of the TLR2-ligand on the infused TLR2+/+ Treg in the TLR2-/- mice. 
 
Collectively, our combined results show that the suppressive function of the regulatory T 
cells themselves is directly controlled by the pathogen associated molecular pattern 
receptor TLR2. In the presence of TLR2-ligand, Treg expansion and a temporal loss of 
suppression is observed. After removal of the TLR2-ligand, the expanded Treg regain their 
suppressive capabilities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: TLR2 controls Treg suppressor function in vivo. (A) TLR2- and TCR-triggering cooperate to 
induce Treg expansion in vivo. TLR2-/- mice were reconstituted with 2 x 106 freshly isolated and CFSE 
labeled OT-II-transgenic Treg (TCR of OT-II transgenic T cells is Vα2 and specific for the Ovalbumin 
derived peptide presented in I-Ab). The reconstituted mice were subsequently challenged i.p. with either 
PAM (20µg/mouse) or OVA-peptide (10µg/mouse) alone or with the combination of PAM and OVA-peptide. 
After four days, splenocytes were isolated and analyzed by flowcytometry for CFSE-fluorescent signal of 
the infused cells. The cells shown are gated for the CD4+, Vα2+, CFSE+ cells and Propidium-Iodide positive 
(death) cells wee excluded from the analysis. The value indicates the percentage of cells within the 
proliferative fraction (>one division). (B/C) TLR2-triggering abrogates Treg mediated suppression of anti-
Candida albicans immunity in vivo. TLR2-/- mice (5 per group) were reconstituted with 4 x 106 wildtype 
PAM-expanded Treg (B) or conventional Th cells (C) and challenged intravenously with 105 live Candida 
cells one day later (day 0). If indicated, mice received an intraperitoneal injection of 100 µl saline 
(controls) or 20 µg PAM/100 µl saline on day –1, 1, 3, and 5. Seven days after the challenge, Candida 
outgrowth (CFU/gram tissue ± SEM) from kidneys was monitored. (D) Ex vivo IFN-γ production (± SEM) by 
Candida stimulated splenocytes was measured as described in the Material and Methods section. 
Representative results of two independent experiments are shown (*= P< 0.05 with TLR2-/- control). 
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Discussion 
 
The identification of CD25high, CD4+ T cells as T cells bearing a suppressive phenotype has 
renewed the interest in the regulatory T cell 5. These Treg are now emerging as major 
regulators of our immune system. Lack of Treg results in various autoimmune syndromes. 
On the other hand, Treg mediated suppression might hinder the development of effective 
immune responses, which are crucial for the elimination of tumors and infections. 
Therefore, the regulators themselves need to be well controlled. We now demonstrate for 
the first time that TLR2 triggering by pathogen associated molecular patterns (PAMPs) 
present on or secreted by infectious organisms can directly modulate Treg function. 
Our initial observation that CD4+CD25+ T cell numbers were decreased in TLR2-
deficient but not in TLR4-deficient mice, led us to investigate the role of TLR2 signaling on 
CD4+CD25+ T cell functionality in more detail. Analysis of blood and spleen of MyD88-
deficient mice revealed that in addition to TLR2, also MyD88 is required for normal 
CD4+CD25+ T cell levels in vivo (Fig. 1). Moreover, massive TLR2-triggering by intravenous 
injection of TLR2-ligand PAM had the opposite effect and resulted in a significant 
proliferation and increase of CD4+CD25+ T cell numbers (Fig. 1).  
The in vivo increase of CD4+CD25+ T cells by TLR2-ligand PAM might be caused by 
an indirect effect via APC or by direct TLR2-triggering of regulatory T cells. In vitro we 
found that all TLR-ligands tested increased Treg proliferation in the presence of irradiated 
APC and anti-CD3 (Fig. 2). However, our results also demonstrate that the TLR2-ligand 
PAM, but not purified LPS or CpG, is able to induce proliferation of Treg cells in the 
absence of APC, by directly affecting the Treg themselves. Next to PAM, also MALP-2, 
Peptidoglycan and heat-killed Candida resulted in Treg activation, emphasizing that besides 
synthetic ligands also natural TLR2-ligands can modulate Treg. Using the TLR2-ligand PAM 
we were able to establish long lived (up to 5 months), proliferating regulatory T cell lines. 
Although the exact mechanism remains to be elucidated, the finding that TLR2-triggering 
of Treg strongly enhances CD25 expression implies that increased sensitivity to IL-2 might 
be involved. The in vitro expanded Treg expressed CD4, CD25, GITR, CTLA-4, CD103 and 
FoxP3 (Fig. 5), all typical regulatory T cell markers1,21. These suppressor T cell lines further 
expressed significant amounts of the PAM receptor TLR2 (Fig. 5), but also remained 
sensitive for TLR2 stimulation further emphasizing the direct interacting between TLR2-
ligands and Tregs (Fig. 6). Furthermore, they fully maintained their suppressive capacities 
following withdrawal of TLR2 ligands (Fig. 8). Interestingly, TLR2-/- Treg expressed the 
same surface markers as wildtype Treg and were equally efficient in the suppression of 
naïve T cell responses (Fig. 8). This indicates that TLR2 is not involved in the suppression 
process itself. We additionally showed that the effects of TLR2-triggering on Tregs 
temporarily abrogates their suppressive capabilities as well (Fig. 9). We hypothesize that 
TLR2 induces proliferation of the Treg during which there is a temporal loss of the 
suppressive phenotype. 
The physiological relevance of our findings was assessed by infusion of TLR2+/+ 
Treg into TLR2-/- mice allowing for the analysis of direct TLR2-effects on Treg function in 
vivo. Importantly, the combination of TCR-and TLR2-signals induced strong proliferation of 
Treg in vivo (Fig. 10a), confirming that TLR2 and TCR signals cooperate in the proliferation 
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of Treg. Furthermore, in line with our in vitro observations, infused WT Treg inhibited anti-
fungal immune responses in TLR2-/- mice, whilst co-administration of TLR2-ligands 
resulted in a loss of the suppressive phenotype of the infused Treg as observed by the 
restored anti-fungal immunity (Fig. 10b-d). 
Recently, it was found that IL-23 and strong TCR signals13 release effector T cells 
from Treg mediated suppression. Furthermore, the presence of the TLR9 ligand CpG-ODNin 
a suppression assay containing APC resulted in a reduced suppression by the Treg. This is 
due to TLR9 triggered production of IL-6 by the APC rendering conventional T cells 
insensitive to Treg mediated suppression12. Another report nicely links TLR4 and TLR9 
signaling with Treg mediated CD8 tolerance25. The authors demonstrate that ligation of 
TLR4 or TLR9 on DC is required for breaking Treg mediated CD8 tolerance in vivo. 
However, in addition to the effects of TLR-ligands on DC, the results described here show 
that it is also possible that a TLR-ligand directly affects Treg, resulting in abrogation of 
suppression and expansion of the Treg subset. A study by Komai-Koma et al.26 showed 
that TLR2-triggering also stimulates activated conventional T cells. We were able to 
confirm their observations on activated conventional CD4+ T cells (data not shown). 
However, using TLR2-deficient conventional T cells, we demonstrate that it is the 
regulatory T cell subset (freshly isolated or in vitro expanded) that is highly sensitive for 
TLR2 stimulation, resulting in profound proliferation and reduced suppression by the Treg. 
The effects of TLR-ligands in vivo might thus be more complicated then initially thought, 
affecting multiple cell types of both the innate and the acquired immune system. 
Recently a role for TLR4 on Treg homeostasis was reported19. We and others17,26 
however did not find any effects of purified LPS on T cells (conventional or regulatory). We 
note that in contrast to purified LPS, commercially obtained LPS (containing contaminating 
TLR2-ligands27) induced a significant CD25 up-regulation on Treg. Thus to exclude bacterial 
contaminations in all our experiments, we only used purified LPS and synthetic TLR2 and 
TLR9 ligands. Moreover, we confirmed the purity of our TLR2 and TLR4 ligands by 
measuring their activation capacity on TLR2- and TLR4-deficient DCs (Fig. 11).  
An intriguing question that remains to be answered is why TLR2 but not TLR4 is 
able to directly affect Treg. TLR2 but not TLR4 is found to promote IL-10 production by 
innate immune cells in vitro28. The accumulating evidence that TLR2 is also involved in 
immuno-suppression in vivo (reviewed in 29) renders TLR2 unique from the other TLRs. In 
this context it is interesting to note a report linking the anti-inflammatory Glucocorticoids 
with TLR2 expression30. These observations strengthen the idea that TLR2, besides an 
activating function, could be involved in tolerance as well by acting directly on APC and 
Treg. In addition, other TLRs not tested here could act on Treg. It was recently shown that 
TLR8 can abrogate the suppressor function of human Treg31. Although TLR8 did not induce 
proliferation of human Treg, this report strengthens our findings of TLR2 mediated control 
of murine Treg. We are now investigating the possibility that different TLR-signals can 
differentially modulate Treg function. 
Our finding of the abrogation of suppression after TLR2-stimulation, is in line with 
reports indicating that Treg rapidly lose their ability to inhibit proliferation after receiving 
 
 
Chapter 6 
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: TLR-ligand induced activation of mouse bone marrow derived DC of wildtype, TLR2-/- 
and TLR4-/- origin. Day 7 bone marrow derived DC were incubated for 24 hours with the indicated TLR-
ligands and subsequently the expression of activation marker CD86 was measured by flow cytometry. A 
representative result from two experiments is shown. 
 
 
strong activation signals13. In addition, Komai-Koma reported that TLR2 functions as a co-
stimulatory molecule for conventional T cells, resulting in increased T cell expansion after 
TLR2-triggering on the conventional T cells themselves26. Furthermore, the finding that 
TLR8-triggering combined with TCR stimulation on human Treg resulted in reversal of their 
suppressive capabilities emphasizes the effect of TLR-signaling on Treg mediated 
suppression31. In line with these reports and our own observations, we envisage that TLR2-
signaling on murine Tregs contributes to the strength of signals received by the Treg. This 
forces Treg into the proliferative pathway, which is paralleled by a reversal of suppressive 
capabilities. Once in a resting state again, the Treg regain their suppressive capacities (see 
also Fig. 12). 
Our observation that PAMPs can directly act on regulatory T cells themselves 
provides new insights regarding the role of Treg in the induction of immune responses. The 
results presented here provide evidence for a strict control of regulatory T cells by TLR2-
ligands. The current opinion holds that TLR mediated recognition of pathogens results in 
DC activation and subsequent initiation of T cell responses. We can now add a direct Treg 
modulating capacity to TLR-ligands. Applying an acute fungal infection model, we 
unequivocally demonstrate that TLR2-triggering on the Treg themselves abrogates their 
suppressive activity in vivo resulting in increased IFN-γ production and decreased fungal 
outgrowth. These data imply that TLR2-ligands provided by a microbial invasion during 
acute infection, mediate Treg expansion and abrogation of Treg mediated suppression, 
thus allowing a potent immune response to occur. However, post-infection, when the 
immune system has cleared the pathogen and hence TLR2-ligands are declining, the 
expanded Treg regain their suppressive activity and could help to restore the immune 
balance (see also schematic model in Fig. 12). Interestingly, two recent reports suggested 
that CD4+CD25+ regulatory T cells control the persistence and memory protective immunity 
against Leishmania major and C. Albicans9,32. Based on the novel findings described herein, 
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one could envisage that TLR2-ligands provided by the pathogens33 could first expand the 
Treg in vivo and abrogate their suppressive phenotype. When only low numbers of the 
pathogen are present as in the persistent phase of Leishmania infection, the Treg regain 
their suppressive phenotype and could be responsible for pathogen persistence. 
Finally, we note that the presence of micro-organisms in the gut might contribute 
to a constant influx of TLR-ligands that can modulate Treg numbers. In support of this 
hypothesis is our unpublished observation that germ-free mice have altered Treg numbers 
as compared to control mice. In addition to microbial derived PAMPs, TLR2-signaling can 
possibly be induced by endogenous proteins (e.g. Heat Shock Proteins, reviewed by 34). 
This would allow the modulation of the Treg compartment in a non-pathogenic, stress 
induced (anti)-inflammatory environment. 
 
Collectively, our findings have major implications for our understanding of immune 
regulation by both regulatory T cells and TLRs. Ultimately the knowledge that TLRs can be 
used to expand and modulate Treg will lead to new methods for Treg based 
immunotherapy of diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Model of TLR2-mediated control of regulatory T cell function. In a pre-infection setting, 
Treg function is mainly regulated by T cell Receptor (TCR) stimulation and IL-2. During an acute infection, 
pathogen derived TLR2-ligands promote proliferation of Treg paralleled by temporarily abrogated 
suppression. As a result, the Treg do not suppress the ongoing immune response. Once the pathogen is 
cleared by the immune system, the source of TLR2-ligands is no longer present and the Treg will regain 
their suppressive capabilities, thus contributing to the balance between tolerance and immunity. 
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Materials and Methods 
 
Mice 
C57BL/6 mice were obtained from Charles River Wiga (Sulzfeld, Germany). TLR2-/-35, 
TLR4-/- and MyD88-/- 36 mice were obtained from S. Akira (Osaka University, Japan). The 
MyD88-/- mice are backcrossed >8 times on the C57BL/6 background. The OVA-specific 
TCR transgenic OT II mice (on a C57BL/6 background) were obtained from The Jackson 
Laboratory. The MyD88-knockout mice were bred in our specified pathogen free animal 
facility using heterozygous breeding pairs. The wildtype littermates were used as controls 
for the comparison of Treg numbers. All animal experiments were approved by the Animal 
Experimental Committee from the St. Radboud University Medical Center and were 
performed in accordance with institutional and national guidelines. 
 
Antibodies and flow cytometry 
Directly labeled monoclonal antibodies used for staining were anti-CD3-PE, anti-CD4-APC, 
anti-Vα2-PE, anti-CD25-FITC (clone 7D4), anti-rat-PE and all isotype controls were obtained 
from BD Pharmingen. Anti-mTLR2-PE (clone T2.5) and anti-mFoxP3-PE (clone FJK, staining 
according to instructions by manufacturer) were obtained from eBioscience, CA, U.S.A., 
Anti-hamster-APC was obtained from Caltag Laboratories (Burlingame, CA, U.S.A.) In 
addition, anti-GITR (DTA-1, a kind gift from Prof. S. Sakaguchi, Japan), anti-CTLA-4 (clone 
9H10), anti-CD86 and anti-CD103 (BD Pharmingen) were used. Analysis of cell surface 
markers on lymphocytes was performed using a FACScalibur™ (Becton Dickinson) and 
CELLQuest™ software. For analysis of relative CD4+CD25+ T cell numbers in vivo 50–100 µl 
blood was collected in heparin-coated tubes and erythrocytes were lyzed using standard 
protocols. The remaining lymphocytes were washed and incubated with anti-CD25-FITC 
and anti-CD4-APC and subsequently analyzed on a flowcytometer 
 
T cell purification and analysis 
Spleens from wildtype or KO mice were mashed, filtered and CD4+ T cells were purified 
using anti-mouse-CD4 Microbeads (MACS, Miltenyi Biotec, Germany) resulting in a 95% 
pure CD3+CD4+ T cell population as measured by flow cytometry. CD4+CD25- and 
CD4+CD25+ T cell subsets were obtained by flow cytometry purification of the presorted 
CD4+ T cells: CD4 cells were stained with APC-conjugated CD4 mAb and FITC-conjugated-
CD25. For exclusion of MHC class II+ cells and B cells, anti-I-Ab (17/227, mouse IgG2a) and 
PE-conjugated Goat anti-mouse IgG were used. Cell sorting was performed on a Coulter 
Altra Hypersort cellsorter. The purity of each cell preparation was > 98%. Purified CD4+ T 
cell subsets were subsequently cultured for three days in complete medium (Iscoves IMDM 
(Gibco), 9% FCS, 2µM L-glutamine, 50 µM β-Mercapthoethanol, 1% Antibiotic-Antimycotic 
(Gibco)) with 1 µg/ml anti-CD3 (Pharmingen), 5 Cetus Units (cU) IL-2/ml with or without 
TLR-ligands. Unless indicated otherwise, TLR-ligands were used at the following 
concentrations: PAM3Cys-SKKK (PAM) and MALP-2, both 2 µg/ml (EMC microcollections, 
Germany), non-purified and purified E. coli LPS 10 µg/ml (obtained from Sigma and 
subsequently purified as described in 27), Peptidoglycan 10 µg/ml (Sigma-Aldrich), purified 
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LTA 10 µg/ml (obtained from Gunthard Stübs, University of Konstanz, Germany), heat-
killed Candida albicans hyphen and conidia 2 x 104 CFU per well of 96-well plate (strain UC 
820) and CpG-ODN 1668 1 µg/ml (5’-TCCATGACGTTCCTGAATGCT-3’) Sigma Genosys, 
Haverkill, UK). After three days of culture the cells were harvested, stained with APC 
conjugated anti-CD4 and FITC conjugated anti-CD25 and analyzed. Data indicate MFI 
(Mean Fluorescence Intensity), presented as the average MFI of three measurements with 
SD indicated. 
 
Treg culture and suppression assay 
Purified CD4+CD25+ T cells, 104 per well of a 96-well plate, were stimulated weekly with 
105 irradiated APC (CD4-MACS bead depleted splenocytes), 2 µg/ml PAM, 1 µg/ml anti-CD3 
(145-2C11, BD Pharmingen) and 20 Cetus units IL-2/ml complete medium. The cells were 
washed three days after stimulation and maintained in culture medium supplemented with 
20 Cetus units IL-2/ml. When necessary, dead cells were removed by ficol density gradient. 
Cultured Treg cells were used in assays at least 6 days after stimulation. Bone marrow cells 
were cultured for seven days in complete medium in the presence of 20 ng/ml mIL-4 and 
mGM-CSF (Prepotech) to obtain bone marrow derived DC (BMDC). Suppression assays: 
Freshly sorted CD4+CD25- naïve T cells (20 x 103) and either cultured or freshly isolated 
Treg cells (5 x 103) were mixed and cocultured for three days. If indicated, the T cells were 
stimulated with TLR-ligands and with either plate bound anti-CD3 (2,5 µg/ml) or soluble 
anti-CD3 (1 µg/ml) plus 105 irradiated APC in complete medium. In a number of coculture 
experiments, resting TLR2-/- CD25- conventional T cells were used as responders. These 
cells were maintained in culture for maximal 6 weeks using weekly restimulation assay with 
irradiated APC, anti-CD3 (1 µg/ml) and 20 cU IL-2/ml. After three days of coculture, 
supernatant was collected for cytokine analysis using a mouse inflammation CBA kit (BD 
biosciences). Proliferation was measured by overnight (20 hours) 3H-thymidine 
incorporation. In addition, suppression/proliferation was monitored by analysis of CFSE (1 
µM) labeled T cells. CFSE-labeled cells (105) were cultured with the indicated stimulus for 
four days and subsequently CFSE fluorescence intensity was measured by flow cytometry. 
The transwell-suppression assay was performed in a 24-well culture plate (Corning) using 
106 freshly isolated CFSE labeled CD4+ T cells cocultured with an equal number of Treg 
cells or with the Treg behind a semi-permeable membrame (0.4µm, Millipore). The T cells 
were stimulated with 106 irradiated APC (also in the upper chamber of the transwell) and 
1µg/ml anti-CD3 in a total volume of 1ml culture medium. For monitoring proliferation of in 
vitro expanded Treg by CFSE-fluorescence (In vitro expanded T cells displayed a broad 
CFSE-signal as compared to freshly isolated T cells), we made use of ModFit LT software 
(Verity Software house, Maine, USA) to illustrate the numbers of daughter generations 
after four days of proliferation. 
 
Quantitative PCR 
Relative mRNA levels were determined using the ABI PRISM 7000 Sequence Detection 
System and SYBR Green Reagent (Applied Biosystems 4309155). cDNAs were synthesized 
from 2.0 µg of total RNA using M-LMV reverse transcriptase (Invitrogen 28025-013). PRISM 
samples contained 1 x SYBR Green Master Mix, 1.5 ul 5 µM primers and 25 ng synthesized 
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cDNA in a 25 µl volume. Following primers were used; mTLR2 forward 
(AACCTCAGACAAAGCGTCAAATC), mTLR2 reverse (ACCAAGATCCAGAAGAGCCAAA) (both 
from Biolegio BV Malden, The Netherlands), mFOXP3 forward 
(AGGAGAAGCTGGGAGCTATGC), mFOXP3 reverse (GGTGGCTACGATTGCAGCAA), PBGD 
forward (CCTACCATACTACCTCCTGGCTTTAC), PBDG reverse 
(TTTGGGTGAAAGACAACAGCAT) (all from Sigma Genosys). Mean relative mRNA expression 
from 3 replicate measurements was calculated using ABI PRISM 7000 SDS software. Values 
are expressed as arbitrary units relative to PBGD. 
 
In vivo Treg proliferation 
Spleen and inguinal lymphnodes from OT-II transgenic mice were isolated and mashed into 
single cell suspension. Subsequently, the cells were stained with anti-CD25-FITC and 
isolated using anti-FITC MACS beads (Miltenyi). Contaminating CD8+ T cells and B cells 
were removed using negative depletion with Dynal beads. In this way up to 95% pure 
CD4+CD25+ T cells were obtained. The OT-II transgenic Treg were CFSE labeled (5µM) and 
injected intra peritoneal into TLR2-/- mice (2 x 106 per mouse). Four hours later, the mice 
were challenged i.p. with 20 µg/mouse PAM and/or 10µg/mouse OVA-peptide 
(ISQAVHAAHAEINEAGR, obtained from Drijfhout, JW, LUMC, Leiden, The Netherlands, 
peptide was synthesized by standard Fmoc chemistry, and purity (95%) was checked by 
HPLC). Four days later, the mice were sacrificed, spleens were isolated and the splenocytes 
were stained with anti-CD4-APC, anti-Vα2-PE and PropidiumIodide and analyzed by 
flowcytometry. In addition, the cells were stained with anti-FoxP3-PE and CD4-APC to 
confirm that the CFSE+ cells were still Foxp3+. 
 
C. Albicans infection model 
We used a non-lethal C. albicans infection model as described10. Briefly, 105 colony forming 
units (CFU) of C. albicans strain UC 820 were injected iv in mice on day 0. The mice, 5 per 
group, received if indicated 2 x 106 wildtype in vitro expanded Treg or Th cells intravenous 
in 100 µl saline on day –2 and –1 (4 x 106 in total per mouse). All mice received on days –
1, 1, 3 and 5 100 µl saline or 20 µg Pam3Cys/100µl saline. At day 7, kidneys and livers 
were aseptically removed, weighed and homogenized in sterile saline in a tissue grinder. 
The number of viable Candida cells was determined by plating serial dilutions on 
Sabouraud dextrose agar plates. The colonies were counted after 24h at 37 °C and 
indicated as CFU per gram tissue. The spleens were also isolated from the mice and were 
used for the analysis of cytokine production in response to heat killed Candida. 5 x 106 
Splenocytes in 1 ml complete medium were stimulated with 107 heat killed C. albicans cells. 
The supernatants were collected after 48h of incubation at 37 °C in 5% CO2, and 
measurement of IFN-γ in the supernatant was performed by a commercial ELISA 
(Biosource, Camarillo, CA; detection limit 16 pg/ml), according to the instructions of the 
manufacturer. 
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Introduction 
 
In the treatment of cancer, chemotherapy, ablation and radiotherapy are commonly used 
to destroy tumors in situ. This thesis discusses how tumor antigens left inside the body 
following in situ tumor destruction can be processed by the immune system to generate 
anti-tumor immunity. It also shows that dendritic cells are important in the initiation of this 
response. These new insights may have significant implications for the implementation of 
immunotherapy in conventional cancer treatments, as it seems possible to create a 
synergistic interplay between these modalities. This chapter provides a general overview 
and discussion about these topics.   
 
Research in the past decennia has led to an enormous progression in the 
application of immunotherapy. It has become a promising strategy for patients with 
transplanted organs, auto-immunity or allergy, in which immunotherapy is successfully 
used to silence destructive responses. In patients with infectious diseases or cancer, 
immunotherapy has shown to be effective in boosting the immune system. The use of 
immunotherapy with the intention to fight human cancer has been established since in the 
1890’s remissions of tumors were observed following administration of bacterial extracts to 
cancer patients1. Since then, numerous studies have been reported using either passive or 
active immunotherapy to fight a large variety of cancers. Passive immunization comprises 
strategies like infusion of antigen specific T cells or infusion of antibodies. Active 
immunization involves infusion of dead tumor cells, cytokine stimulation or dendritic cell 
vaccination. Although anti-tumor responses have been observed in all of these strategies, 
clinical research in the past decade has been largely focussed on active immunization with 
dendritic cell vaccines. 
Human as well as animal studies have demonstrated that vaccination with DCs can 
induce immunity to otherwise weakly immunogenic tumor antigens, and clinical trials 
applying DC-based vaccines have shown promising results in patients with a variety of 
tumors2-4. Although these positive results have been obtained, it will remain a tremendous 
task to create specific vaccines for each specific patient. First of all, ex vivo generation of 
DC and the DC vaccine is very labour intensive and costly. Therefore, improvements that 
will allow in vivo loading of endogenous DC would be very helpful. Secondly, our 
knowledge on specific antigens that should be chosen in each particular cancer is limited. 
Letting the immune system itself decide against which antigens it will mount an immune 
response would reduce complexity to a great extend. 
In surgical oncology, in vivo tumor destruction procedures like radiotherapy or 
radiofrequency ablation are successfully applied. Upon tumor destruction in situ, large 
amounts of tumor antigens are released. Recent studies performed by us and others 
suggest that the tumor debris left in situ can act as an antigen source for the immune 
system in general5-7, and the induction of anti-tumor immunity by DCs in particular8. 
However, to optimally exploit the immunity inducing capacity of the DC that acquired 
tumor debris, a better understanding of how DCs succeed to induce and modulate 
immunity in vivo is necessary. Chapter 2 of this thesis provides an overview of the current 
thinking about issues like DC loading, maturation and migration of ex vivo produced DC 
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vaccines9. These ideas might, however, also be relevant and useful in the in vivo situation. 
Moreover, our new data suggest that the way DCs handle tumor antigens can be 
influenced by the type of tumor destruction and carefully timed additional immuno 
modulation. These novel findings may create possibilities for combination of immuno 
therapy with surgical tumor destruction, but may also have impact on the future design of 
ex vivo-generated DC vaccines. 
 
 
In situ tumor destruction: creating an in vivo source of tumor antigens 
 
In order to initiate de novo antigen-specific immune responses, the immune system must 
first of all be provided with the appropriate antigens. Antigen presenting cells like DC are 
able to take up these antigens and process them for presentation on their MHC molecules. 
Potential tumor antigens are thought to be present in every tumor, which theoretically 
makes all tumors immunogenic10. Among these antigens are ‘self’ antigens and ‘new’ 
antigens. Self antigens are antigens that the immune system has been ‘dealing with’ for a 
longer time, and for which tolerance has been developed. ‘New’ antigens contain epitopes 
for which the immune system is not tolerant. Examples are tumor residing oncogenic 
viruses, but also altered or mutated self antigens. On the other hand, the immune system 
may not be tolerant for all self antigens, as some of the self antigens have only limited 
expression in the body, making them ‘less known’ for the immune system. It is commonly 
said that the immune system is ignorant for these antigens11. Examples of antigens that 
contain these cryptic or sequestered epitopes are proteins that are only expressed in testis 
tissue or molecules of the MAGE gene family, present in many tumors. The optimal start of 
an immune response against a tumor will thus theoretically be providing APC with sufficient 
amounts of the ‘new’ antigens or ‘less known’ antigens. 
In situ tumor destruction leaves the generated tumor debris inside the body. Since 
this debris has to be ‘cleared’ by APCs, it will create a source of antigens to generate anti-
tumor immunity. Among these antigens may well be ‘new’ and ‘less known’ antigens. Due 
to the tumor ablation, tumor antigens normally present in low concentrations may now 
enter immunological presentation pathways, thereby becoming candidates to develop an 
immune response against. APC, and in particular DCs, determine whether processed 
antigens elicit an immune response or not12. Of importance in this are the signals a DC 
receives from its surroundings at the time of antigen uptake. In chapter 4 we have shown 
that upon in situ tumor destruction by cryo or radiofrequency ablation, the ablated tumor 
indeed forms an antigen depot from which DCs in the draining lymph node acquire their 
antigens. Efficient antigen loading of DC was critically dependent on ablation of the tumor 
as in tumor-bearing mice far less antigen or antigen-positive DC could be discerned. We 
used cryo ablation and radiofrequency ablation to destruct tumors, but more types of 
tumor destructing techniques likely also have the ability to provide the immune system with 
tumor antigens. 
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In situ tumor destruction: Some examples 
 
In situ release of antigens can be induced in several ways, e.g. chemotherapy or 
radiotherapeutic treatment. Although not studied comprehensively, factors like the amount 
of antigens released, quality of the antigens released and the time-frame of antigen 
exposure will likely be different in these different strategies. These variations will however 
affect the loading of APC. In the next part, we will summarize some of the candidate 
methods possibly effective in releasing antigen in situ. 
 
Local tumor ablation  
To provide a treatment for cancer that could be used alongside conventional resection of 
cancer, a variety of tumor ablative techniques has been explored over the past decades. 
The term ‘local tumor ablation’ is defined as the direct application of chemical or thermal 
therapies to a specific focal tumor in an attempt to achieve eradication of the tumor 
tissue20. It is now accepted that tumor ablation is an effective adjunct to resection in 
achieving complete tumour clearance21. It is, for instance, successfully used to ablate small 
metastases alongside excision of the primary tumor22. Ablation furthermore reduces pain 
and other side effects compared to other treatments, which improves the quality of life for 
patients21. The methods of tumor ablation most commonly used in current practice can be 
divided into two main groups: chemical ablation and thermal ablation. 
Chemical ablation comprises direct intra-tumoral instillation of ethanol (PEI, PAI), 
acetic acid or a chemotherapeutic compound, which induce coagulation necrosis and cause 
tumor ablation23. Thermal ablation uses an energy source to disrupt tissue integrity and to 
produce necrosis. Radio frequency ablation is coagulation induction by electromagnetic 
energy sources with frequencies less than 900 kHz 24. When frequencies greater than or 
equal to 900kHz are used, the technique is called microwave ablation25. Laser ablation 
(LITT, laser coagulation therapy) is destruction of tumor tissue via light energy26,27, 
whereas cryo ablation uses cold to freeze lesions28. An emerging method of tumor 
destruction is via ultrasound. There are currently two novel methods for applying 
ultrasound energy: transcutaneous (focussed ultrasound ablation)29 or direct with a needle-
like applicator (direct ultrasound ablation)30. 
Although many have hypothesized about the immunological effects caused by local 
tumorablation, not much solid evidence is available. Also the differences with respect to the 
antigens released are not known. Most recent studies combined the ablation of tumors with 
systemic immune modulation and will be discussed later. 
 
Radiotherapy 
In the treatment of solid tumors mostly combinations of surgery, radiotherapy and 
chemotherapy are used. In the earlier stages of cancer, surgery alone may be curative, but 
may fail because of inadequate local excision with residual microscopic disease or 
micrometastases present at the time of diagnosis. Therefore, radiotherapy is a local 
treatment which is often used after surgery to reduce the chance of local recurrence. In for 
instance breast and rectal cancer, this combination gives promising results, reducing 
chances of local relapse. In some solid tumors, like laryngeal cancer, radiotherapy is used 
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on itself with curative intent31. In general, radiotherapy damages the DNA of tumor cells, 
which makes these cells unable to divide, after which they become apoptotic. A recent 
study by Teitz-tennenbaum and colleagues using murine tumors demonstrates that when 
intratumoral injection of DC and radiotherapy were combined, better anti-tumor immunity 
was observed than when the individual treatments were given8. This illustrates that 
antigens released after radiotherapy may also be useful for the in situ induction of anti-
tumor immunity. 
 
Chemotherapy 
Although chemotherapies all have the same goal: kill tumor cells, not every chemotherapy 
does this in the same way. Most chemotherapies will induce cell-death by triggering cellular 
apoptosis signalling, an intrinsic mechanism for cells to shut down their machinery and to 
eliminate themselves from the body. Apoptotic cells will die quickly and will be recognized 
and phagocytosed by for instance macrophages and DCs13. Chemotherapies like 
doxorubicin or cyclophosphamide are effective in cancer because cancer cells are more 
sensitive to the apoptosis signals induced by the drug than normal cells. Other drugs 
induce non-apoptotic death of tumor cells. This includes necrosis, autophagy (e.g. 
Temozolomide) or mitotic catastrophe (e.g. Paclitaxel). The different kinds of cell death will 
lead to different kinds of antigens and, subsequently, different immune responses14,15. 
In support of the hypothesis that chemotherapy can deliver antigens to the immune 
system, recent studies described enhanced immune responses upon the combination of 
systemic chemotherapy with the intra-tumoral infusion of DCs16,17. Together with studies 
combining for instance CD40 triggering and chemotherapy, discussed later, this suggests 
that immunotherapy can indeed be a functional additive treatment to chemotherapy. 
Although promising, it is likely that not every kind of chemotherapy can be effectively 
combined with immunotherapy. Many types of chemotherapy will, for instance, eliminate 
vital parts of the immunesystem, which might be important, besides the DC, in the 
generation of an effective immune response18. Implications of combining chemotherapy 
with immunotherapy are extensively discussed by Lake et al.19. 
 
 
In situ tumor destruction: tumor-derived antigens and dendritic cells 
 
Although in situ tumor destruction techniques have been successfully used to generate 
anti-tumor immunity, many issues still have to be elucidated, including an exact 
mechanism. And although postulated frequently, even the direct involvement of 
endogenous DCs has not been demonstrated. Applying a novel mouse model using 
radiofrequency or cryo ablation of established (5-7mm) murine B16OVA melanomas we set 
out to determine the immunological consequences of in situ tumor destruction and in 
particular the effects on DC. In chapter 3 we demonstrated that radiofrequency ablation 
generates antigens for the induction of specific anti-tumor responses. Adoptive transfers 
further showed that these responses were predominantly T cell-dependent. Subsequently, 
applying intra-tumoral injection of radioactive or fluorescently labelled ‘tumor antigens’ 
(KLH and OVA) we were able to show in chapter 4 that, following ablation, tumor-derived 
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antigens were present inside the draining lymph node, where they appeared to be taken 
up by DCs. Within the LN, up to 25% of DC contained antigen as soon as one day and for 
at least three days following ablation. Importantly, the tumor-derived antigens were only 
present in the DC fraction, whereas macrophages etc. were essentially negative. The 
antigens were not just ‘sticking to’ the DCs, as confocal microscopy demonstrated 
structures inside the cytoplasm containing OVA (Figure 1). Interestingly, antigen positive 
DCs were only present in the tumor draining lymph node and only in case ablation of the 
tumor was performed. Moreover, DCs were present in much higher numbers compared to 
a naïve or no-ablation situation. When compared to a conventional DC vaccine (using 
peptide loaded GFP-DC), ablation resulted in much more antigen-loaded DCs in the 
draining LN (chapter 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is currently not known whether antigens are taken up by DCs migrating into the 
tumor tissue and subsequently to the draining lymph node or that antigen is floating 
passively towards the draining lymph node where lymph node residing DC take it up. 
Studies using toxins that block migration may be useful to determine the contribution of DC 
migration. A recent study demonstrated that LN-DC accumulated antigen deposited in 
subcutaneous tissue32. It showed that after injection antigen was first detected in LN-
residing DC, followed by a second wave of antigen positive DC that migrated from the 
periphery into the LN. Both waves were required for efficient immune response induction 
and were dependent on the presence of the challenge site. Our finding that both at day 1 
and day 3 after ablation antigen-loaded DC could be discerned from the LN suggests that 
similar dynamics take place following in situ tumor ablation. In this context, it is interesting 
to note that antigen loading on DC in tumor-bearing control mice seemed to decline in 
these 3 days (chapter 4). Furthermore, antigens from the tumor depot preferentially 
 
Fig. 1: Dendritic cells take up and internalize tumor-derived antigens. Prior to cryo ablation 
of established B16-OVA tumors, ovalbumin coupled to the fluorophore Alexa-488 was injected i.t.. 
Two days later, DCs were isolated from the draining lymph nodes by magnetic bead sorting on 
CD11c and co-stained for CD86 (red). Pictures show sections at 400x from CLSM Z-scans 
demonstrating an antigen negative DC (A) and an antigen positive DC (B). Arrows point to the 
vesicle-like structures containing OVA-Alexa488 (green). Cells from CD11c negative fractions or from 
mice that did not receive OVA were negative for Alexa-488. 
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accumulated in DC, but not in B-cells or macrophages. The basis for the observed antigen 
accumulation in DC remains to be studied in more detail, but is likely related to their 
strategic location within the LN and their ability to retain antigens within their endocytotic 
compartment, whereas cells like macrophages rapidly degrade antigens in their 
lysosomes33. 
Irrespective of the strategy selected to load the DCs, it is now evident that 
activation of both CD4+ and CD8+ T cells is highly beneficial for the induction of anti-
tumor immunity. Therefore, loading of both MHC class I and MHC class II molecules on the 
DC is important to boost a strong immune response. Whereas pulsing of DCs with a 
peptide epitope results in direct loading of MHC class I molecules, efficient presentation of 
intact tumor antigens or tumor cells relies on the unique capacity of DCs to cross-present 
exogenous antigens in MHC class I 34. Importantly, even though in our experiments lymph 
node residing DC appeared to have taken up large amounts of antigens following ablation, 
no elevated levels of antigen specific CD8+ T cells could be observed (chapter 4 and 5). 
Antigen presentation assays demonstrated that MHC class II processing did occur, 
corresponding to the antigen uptake, but MHC class I processing failed. Also in other 
studies using tumor destruction alone the amounts of tumor specific CTL were never 
increased. This suggests that in general, upon tumor destruction, cross-presentation of 
antigens is limited. 
The molecular pathways involved and the factors that trigger cross-presentation of 
antigens are still poorly understood. Recent studies in mice suggested that cross-
presentation is dependent on the intracellular stability of the antigens35 and is tightly 
controlled by DC maturation36,37. This DC maturation may be accomplished by many 
factors, as will be discussed in the next sections. 
 
 
In situ tumor destruction: stimulating immunity by endogenous triggers 
 
Although solid human tumors are frequently infiltrated by DCs, the onset of a proper 
immune response is nevertheless often hampered. As DC maturation is of crucial 
importance for immune response induction, the lack of potent DC maturating compounds 
like microbial PAMPs may well be responsible for this. The necessity of DC maturation to 
induce potent immune responses has now been well established. Whereas immature DCs 
have proven to be weak immune stimulators and even can be tolerogenic, mature DCs 
induce functionally superior CD8+ T cells and concomitant anti-tumor immunity38. 
Accordingly, injection of monocyte-derived immature DC vaccines in cancer patients yielded 
little T cell-mediated immune responses, whereas following injection of mature DCs these 
responses were readily detected39,40. 
 Inducing potent immune responses by in vivo loaded DCs, can thus not go without 
maturation of these DCs. But what does it take to optimally mature a DC, and, more 
importantly, how do we actually define ‘optimal maturation’? Although this issue is still 
subject to debate, it is generally accepted that DCs mature when they experience 
immunological ‘danger’. In the ‘danger hypothesis’, Matzinger and others hypothesized that 
effective immune responses are only induced when antigens are taken up in the context of 
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‘danger’41. Moreover, it was stated that ‘danger recognition’ not only consisted of 
identifying microbial invasion, but also sensing of tissue disruption and dying cells. When 
seen in this context, in situ tumor destruction by itself should thus not be a null event for 
DCs. 
 
Apoptosis vs. necrosis 
There has been much controversy about the differences in induction of immune responses 
by apoptotic vs. necrotic cells. Several studies, mainly performed in vitro, have found that 
cell death by necrosis induces APCs to act as potent immune stimulators, whereas 
apoptotic cells do not cause this effect42,43. Since the hypothesis by Matzinger41 has largely 
been confirmed, it seems logical that apoptotic death will only induce tolerance. After all, 
apoptosis is occurring all the time in the steady state turnover of cells in normal healthy 
tissue, whereas necrosis occurs only in infection. Virally induced apoptosis is emerging as 
an important exception to this concept. This kind of apoptosis actually promotes the 
activation of immune responses, which is mediated via expression of caspases in the 
apoptotic cell and possibly enhanced by intracellular remnants of the viral machinery44. 
From a theoretical point of view, the apoptotic killing by for instance chemotherapy 
would thus mainly cause tolerance to the released antigens, since there are only very few 
of these drugs that induce direct necrosis in tumors. The situation after massive apoptotic 
cell death following chemotherapy or radiotherapy is, however, likely to be more complex. 
Large parts of the tumor will go into secondary necrosis, which together with endogenous 
mediators released upon cell death will affect the immunological outcome15,45. 
 
Endogenous mediators 
As discussed, DC activation upon the recognition of ‘danger’ does not only involve 
detection of molecules derived from potential pathogens, but also the recognition of 
endogenous host-derived molecules released by dying cells. It has, for instance, been 
shown that heat shock proteins and uric acid are present in cellular debris, which both 
influence DC and other parts of the immune system15,46,47. Such endogenous ‘danger’ 
signals may, in some cases, act as ligands for PRRs, like TLRs. In recent years, fibronectin 
A, hyaluran derivatives, inflammatory cytokines, fibrinogen, heat shock proteins, b-
defensins and endogenous DNA have all been put forward as putative endogenous TLR 
ligands15,45,48. Some of these studies are still subject to debate, as it is suggested that 
impure reagents may have biased the outcome. 
Endogenous stimuli may be of critical importance for in situ tumor destruction 
procedures to generate an immune response. Upon in situ tumor destruction endogenous 
danger signals are readily released from the damaged tissue/tumor, which may contribute 
to immune activation. For instance, it has recently been demonstrated in a human study 
that TNF-α and IL-1β levels were markedly enhanced following radiofrequency ablation or 
ablation by ethanol instillation49. Others found that heat shock protein expression at the 
tumor margins was increased when tumors were ablated by laser ablation50. These 
mediators may all contribute to immune activation. Indeed, in our research we found that 
DCs following cryo or radiofrequency ablation were more mature compared to the DCs 
from tumor-bearing mice (chapter 4 and 5). Also in a recent clinical study using 
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radiofrequency ablation of hepatocellular carcinoma, it was demonstrated that DCs 
underwent a transient activation as shown by maturation marker expression49. As a 
contrasting view, one can hypothesize that eradication of the tumor also deletes the 
suppressive milieu surrounding the tumors, which could be a possible explanation for 
increased DC maturation after ablation. However, in one of our experiments injection and 
subsequent ablation of ex vivo prepared tumor lysates gave exactly the same results as 
compared to ablation of intact tumors (chapter 5). This suggests that it is more likely that 
the maturation increase is ablation-dependent. It still needs more clarification what exactly 
are the endogenous PRR ligands or cytokines involved in these ablation-dependent effects. 
Although there has been controversy about the magnitude of the role endogenous 
mediators play, it seems more and more likely that there is a synergistic interplay between 
the endogenous inflammatory mediators and recognition of PAMPs. Recent studies using ex 
vivo produced DCs support this view. For example, human DCs cultured in a combination of 
IL-1β/TNF-α with type I and II interferons (IFN-α and IFN-γ) and the TLR ligand poly I:C 
were much more potent IL-12 producers and better inducers of CTLs in vitro then either 
modality alone51. Moreover, it was demonstrated that activation of DCs by solely pro-
inflammatory cytokines yielded DCs that supported CD4+ T cell clonal expansion, but failed 
to efficiently direct helper T cell differentiation. In contrast, exposure of these cells to 
cytokines plus pathogen components generated DCs that did promote T cell help51,52. 
Recent studies suggest that the interplay of multiple TLRs and other pathogen receptors 
like C-type lectins and nucleotide-binding oligomerization domains (NODs, intracytoplasmic 
microbial-recognition proteins sensing for specific peptidoglycan muropeptides) may work 
synergistically53,54. Simultaneous stimulation of different pathogen recognition receptors 
might indeed more closely resemble the natural situation where pathogens containing 
several molecular triggers will initiate multiple defense mechanisms. 
Importantly, although DC maturation is significantly enhanced after the used 
ablative treatments, only weak immune responses were induced according to our tumor 
rechallenge models. As shown in chapter 4, when we used cryo ablation of established 
B16OVA tumors, only 30-40% of the mice were protected from a lethal B16OVA re-
challenge. Moreover, although DC maturation following radiofrequency ablation was equal 
to maturation following cryo ablation, less potent immunity was induced with 
radiofrequency ablation (20%, chapter 3 and 4). In conclusion: although in situ tumor 
ablation releases mediators that do mature DCs, this maturation may not be sufficient to 
induce potent immunity. The data also suggest that maturation of DC is not the only factor 
modulated by tumor ablation. Possibly, changes in Tregs, granulocytes, neutrophils and 
macrophages also significantly contribute to the generation of the anti-tumor immunity.  
Although the weak responses may seem disappointing, it has been demonstrated 
by us and others that in situ tumor destruction can, however, provide a fertile ‘breeding-
ground’ for potential immune responses. Treating the entire process of in situ tumor 
destruction as an -in vivo DC vaccine- will give us the enormous benefit that we can use all 
the known strategies to induce cross-presenting, activated DC already explored in 
conventional DC vaccines. This view has led us to explore the combination of in situ tumor 
destruction with various local or systemic immune modulations. 
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In situ tumor destruction: stimulating immunity by exogenous triggers 
 
From ex vivo produced anti-tumor vaccines we have learned that modulation of immune 
responses can take place at the level of antigen processing, but also at the level of T cell 
induction (chapter 2). Certain ways of maturation of tumor antigen positive DCs may 
establish better cross-presentation of the antigens taken up, increase migration of these 
DCs to the draining lymph nodes and subsequently lead to a better presentation to the T 
cells. Immunological intervention at the interface of interaction between DC and T cell may 
consecutively skew the functional outcome of antigen presentation. When for instance the 
relevant co-stimulatory or co-inhibitory molecules are increased or inhibited, more potent 
activation of T cells will occur. Another target for intervention comprises the regulation of T 
cell responses. Regulatory T cells, for instance, may down-regulate T cell activity in the 
periphery and even tolerize them. In this section we will discuss interventions relevant for 
the stimulation of immunity following in situ tumor destruction.  
 
Modulation of DC function and T cell priming 
Administration of stimuli containing PAMPs is the most common way to induce DC 
maturation. Several PRR (TLR, NOD) ligands have been described to mature DC, increase 
cross-presentation and excretion of cytokines53,55. Recently, it was shown that 
combinations of different ligands could even work together in synergy, altering the 
responses seen with the individual ligands alone54. 
In combination with in situ tumor destruction very few TLR ligands have been 
tested. We and others have focussed mainly on CpG-ODN, a ligand for TLR-9 (chapter 5). 
Unmethylated CpG-ODN stimulates DCs to express co-stimulatory molecules, increase 
antigen presentation and secrete particularly Th1-associated cytokines, such as IL-1256. 
Moreover, the addition of CpG-ODN has shown to overcome the inhibitory effects of 
immune suppressive factors secreted by B16 melanoma cells on bone marrow derived DCs 
and to restore their capacity to activate allogeneic T cells57. It has been demonstrated that 
peri-tumoral CpG-ODN initiates strong immune responses mediated by CD8+ T cells and 
innate effector cells. This results in growth delay and cure of tumors in various settings58. 
The efficacy of CpG-ODN is, however, often negatively correlated with the size of tumors 
and also seems to be less when the treated tumor is less immunogenic. 
However, recently it was shown that CpG-ODN also improved the MHC class I 
peptide-processing pathway, leading to an increased number of cross-presented epitopes 
on the cell surface of DCs36,59. Since in immunotherapy of cancer it is believed that 
especially MHC class I presentation is needed for effective eradication of tumor cells, CpG-
ODN might therefore be a promising adjuvant for in situ tumor destruction. In the 
experiments presented in chapter 5, in situ ablation was able to significantly enhance MHC 
class II processing and presentation of antigens, while MHC class I presentation was not 
affected. Interestingly, when we combined in situ tumor ablation with CpG-ODN, we were 
able to show an increased amount of cross-presented antigens on the surface of DCs. 
Importantly, cross-presentation was absent when no ablation or CpG-ODN injection alone 
was performed. 
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The combination treatment not only influenced cross-presentation but also 
maturation of DCs. When we injected CpG-ODN alone into tumor-bearing or naïve mice, we 
observed an increase in the expression of maturation markers on isolated DC. However, 
when we performed this injection directly after ablation of the tumor, the increase was 
higher than the increase seen with ablation or CpG-ODN alone. This synergistic maturation, 
together with the increased cross-presentation, suggest a superior advantage over 
conventional CpG-ODN use. In line with this, only the combination treatment led to T cell 
induction and subsequent tumor growth delay of non-immunogenic B16 melanomas 
(Chapter 5). Moreover, in the course of the experiments we did a striking observation: 
when we normally performed cryo ablation on tumor-bearing mice, we were used to have 
a constant rate of recurrent tumors at the site of ablation (comparable to clinical situation). 
Interestingly, when we added CpG-ODN at the time of ablation we noticed an almost 
complete absence of recurrences. Although the recurrence rates were strongly related to 
the initial size of the treated tumor, CpG-ODN was able to reduce recurrences for all tested 
tumor sizes (Figure 2). In support of this, it was shown that CpG-ODN given as a single 
peri-tumoral injection following in situ radiation of murine tumors dramatically enhanced 
tumor growth delay in sarcoma-bearing mice5 and in rats with 9L-glioma60. Although no 
relation with APC was studied, the authors found heavy infiltration by inflammatory cells 
inside the radiated tumor. Similar results were obtained when topotecan, 
cyclophosphamide or gemcitabine treatment of mice bearing tumors was combined with 
CpG-ODN treatment7,61. It will be very interesting to translate this combi-approach to a 
clinical setting. However, as TLR expression on DCs is different between species, analysis 
of different TLR ligands in combination with ablation will be important. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: CpG-ODN improves therapeutic outcome of ablation. At various timepoints after inoculation 
of B16-OVA tumors, the tumordiameter was examined. Mice were selected for the depicted diameter 
groups (n=10) after which their tumors were cryo ablated. Next, part of the mice received 100µg CpG-
ODN 1668 intratumorally. Shown are the percentages of mice that did not get a recurrent tumor at the 
ablation site. 
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 A different method to obtain maturation of DC is via CD40 triggering. Besides 
maturation of DC, CD40 stimulation also enhances the capacity of DC to cross-present 
antigens to T cells59. In addition, these tumor-specific CTL do leave the lymph node more 
easily, thereby entering the circulation62. Van Mierlo and co-workers showed that CD40 
triggering via systemic anti-CD40 antibodies is indeed able to cure mice from tumors when 
applied intratumorally59. Via isolation of CD11c+ cells from lymph nodes they were able to 
show increased DC maturation, which enhanced T-cell priming and expansion. Similar as 
with CpG-ODN, CD40 triggering is less effective when delivered to hosts bearing very large 
non-immunogenic tumors. It may, however, be a promising alternative to combine with in 
situ tumor destruction. In this context, Nowak and co-workers demonstrated that induction 
of tumor cell apoptosis by gemcitabine in combination with CD40 triggering increased 
tumor antigen cross-presentation, which was able to prime specific T cells63. Antibody 
triggering of other stimulatory members of the tumor-necrosis factor receptor (TNFR) 
family: OX40, 4-1BB, CD27, CD30 has similar effects as CD40 triggering, when studied in 
conventional tumor models (reviewed by Croft et al.64). It will be extremely interesting to 
see if future studies can demonstrate a synergistic effect of these antibodies in 
combination with in situ tumor destruction. 
In addition to the stimulatory pathways discussed, also blockade of inhibitory 
receptors, e.g. CTLA-4, has been applied successfully to induce tumor rejection65. In the 
experiments described in chapter 3 and 4, we successfully applied a blocking antibody to 
CTLA-4 after radiofrequency or cryo ablation of established tumors. By tetramer analysis 
we could demonstrate that tumor specific T cells were only observed following the 
combined ablation/antibody treatment. These results were recently confirmed by Demaria 
and co-workers who demonstrated that CTLA-4 blockade could be efficiently combined with 
radio-therapeutic treatment of murine tumors66. 
 
Regulating regulatory T cells 
Tumors can escape immune recognition and their subsequent elimination by creating a 
state of immunological unresponsiveness or self-tolerance to tumor antigens (reviewed by 
Zou et al.67). Moreover, in tumor-associated lymph nodes and peripheral tissues, T cells 
expressing a CD4+CD25+ regulatory phenotype (Regulatory T cells, Tregs) can be found. 
Tregs have been shown to be of critical importance in regulation of T cell dependent 
immune responses and in creating the immunological tolerance to self and non-self68. 
These regulatory T cells are able to suppress T cell and DC function in a cell contact 
dependent manner and represent one of the feedback mechanisms used by the immune 
system to limit excessive immune activation. To enhance the effectiveness of ex vivo 
produced DC vaccines, many have combined anti-tumor vaccination with regulatory T cell 
depletion. This depletion was mostly established via depleting antibodies directed against 
the Treg marker CD25. Indeed, depletion of CD25+CD4+ T cells combined with DC 
vaccination before a subsequent tumor challenge provided effective anti-tumor immunity in 
otherwise non-responding mice68.  
 We reasoned that in situ tumor ablation could function as an in situ DC vaccine, 
which would enable combination with regulatory T cell depletion. The data in chapter 4 
showed us that when the depleting antibodies were given 4 days prior to tumor ablation by 
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cryo or radiofrequency ablation, mice were increasingly protected to a subsequent tumor 
rechallenge. After ten days, more specific T cells could be found, which also produced 
more IFN-γ. 
 Recently, Ercolini and co-workers demonstrated that chemotherapy 
(cyclophosphamide) was also able to significantly affect regulatory T cell populations69. 
Interestingly, they found that a tumor specific vaccine was only then effective when 
combined with the T reg-reducing chemotherapy. In line with this finding, it was 
demonstrated in patients receiving lympho-depleting chemotherapy (cyclophosphamide 
with fludarabine) that subsequent transfer of tumor-directed T cells was more effective as 
compared to when no chemotherapy was given70. Although no causal relation was 
investigated, it was suggested that the abrogation of the suppression by Tregs could be a 
cause for enhanced responsiveness to the T cell transfer. 
 To exploit the full benefit of DCs in in situ DC vaccination, it is important to learn 
more about in vivo inhibitory processes that prevent the immune system to become fully 
activated. Controlling DC activation, regulatory T cells and immune inhibitory molecules on 
the cells of the immune system will be rewarding strategies to combine with tumor 
destruction. 
 
 
Directions to an effectively co-ordinated immune response 
 
Many of the strategies advocated above, may have effects on other parts of the immune 
system then already described. When applied in combination with in situ tumor destruction, 
these effects could be crucially important in determining the functional outcome. It would 
be of particular interest if we could manage to effectively co-ordinate the anti-tumor 
response to be more effective by combining different strategies. 
Future research will have to determine if other TLR ligands have similar effects in 
combination with in situ tumor destruction as described for CpG-ODN. Possible candidates 
may be Pam3cys (TLR2), Poly I:C (TLR3), LPS (TLR4) or TLR 7/8 ligands like in use for 
treatment of warts: Imiquimod or R84871. Moreover, different TLRs may work in synergy 
when stimulated. It was recently shown in human and mouse DCs that TLR3 and TLR4 
triggering combined positively with TLR7, TLR8 and TLR9 stimulation54. It will be very 
interesting to see if these particular combinations are also effective in relation to in situ 
tumor destruction.  
Furthermore, it might be rewarding to consider the effects of different TLR stimuli 
on other parts of the immune system. For instance, it was recently demonstrated that a 
TLR8 ligand was effective in temporarily ceasing the suppressive capacities of Tregs by 
direct triggering of these cells72. The authors successfully applied adoptive transfer of 
TLR8-stimulated Tregs into tumor bearing mice to enhance anti-tumor immunity. Recently, 
we demonstrated that the TLR2 ligand Pam3cys was also able to abrogate Treg-mediated 
suppression of T cell expansion (chapter 6). Consistently, this enhanced responses in an in 
vivo infection model. Intra-tumoral injection of different TLR ligands following in situ tumor 
destruction may thus be aimed at enhancing DC activation, but also at Treg suppression. 
Targeting DCs as well as Tregs may result in an increasingly effective anti-tumor response. 
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TLR stimulation may also act simultaneously on NK cells and various subsets of DC. 
Activated NK cells have shown to promote DCs that have captured antigen, and vice versa, 
DCs have shown to promote proliferation of NK cells and increase their cytotoxic 
activity73,74. Recently it was demonstrated that in the presence of IL12, human NK cells 
also respond to double-stranded RNA or unmethylated CpG-DNA75. The authors claim that 
IL-12 or IFN-α produced by DC will first activate NK cells that in turn eliminate DCs that 
failed to take up antigen or did not express HLA class I molecules to levels required for 
resistance against NK-mediated killing. In addition, NK cell-derived IFN-γ might induce up-
regulation of TLR expression by DCs. Another recent study demonstrated an even more 
complex interplay between myeloid DC, plasmacytoid DC and NKT cells in response to TLR 
stimulation. It showed that plasmacytoid DC can regulate effector activity of antigen-
stimulated NKT cells in a cell contact-dependent manner. In their model, myeloid DC 
appeared to be responsible for the presentation of the cognate NKT cell antigen alpha-
galactosylceramide (alpha-GalCer), whereas plasmacytoid DC appeared to be the most 
sensitive for CpG-ODN stimulation. In turn, the IFN-α and a cell-contact-mediated signal 
from the plasmacytoid DC enabled full activation of the NKT cells. Currently not much is 
known about the activation status of NK or NKT cells in response to tumor destruction. 
Therefore, it will be very interesting to examine the effects of intra-tumoral administration 
of exogenous alpha-GalCer (combined with CpG-ODN) following in situ tumor destruction. 
The above-mentioned studies demonstrate that co-ordinating an immune response 
following in situ tumor destruction is extremely complex. For this, we will need extensive 
basic knowledge about the intricate processes taking place in both the innate and the 
adaptive immune system in response to immune modulation. 
 
 
In situ tumor destruction: an in vivo anti-tumor DC vaccine 
 
Based on the data presented in this thesis we believe that there may be certain advantages 
of combining immunotherapy and in situ tumor destruction over other combinations, which 
we illustrated in Figure 3. 
First, in the past decades immunotherapy has demonstrated to generate efficient 
immune responses, which can efficiently attack tumor cells. However, in immunotherapy 
the rapid growth of tumors will often exceed the capacity of the immune system to clear all 
tumor cells. Combination with destruction of large tumor burdens or debulking in situ will 
therefore give an enormous advantage over immunotherapy alone. 
Secondly, in clinical studies using immunotherapy there is in general a specific need 
to know the right antigen to ‘fit’ the patient’s tumor. When antigens are loaded onto DCs 
via in situ tumor destruction there is no need to define or purify the best tumor antigens 
anymore. DCs will pick the most immunodominant epitopes by themselves. Almost all the 
studies using in situ tumor destruction described an increased availability of tumor 
antigens, which makes it likely that in theory every human tumor can be used to deliver 
the right tumor antigens. Immunotherapy should be used to boost subsequent immunity to 
these antigens. 
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Fig. 3: Advantages of combining immunotherapy and in situ tumor destruction. The circles 
depict three important goals in anti-cancer treatments. Yellow (left) circle: The elimination of large 
volumes of tumor tissue, by for instance excision, is a very straightforward, but important goal in surgical 
oncology. Although it can clear the body from many tumorcells, it usually does not lead to antigen specific 
immune responses. Antigen-specific kill of tumor cells (Blue, right circle), like for instance obtained with 
DC vaccination, enables the immune system to eliminate previously macroscopically unnoticed 
tumorcells/metastases. On itself, vaccination often does not produce sufficiently strong immune responses 
to clear the entire tumor burden. Active downregulation of immune responses by tumorcells or for 
instance regulatory T cells might well be responsible for this. For this reason, effective ‘guidance’ of the 
immune response is needed. This can be done by exogenous or endogenous stimulation. Most desirable, 
however, are efficient combinations of those two groups. This will result in a powerfull stimulation of 
immune responses (Purple, upper circle). Clinical research has shown us that the strongest anti-cancer 
treatments can be found in the overlapping regions of the different circles. We believe that in situ 
tumorablation with immune modulation like with CpG-ODN deserves a place in the centre of the figure, 
although we are convinced that more treatment modalities will fit in there. 
 
 
A third lesson learned from animal models is that one should carefully choose the 
right type of tumor destruction to combine with immunomodulation. As we have discussed 
in this chapter, in situ tumor destruction can have imperative effects on the immune 
system. We demonstrated that ablation on itself is inducing maturation of DCs and a low 
level of immunological protection. But importantly, the combination with CpG-ODN worked 
synergistically, as compared to the individual treatments. It will be also interesting to 
investigate if other destructive techniques like for instance radiation therapy have similar 
beneficial effects on DCs in combination with immunological interventions. Moreover, it will 
be essential to know the effects on the immune system in general. 
Immunotherapy applying tumor-antigen-loaded DCs has proven to be feasible and 
effective in some patients, but a better understanding of how DCs succeed to induce and 
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modulate immunity is necessary to optimally exploit DCs in these vaccines. We believe 
that, besides that combination of in situ tumor destruction with immune modulation is a 
promising approach for treatment of cancer, it also comprises a valuable tool to learn more 
about DC behaviour in vivo. This knowledge may be vital for future vaccine design applying 
ex vivo generated DC. One can envisage many variables that can be optimized, including 
the mode of DC preparation, the subtype, maturation status of DCs, the route of 
administration and the mode of antigen loading. Understanding the complex interactions 
between the processing of the in vivo provided antigens and maturation stimuli, including 
their time constraints, will be of critical importance to induce optimal cross-presentation 
and subsequent CD8 T cell responses.  
The challenge in the next years will be to encourage surgeons and immunologists 
to ‘stay in touch’. The technically difficult protocols should not prevent them from initiating 
clinical trials. Proving efficacy in this kind of studies, by carefully monitoring the immune 
responses, will ultimately lead to a combination therapy of incontestable efficacy, and 
provide a well-tolerated cancer treatment for use alongside the conventional treatment 
modalities. 
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Summary 
 
Our immune system is dedicated to protect the body from invading microorganisms, 
like bacteria and viruses. This complex defence system comprises many different cells, 
mainly leukocytes, which orchestrate the resistance to pathogens. In this, dendritic 
cells (DCs) are important players that function as the system’s sentinels. They reside 
in peripheral tissues as immature DCs where they continuously sample their 
environment in search for antigens. They take up and degrade these antigens into 
small pieces (peptides), which are presented on the MHC molecules on the surface of 
the DCs. The context the DC perceives when taking up the antigens has important 
immunological consequences. If the antigens are, for instance, derived from bacteria, 
the DC will decide to initiate an immune response. On the other hand, if the antigens 
are derived of structures from the own body (self-antigens), then the DC will help to 
create a quiescent state and initiate tolerance for the antigen. 
In the past decades, it has become clear that DCs can sense the difference 
between these two situations. The signals that a DC receives when it encounters an 
antigenic structure appear to be responsible for this. Microbes often carry common 
structures essential for their existence, and these Pathogen-Associated Molecular 
Patterns (PAMPs) can be recognized by specialized receptors in the immune system. 
Toll-like receptors (TLR) are well known examples of this. When a DC recognizes 
‘danger’, it will undergo a phenotypical change called ‘maturation’. Upon maturation, 
DCs migrate from the site of antigen encounter to the draining lymph nodes (LN). Here 
they interact and present the MHC-peptide complexes to naïve T cells. Only mature 
DCs have up-regulated expression levels of so called costimulatory molecules, which 
enable them to translate their ‘sense of danger’ into a full activation of the T cells. In 
the following fight against the infection, activated T cells play a very important role. 
There are, however, situations in which (by mistake) immunity to self-antigens 
is created. If these responses are not dampened they will result in autoimmune 
disease. Regulatory T cells play an important role in the regulation of T cell 
responses. Regulatory T cells (Treg, CD4+CD25+ cells) inhibit auto-reactive immune 
responses and suppress T cells. It is generally believed that these Treg cells are 
actively induced in the thymus and suppress other cells via cell-contact-dependent 
mechanisms, although the exact mechanism is still not elucidated. 
Immunotherapy applying ex vivo generated DCs has been successfully 
introduced in a variety of clinical vaccination protocols. They can be artificially loaded 
outside the body with relevant peptides to initiate immune responses inside the body. 
Also peptides from tumor antigens can be used for loading onto DCs. This kind of 
vaccination has been extensively studied the past years and has proven to be feasible 
and effective in some cancer patients. Importantly, because DC maturation near 
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tumors is often hampered and Treg activity is suppressing anti-tumor immunity, 
vigorous immune responses are not readily observed in all patients. 
 
In Chapter 1 and 2, a general introduction is given about the regulation of 
immune responses, the characteristics and properties of DCs, and their role in current 
anti-cancer vaccines. Although promising data have been obtained with DC 
vaccination, a better understanding of how DCs induce and modulate immunity is 
necessary to optimally exploit the DC’s capacities. The first part of chapter 2 therefore 
describes current insights in antigen loading, activation and migration of DCs and their 
impact on the application of ex vivo generated DC vaccines. Current vaccines mostly 
use tailor-made ex vivo generated DCs to induce immunity, but it has become evident 
that this is a costly and labour intensive procedure. Efforts to load and activate DCs 
directly in vivo will greatly facilitate the application of DC-based vaccines. The second 
part of chapter 2 discusses this subject and describes novel approaches of loading and 
activation of DCs directly in situ. However, DC vaccines will only then become fully 
effective when we learn more about in vivo inhibitory processes that prevent the 
immune system to become fully activated. So finally, the possible obstacles that should 
be overcome to induce long-lasting immunity in therapeutic settings are considered. 
Chapter 3 describes a newly developed mouse model for in situ tumor 
destruction. This model was used to illustrate our view on in situ loading of dendritic 
cells. Tumor-destructing techniques, like radiofrequency ablation, allow eradication of 
large tumors, but at the same time may provide the immune system with an antigen 
source for the induction of anti-tumor immunity. We use the murine B16-OVA 
melanoma cell line to explore: 1) the immunological consequences of in situ tumor 
destruction and 2) the efficacy of a combination approach of tumor destruction and 
immunostimulation. Applying this model system we demonstrate that following 
radiofrequency ablation, a weak but detectable immune response develops, directed 
against OVA, but also against a broader range of B16 antigens. Adoptive transfer 
experiments further indicate that anti-tumor reactivity could be transferred to naïve 
mice by splenocytes. Administration of a blocking antibody against the co-inhibitory 
molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) at the time of tumor 
destruction strongly enhances anti-tumor immunity resulting in long-lasting tumor 
protection. These results were our first proof that in situ tumor destruction could 
provide a useful antigen source for the induction of anti-tumor immunity, provided that 
additional immune modulation is administered. 
Chapter 4 describes the first data on involvement of DCs in the initiation of 
immune responses following ablation. It also provides a comparison between the 
immune effects induced by cryo ablation and radiofrequency ablation. In this chapter 
we demonstrate that upon tumor destruction by radiofrequency ablation, up to 10% of 
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the total draining lymph node DCs acquire antigens. Interestingly, after tumor 
destruction by cryo ablation this amount is doubled. Compared to conventional DC 
vaccination, far more antigen positive DCs could be discerned in the lymph node after 
ablation. Analysis of DC maturation revealed that both destruction methods are able to 
enhance maturation. Finally, we show that in situ tumor ablation can again be 
efficiently combined with immune modulation by anti-CTLA-4 antibodies, but also with 
regulatory T cell depletion by anti-CD25 antibodies. These combinations lead to in vivo 
enhancement of tumor-specific T cell numbers, protecting them from lethal tumor 
challenges. The data in chapter 4 were our first evidence that in situ tumor destruction 
in combination with immune modulation creates a unique, ‘in situ DC-vaccine’. 
Interestingly, this strategy could form a promising, readily applicable treatment in the 
clinic, for which no prior knowledge of tumor antigens is necessary. 
In Chapter 5 this view is further explored. Using cryo ablation of B16-OVA 
tumors that were injected with marker proteins we could see that tumor antigen 
positive DCs were more mature compared to antigen negative DCs, while maturation 
was further enhanced by ablation. But most importantly, we showed that in situ tumor 
ablation synergizes with the TLR9 ligand CpG-ODN in inducing DC maturation. Only the 
combination treatment enabled in vivo cross-presentation of the antigens taken up, 
leading to superior DC function in vivo. The combination treatment was far more 
effective in the eradication of local and systemic tumors than either treatment modality 
alone. The data suggest that the complex interplay between antigen uptake, mediators 
released by the destruction treatment, and immunological skewing by carefully timed 
exogenous stimuli are of key importance for in situ DC-vaccination. This implicates that 
a combination of an optimal kind of in situ tumor destruction with an optimal kind of 
immune stimulation exists. 
Chapter 6 describes that immunological stimulation by TLR-ligands not only 
affects DCs, but also Tregs. Although mature DCs are more competent inducers of 
immunity, T cell responses will not be optimal when negative regulation by Tregs is still 
present. However, in this chapter we demonstrate that this is not always the case. The 
data showed that direct triggering of Tregs by a TLR2 ligand temporarily ceased their 
suppressive capacities. Consistent with this, we demonstrate in an in vivo infection 
model that the TLR-ligand can modulate outgrowth of microbes. In the context of our 
ablation model, we therefore suggest that modulation in the effector (T cell) phase of 
immune responses can be an effective tool in conjunction to modulation in the 
initiation (antigen/DC) phase.  
Finally, in Chapter 7, a general discussion and future prospective on the topics 
presented in this thesis are given. 
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Het immuunsysteem beschermt ons lichaam tegen binnengedrongen micro-
organismen, zoals bacteriën en virussen. Dit complexe verdedigingssysteem bestaat uit 
vele verschillende cellen, voornamelijk leukocyten, die de weerstand tegen pathogenen 
coördineren. Dendritische cellen (DCs) spelen hierbij een belangrijke rol. Zij 
functioneren als het ware als de poortwachters van het immuunsysteem. DCs bevinden 
zich in allerlei perifere weefsels in het lichaam, waar ze veelal als onrijpe DCs de 
omgeving verkennen. Ze nemen daarbij steeds een sample van hun omgeving op zoek 
naar antigenen. Deze antigenen worden opgenomen en eenmaal binnen gedegradeerd 
tot kleinere fragmenten (peptides). De peptides worden vervolgens aan de buitenkant 
van de cel gepresenteerd op zogenaamde MHC moleculen. De context die een DC 
waarneemt op het moment dat hij antigenen opneemt heeft belangrijke 
immunologische consequenties. Wanneer een DC bijvoorbeeld antigenen opneemt van 
bacteriën, zal hij hoogst waarschijnlijk een immuunrespons initiëren. Echter, wanneer 
de antigenen afkomstig zijn van structuren van het eigen lichaam (zelfantigenen), dan 
zal de DC proberen een immuunrespons te onderdrukken en tolerantie te ontwikkelen 
voor het antigeen. 
 In de afgelopen jaren is het duidelijk geworden dat DCs het verschil tussen 
deze twee situaties kennen. De signalen die een DC krijgt op het moment van antigen 
opname blijken hiervoor verantwoordelijk. Micro-organismen bezitten vaak 
gemeenschappelijke structuren die onmisbaar zijn voor hun voortbestaan. Deze 
Pathogeen Geassocieerde Moleculaire Patronen (engels: PAMPs) kunnen worden 
herkend door gespecialiseerde receptoren binnen het immuunsysteem. De 
zogenaamde ‘Toll-like’ receptoren (TLRs) zijn bekende voorbeelden hiervan. 
Wanneer een DC (via zijn TLRs) ‘gevaar’ waarneemt, ondergaat hij een uiterlijke 
verandering, maturatie geheten. Nadat maturatie heeft plaatsgevonden, migreren DCs 
van de plek waar ze het antigen opnamen naar de drainerende lymfeknopen. In de 
lymfeknopen gaan ze een interactie aan met naïeve T cellen waaraan ze de MHC-
peptide complexen presenteren. Alleen de gematureerde DCs hebben grote 
hoeveelheden zogenaamde co-stimulatoire moleculen op hun oppervlak, welke hen in 
staat stellen hun perceptie van het ‘gevaar’ te vertalen in een volledige activatie van de 
T cel. In het daarop volgende gevecht tegen de infectie spelen geactiveerde T cellen 
een zeer grote rol. 
 Er komen echter situaties voor waarin (per ongeluk) een immuunrespons tegen 
zelfantigenen is gecreëerd. Indien deze responsen niet onder controle worden 
gehouden zullen ze resulteren in auto-immuunziekten. Regulatoire T cellen (Treg, 
CD4+CD25+ cellen) spelen een belangrijke rol in de regulatie van T cel responsen. 
Treg cellen remmen zelfgerichte immuunresponsen en onderdrukken gewone T cellen. 
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Ook weten we dat deze Treg cellen actief worden geïnduceerd in de thymus en dat ze 
andere cellen remmen via een celcontact afhankelijk mechanisme en cytokines als IL-
10 en TGF-β. 
 Immuuntherapie met buiten het lichaam (ex vivo) gemaakte DCs heeft een 
succesvolle plek weten te bemachtigen binnen de klinische vaccinatieprotocollen. Deze 
DCs kunnen in kweek beladen worden met de relevante peptiden om vervolgens, na 
teruggegeven te zijn aan het lichaam, immuunresponsen te genereren. Ook 
tumorantigenen kunnen worden gebruikt voor belading van DCs. In recente jaren is 
deze vorm van vaccinatie intensief bestudeerd en het is gebleken dat de methodiek 
praktisch mogelijk is en zelfs effectief in sommige patiënten. Het is daarbij belangrijk te 
vermelden dat in veel patiënten geen voldoende sterke immuunresponsen 
waarneembaar zijn. Tegenwerking van DC maturatie in de buurt van tumoren en T cel 
remming door regulatoire T cellen (tumoren zijn immers afkomstig van eigen weefsels) 
zijn hiervoor aannemelijke verklaringen. 
 
 In Hoofdstuk 1 en 2 wordt een algemene introductie gegeven over de 
regulatie van immuunresponsen, de eigenschappen van DCs en hun rol binnen de 
huidige antikanker vaccins. Alhoewel veelbelovende resultaten zijn geboekt met DC 
vaccinatie, is een grotere kennis over hoe DCs immuniteit induceren en reguleren 
nodig om de capaciteiten van de DC volledig te kunnen benutten. Het eerste gedeelte 
van hoofdstuk 2 beschrijft daarom de huidige inzichten in antigen belading, activatie 
en migratie van DCs en hun invloed op het gebruik van ex vivo geproduceerde DC 
vaccins. De huidige vaccins gebruiken veelal ex vivo op maat gemaakte DCs om 
immuniteit te induceren, maar het wordt steeds duidelijker dat dit een uiterst kostbare 
en arbeidsintensieve methode is. Belading en activatie van DCs in het lichaam zelf 
zouden een grote sprong voorwaarts betekenen voor de toepassing van DC vaccinatie. 
Het tweede gedeelte van hoofdstuk 2 behandelt dit onderwerp en beschrijft de recente 
benaderingen om DCs direct in vivo te beladen. Elke vorm van DC vaccinatie zal echter 
pas effectief zijn wanneer negatieve regulatie door het immuunsysteem kan worden 
verminderd. Aan het eind van hoofdstuk 2 wordt daarom bediscussieerd welke 
obstakels nog moeten worden genomen om het mogelijk te maken langdurige 
immuniteit in therapeutische settings te creëren. 
 Hoofdstuk 3 beschrijft een nieuw ontwikkeld muismodel voor in situ (lokaal in 
het lichaam) tumor destructie. Dit model gebruiken we om onze visie op in vivo 
belading van DCs te illustreren. Tumor destructie technieken als radiofrequentie ablatie 
zijn in staat grote tumoren te elimineren, maar op hetzelfde moment kunnen ze een 
bron van tumorantigenen scheppen die gebruikt kan worden voor de inductie van 
immuunresponsen. We gebruiken de muizen-melanoom cellijn B16-OVA om te 
onderzoeken wat A) de immunologische consequenties zijn van in situ tumor destructie 
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en B) de gevolgen zijn van een benadering waarin we tumor destructie combineren 
met immuunstimulatie. Met dit model tonen we aan dat volgend op radiofrequentie 
ablatie zich een zwakke maar detecteerbare immuunrespons ontwikkelt. Deze is gericht 
tegen het eiwit OVA, maar ook tegen andere B16 antigenen. Experimenten waarbij we 
T cellen (splenocyten) transplanteren, laten verder zien dat de antitumor reactiviteit 
over kan worden gedragen op naïeve muizen. Wanneer nu een blokkerend antilichaam 
tegen het immuun remmende molecuul ‘cytotoxic T lymphocyte-associated antigen 4’ 
(CTLA-4) gegeven word op het moment van tumordestructie, word de antitumor 
respons sterk verhoogd. Dit resulteert dan ook in langdurige bescherming tegen tumor 
uitgroei. Deze resultaten zijn ons eerste bewijs dat in situ tumor destructie een 
effectieve bron van antigenen kan bieden voor de inductie van antitumor immuniteit, 
gegeven dat additionele immuunmodulatie wordt toegediend. 
 Hoofdstuk 4 beschrijft onze eerste data over de betrokkenheid van DCs in de 
initiatie van immuunresponsen volgend op ablatie. Ook biedt het een vergelijking 
tussen de geïnduceerde effecten door radiofrequentie ablatie en cryo ablatie. In dit 
hoofdstuk tonen we aan dat, na in situ tumor destructie door radiofrequentie ablatie, 
bijna 10% van alle drainerende lymfeknoop DCs antigenen op hebben genomen. 
Interessant is echter dat na tumordestructie via cryo ablatie deze hoeveelheid is 
verdubbeld. Wanneer we dit vergelijken met een conventioneel DC vaccin, zien we dat 
met beide ablatie methoden enorm veel meer antigeen beladen DCs in de drainerende 
lymfeknoop komen. Uiteindelijk laten we zien dat beide vormen van in situ tumor 
ablatie wederom uitstekend kunnen worden gecombineerd met anti-CTLA-4 
antilichamen. Deze keer laten we echter ook zien dat in vivo depletie van regulatoire T 
cellen een even effectieve strategie is. Deze combinaties leiden tot verhoogde 
aantallen tumor-specifieke T cellen in het lichaam, die de muizen bescherming bieden 
tegen opnieuw geïnjecteerde en normaal dodelijke tumor-challenges. De resultaten 
van hoofdstuk 4 waren ons eerste bewijs dat in situ tumordestructie in combinatie met 
immuunmodulatie een uniek ‘in situ DC vaccin’ kan vormen. Dit is uiterst interessant, 
omdat deze strategie een veelbelovende, direct toepasbare, behandeling in de kliniek 
zou kunnen worden. Er is immers geen voorafgaande kennis van de juiste 
tumorantigenen nodig om dit vaccin toe te passen. 
 In Hoofdstuk 5 wordt deze visie verder uitgewerkt. Met behulp van marker 
eiwitten tonen we aan dat na cryo ablatie van B16OVA tumoren de tumorantigen 
positieve DCs meer gematureerd zijn vergeleken met antigen negatieve DCs. Maturatie 
wordt daarop nog eens verder verhoogd door ablatie. Het belangrijkste resultaat is 
echter dat in situ tumor ablatie in synergie blijkt te werken met de effecten die het 
TLR9 ligand CpG-ODN teweeg brengt. Alleen de combinatie behandeling leidt tot 
zogenaamde cross-presentatie van de opgenomen antigenen, wat een superieure 
functie van deze DCs weergeeft. De combinatie is vervolgens veruit het meest effectief 
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in het elimineren van locale of systemische tumoren, vergeleken met elke behandeling 
apart. De resultaten suggereren dat het complexe samenspel van antigen opname, 
endogene mediatoren die vrijkomen tijdens de destructie van de tumor en zorgvuldig 
getimede immuunmodulatie door exogene TLR-liganden een zeer belangrijk aspect is 
in deze vorm van in situ DC vaccinatie. Dit samenspel kan mogelijk een voordeel 
bieden op andere recent voorgestelde vormen van in vivo belading van DCs. 
 Hoofdstuk 6 beschrijft dat immunologische stimulatie via TLR-liganden niet 
alleen effecten heeft op DCs, maar ook op Tregs. Alhoewel gematureerde DCs zeer 
goed immuunresponsen kunnen induceren, zal een T cel respons nooit optimaal zijn 
wanneer negatieve regulatie door Tregs aanwezig blijft. Zoals in hoofdstuk 4 al 
beschreven was, leidt Treg depletie immers tot verhoging van de immuunrespons. In 
dit hoofdstuk tonen we aan dat er situaties bestaan waarin Tregs hun remmende 
capaciteit op een natuurlijke manier tijdelijk verliezen. De resultaten laten zien dat 
directe stimulatie van Tregs via het TLR2 ligand Pam3Cys (ook aanwezig op bepaalde 
bacteriën) tijdelijk hun suppressie kan stilleggen. In samenhang hiermee tonen we aan 
dat het TLR2 ligand uitgroei van micro-organismen kan moduleren in een in vivo 
infectie model. In de context van ons ablatie model kunnen we dus bedenken dat 
modulatie in de effector fase van de immuunrespons (T cellen) een effectieve 
behandeling kan zijn in samenspel met modulatie in de initiatie fase (DCs en antigeen). 
 Uiteindelijk wordt in Hoofdstuk 7 een algemene beschouwing en 
toekomstvisie op de in dit proefschrift gepresenteerde onderwerpen gegeven. 
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Throughout this thesis the following abbreviations are used 
 
111In 111-Indium (isotope) 
AICD Activation-induced cell death 
APC Antigen presenting cell or allophycocyanin (fluorophore) 
CD8 Cluster of differentiation (number 8)  
CFSE Carboxyfluorescein diacetate succinimidyl ester (fluorophore) 
CLSM Confocal laser scanning microscopy 
CPM Counts per minute 
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T lymphocyte-associated antigen (number 4)  
DC Dendritic cell 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence activated cell sorter 
FITC Fluorescein isothiocyanate (fluorophore) 
FCS Foetal calf serum 
GM-CSF Granulocyte/macrophage colony stimulating factor 
HSP Heat shock protein 
IgG Immunoglobulin (type G) 
IFN-γ Interferon (type gamma) 
IL-2 Interleukin (number 2) 
KLH Keyhole limpet hemocyanin 
LTC-4 Leukotriene (type C4) 
LPS Lipopolysaccharid 
LN Lymph node 
MIP Macrophage inflammatory protein 
MHC Major histocompatibility complex 
MLR Mixed lymphocyte reaction 
mAb Monoclonal antibody 
mDC Myeloid dendritic cell 
NK cell Natural killer cell 
CpG-ODN Oligodeoxynucleotide containing CG motif 
OVA Ovalbumin 
PAMP Pathogen associated molecular pattern 
PRR Pattern recognition receptor 
pDC Plasmacytoid dendritic cell 
PCR Polymerase chain reaction 
PGE2 Prostaglandin E2 
RFA Radiofrequency ablation 
Treg Regulatory T cell 
PE R-phycoerythrin (fluorophore) 
TCR T cell receptor 
Th T helper cell 
TLR Toll-like receptor 
TGF-β Transforming growth factor (type beta) 
TNF-α Tumor necrosis factor (type alpha) 
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Dankwoord 
 
Het proefschrift is eindelijk af! Echter, zonder de hulp van velen zou dit boekje 
er nooit gekomen zijn. Een aantal van hen wil ik daarom graag met naam 
noemen.  
 
Allereerst wil ik graag mijn twee promotores bedanken dat ik op hun afdeling 
mijn promotie onderzoek heb mogen doen. Ik vind dat door de jaren heen een 
ontzettend gezellig en succesvol lab is opgezet, waar jullie voor een groot deel 
voor hebben gezorgd. Beste Gosse, jouw enthousiasme over mijn experimenten 
hebben me meer dan eens de zonnige kant van een slecht uitvallende proef 
doen inzien. Ik heb vooral veel opgestoken van je scherpe blik op de zaken, 
waar ik denk ik nog lang profijt van zal hebben. Bedankt voor het vertrouwen 
dat je in me hebt gesteld en de gezellige tijd samen! Beste Carl, jou wil ik graag 
bedanken voor de nooit aflatende interesse in mijn werk. Door je kritische 
kanttekeningen is het ons vaak gelukt om onze resultaten vele malen steviger 
neer te zetten.  
 
Naast twee promotores, wat op zich best bijzonder is, bevind ik me ook nog 
eens in de luxe positie dat ik twee co-promotores heb! Een gezellige familie! 
Beste Theo, ik vind het nog steeds een enorme prestatie dat jij als chirurg 
zoveel energie in je interesse voor het immunologisch onderzoek steekt. Ik 
denk dat we samen een solide basis hebben gelegd voor verder muizen 
onderzoek in samenwerking met de afdeling chirurgie. Ontzettend bedankt voor 
de fijne tijd! Roger, eerst mijn ‘U-genoot’, daarna ook nog eens mijn co-
promotor…! Wat hebben we gelachen in ons U-tje, niet?! Erg jammer dat dat 
nu langzaamaan minder moet worden, maar goed, het is niet anders. Bedankt 
voor je luisterend oor en begrip, je altijd goede adviezen en de fantastische tijd 
in U-3! Ik vind het een eer dat jij mijn co-promotor bent.  
 
Het lachen in U-tje 3 brengt me meteen bij mijn twee dierbare paranimfen. Erik 
en Stefan, jullie hebben er samen met Liza voor gezorgd dat de lol in U3 
compleet was. Ik ben dan ook ontzettend blij dat jullie mijn paranimfen willen 
zijn. Erik, jouw positieve instelling en nooit aflatende vrolijkheid hebben me 
vaak door sombere dagen heen gesleept. Ik denk dat we samen het fenomeen 
‘fluiten op het lab’ tot een ware kunst hebben verheven! Ook wil ik je bedanken 
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voor de enorme hoeveelheid werk die je voor me hebt verricht: zonder jou was 
dit proefschrift er in de verste verte niet geweest! Stefan, als opvolger op mijn 
project ken ik je nog maar kort, maar toch weet ik nu al zeker dat het werk in 
goede handen terecht is gekomen. Bedankt voor al je hulp, gezelligheid en 
natuurlijk ook voor het verzorgen van mijn guppen…! Enorm veel succes 
toegewenst en je weet: driemaal bij Nature Medicine aan de deur kloppen is 
scheepsrecht he?  
 
De afdeling tumorimmunologie is altijd een enorm fijne plek geweest om AIO te 
zijn en dat is vooral te danken aan de leuke mensen die er werken. Iedereen 
ontzettend bedankt voor de fantastische tijd samen! Met name de 
sportievelingen wil ik hier nog even noemen. Ben, Erik, Daniel, Frank, Hans, 
Hugo, Joost, Lieke, Liza, Luuk, Matthijs, Oliver, Richard, Robbert, Roger en 
Stefan: bedankt dat jullie er zoveel energie in hebben gestoken om me het 
squashen, biken, bierspelen en snowboarden bij te brengen. Ik bak d’r nog 
steeds niks van, maar dat geeft niet, het gaat om het meedoen hè (euhm…)? Ik 
hoop dat we nog lang door zullen gaan met onze tradities! Robbert, mijn 
vroegere strenge leermeester, bedankt dat je me ‘fijne kneepjes van het vak’ 
hebt bijgebracht. Jouw scherpe visie op wat wel en niet belangrijk is hebben 
zeker aan de basis gestaan van een stuk efficiënter werken…! Dat er in onze 
keukens ook ‘fijne kneepjes’ bestaan hebben we meerdere malen bewezen. Ik 
vind dat de naam Meesterkok maar door weinig personen gedragen mag 
worden, maar jij bent er een van! Ik denk trouwens dat je de pannen weer 
tevoorschijn kunt halen, want je vrouw heeft volgens mij weer enkele gangen 
‘verhandeld’ met me…! Dat brengt me natuurlijk meteen bij Alessandra. Ik ben 
enorm blij dat ik via jou zo veel van Italie heb geleerd. Het trouwfeest was 
super, maar ook natuurlijk de vele taal-oefeningen… Laat het voor eens en 
altijd duidelijk zijn:Tu hai degli occhi molto bello…! Bedankt voor de fijne tijd 
samen! Ook twee andere buitenlanders, Friederike en Vassilis, hebben me laten 
zien dat de wereld eigenlijk best klein is. Bedankt daarvoor! Frank W., waarbij 
de W eigenlijk zou moeten staan voor Wonderful, bedankt dat je me zo vaak de 
zonnige kant van dingen hebt laten zien en zo’n fantastische collega bent 
geweest. Ben, enorm bedankt voor de lol die we samen hebben beleefd in en 
buiten het lab, aaaight? Ik weet nu: punken is VET! Louise en Jeanette, 
misschien wel de belangrijkste personen in het lab, bedankt dat jullie altijd klaar 
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voor me stonden wanneer er weer eens iets nu nodig was! Suzanne, Danielle 
en Karlijn, bedankt voor al die avondjes Catannen die jullie me hebben laten 
winnen ;-). We moeten het snel hervatten! Ruurd, Jolanda, Frank dL & vL: 
bedankt voor de gezellige tijd samen, als staf of TILCOM. Ik heb veel van jullie 
geleerd! Ook de TIL-band, borrelcommissies en de Vetput-commissie verdienen 
een bedankje. Hoop nog vele acties van jullie te zien!  
En ook al zijn er nog veel meer Tillers te bedanken, ik moet een keer eindigen. 
En dat wil ik doen met Liza. Als de ongekroonde koningin van het 
muizengroepje moest je vaak je mannetje staan tussen al die kerels, maar dat 
ging je enorm goed af! Ontzettend bedankt voor de hulp bij mijn experimenten, 
maar ook voor de dance-avondjes-uit! Wanneer gaan we weer?  
 
Sommige experimenten in dit proefschrift zijn niet alleen door het 
tumorimmunologie lab gedaan of ondersteund, maar ook door anderen. Ik wil 
daarom de afdelingen Reumatologie, CHL, Interne Geneeskunde, de ‘5de 
verdieping’ en de labs in Leiden hartelijk danken voor het feit dat ik van hun 
lab-equipment en expertise gebruik heb mogen maken. Het was altijd prettig 
samenwerken! De afdeling die hier toch wel bovenuit steekt is de afdeling 
Nucleaire Geneeskunde. Otto en Cathelijne, zonder jullie zouden de resultaten 
in dit boekje er nooit zo fraai uit hebben gezien als nu. Ik denk dat ik jullie nog 
veel te weinig heb bedankt voor jullie hulp. Bij deze: bedankt! 
 
Natuurlijk had al dit wetenschappelijk geneuzel niet kunnen ontstaan als er niet 
af en toe wat afleiding en ontspanning was geweest! Dit super-bedankje gaat 
uit naar al mijn vrienden die me die broodnodige ontspanning hebben bezorgd. 
Vrienden uit Nijmegen, van de universiteit, van de bios, van mijn huis, uit 
Nistelrode en omstreken, Synthon, Ongenoemde vrienden en Vrienden van 
vrienden: Allemaal enorm bedankt voor de knotsgekke dingen die we hebben 
beleefd. Ik ben blij dat er nu meer tijd voor ons samen is…! 
 
Een ontzettend belangrijk bedankje is die voor mijn familie. Pap, Mam en Wilco, 
ook al was het voor jullie soms moeilijk te begrijpen waar ik nu weer allemaal 
mee bezig was, ik ben blij dat jullie altijd achter me hebben gestaan en me 
gesteund hebben op alle soms rare wegen die ik insloeg. Zonder jullie was ik 
nooit zo ver gekomen!   
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Lieve Annemarie, ik heb je pas in het laatste jaar van mijn promotie leren 
kennen en dat was, ook al was de tijd met jou fantastisch, denk ik niet de beste 
timing. De drukte van het promoveren is tot mijn grote spijt vaak de oorzaak 
geweest dat ik je niet mijn volledige aandacht kon geven. Bedankt voor je 
begrip, onvoorwaardelijke steun en liefde, en het simpele feit dat je bij me 
bent. Als er iemand is die medefelicitaties voor dit proefschrift zou moeten 
ontvangen, dan ben jij het wel!  
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